var title_f39_39_40560="Colostomy allergic contact";
var content_f39_39_40560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Allergic reactions can occur with any of the products used to protect the peristomal skin or to assure adhesion of the pouching system; allergic reactions are characterized by pruritus, erythema, and blistering in the area corresponding to contact with the offending agent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy B Doughty, MN, RN, CWOCN, FAAN.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40560=[""].join("\n");
var outline_f39_39_40560=null;
var title_f39_39_40561="Battles sign";
var content_f39_39_40561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69660&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Battle sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retroauricular or mastoid ecchymosis (ie, Battle sign) typically appears one to three days after a basilar skull fracture is sustained",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Basilar Skull Fracture. In: Color Atlas of Emergency Trauma, Mandavia, DP, Newton, EJ, Demetriades, D, Cambridge University Press, Cambridge, UK 2003. Reprinted with the permission of Cambridge University Press. Copyright &copy; 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40561=[""].join("\n");
var outline_f39_39_40561=null;
var title_f39_39_40562="Hydroa vacciniforme 1";
var content_f39_39_40562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hydroa vacciniforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scars and crusted papules are present on the face. This 10-year-old boy had a history of recurrent blisters in sun exposed areas that healed with depressed vaccination-like scars.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40562=[""].join("\n");
var outline_f39_39_40562=null;
var title_f39_39_40563="Schematic of the breast and regional lymph nodes";
var content_f39_39_40563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Schematic of the breast and regional lymph nodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40563=[""].join("\n");
var outline_f39_39_40563=null;
var title_f39_39_40564="Bacillus Calmette-Guerin (BCG) vaccine: Patient drug information";
var content_f39_39_40564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bacillus Calmette-Guerin (BCG) vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/30/28135?source=see_link\">",
"     see \"Bacillus Calmette-Guerin (BCG) vaccine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BCG Vaccine;",
"     </li>",
"     <li>",
"      TheraCys&reg;;",
"     </li>",
"     <li>",
"      TICE&reg; BCG",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      BCG Vaccine;",
"     </li>",
"     <li>",
"      ImmuCyst&reg;;",
"     </li>",
"     <li>",
"      Oncotice&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bladder cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705223",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to BCG or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703209",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Active TB (tuberculosis), a high fever, HIV infection, a bladder infection, or a weak immune system.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, use a latex condom even if you have had a vasectomy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696438",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All bad side effects to this vaccine must be reported to the U.S. Department of Health and Human Services Vaccine Adverse Event Reporting System. Ask your doctor to file the report. You may also call to file a report at 1-800-822-7967.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698085",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. Mild pain drugs may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696420",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Bladder cancer treatment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697898",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs lasting for more than 3 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4085107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bright red blood or clots in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696420",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Bladder cancer treatment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696026",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the bladder.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3922562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need to try to keep this drug in your bladder for up to 2 hours, but no longer than 2 hours. Keep a note of how long you were able to hold it so you can tell your nurse or doctor at your next visit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3922564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is most often given once a week for 6 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use the same toilet each time you use the bathroom in your home. Sit down on the toilet to urinate to keep urine from splashing or spraying.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Before flushing, add 1 cup of bleach to the urine. Wait 15 minutes, then flush. Do this for the first 6 hours after BCG is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11142 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40564=[""].join("\n");
var outline_f39_39_40564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139164\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139165\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030204\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030206\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030205\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030210\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030211\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030213\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030208\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030215\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/30/28135?source=related_link\">",
"      Bacillus Calmette-Guerin (BCG) vaccine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_39_40565="Prostate cancer treatment; stage I to III cancer";
var content_f39_39_40565=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/39/40565/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40565/contributors\" id=\"au5322\">",
"       Eric A Klein, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/39/40565/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40565/contributors\" id=\"se5250\">",
"       Nicholas Vogelzang, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40565/contributors\" id=\"se1298\">",
"       W Robert Lee, MD, MS, MEd",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40565/contributors\" id=\"se3217\">",
"       Jerome P Richie, MD, FACS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/39/40565/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40565/contributors\" id=\"de7369\">",
"       Michael E Ross, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/39/40565?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Prostate cancer is a cancer of the prostate gland, an organ that forms a ring around the urethra, near its connection to the bladder (",
"     <a class=\"graphic graphic_figure graphicRef65675 \" href=\"mobipreview.htm?36/32/37382\">",
"      figure 1",
"     </a>",
"     ). The urethra is the tube that carries urine from the bladder to the outside of the body.",
"    </p>",
"    <p>",
"     Over the last 20 years, more men are being diagnosed with prostate cancer at an early stage, when the cancer is highly curable. A separate article discusses screening tests for prostate cancer. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=see_link\">",
"      \"Patient information: Prostate cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     This article discusses symptoms, diagnosis, and treatment of stage I to III prostate cancer. Treatment of advanced prostate cancer is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"      \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information about early-stage prostate cancer is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16969?source=see_link\">",
"      \"Initial approach to low-risk clinically localized prostate cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PROSTATE CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Prostate cancer is usually found before symptoms develop. However, early symptoms of prostate cancer may include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A need to rush to the bathroom frequently or a slow urine stream. These symptoms are usually related to an enlarged prostate (called BPH), not prostate cancer. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"        \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Erectile dysfunction (difficulty having an erection). Erectile dysfunction is more commonly caused by problems other than prostate cancer. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"        \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Blood in the urine or semen",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PROSTATE CANCER DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Your doctor or nurse may suspect that you have prostate cancer if you have an abnormal blood test (PSA, or prostate-specific antigen) or an abnormal rectal examination. To be certain about the diagnosis, you will need to have a prostate biopsy. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"      \"Clinical presentation and diagnosis of prostate cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Prostate biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prostate biopsy is usually performed in a doctor's office. You will be given a course of antibiotics to take before and after the biopsy to reduce the risk of infection from the procedure.",
"    </p>",
"    <p>",
"     The biopsy is done after you are given local anesthesia (a shot or gel in the rectum). Most men feel mild to moderate pain during the procedure. The entire procedure usually takes about 15 minutes.",
"    </p>",
"    <p>",
"     After the procedure, you will probably feel soreness in your rectum or the area around the rectum (called the perineum). You may have some bleeding from your rectum, in your urine (for several days), or in your semen (for up to several months).",
"    </p>",
"    <p>",
"     The tissue taken during the biopsy will be examined by a pathologist using a microscope. The results are usually available within one week.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Gleason grade",
"     </span>",
"     &nbsp;&mdash;&nbsp;If cancer is found in the prostate biopsy, the amount of cancer and aggressiveness of the tumor will be determined. The Gleason grade depends on how the tumor looks under the microscope. The higher the Gleason grade, the more likely the tumor is to behave aggressively (grow faster).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Prostate cancer stage",
"     </span>",
"     &nbsp;&mdash;&nbsp;Once prostate cancer is diagnosed, the next step is to determine its stage. Staging is a system used to describe the size, aggressiveness, and spread of a cancer. A cancer's stage helps to guide treatment and can help predict the chance of curing the cancer.",
"    </p>",
"    <p>",
"     A prostate cancer's stage is based upon:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       How far the tumor extends in the prostate and surrounding tissue",
"      </li>",
"      <li>",
"       Possible spread of the cancer to the nearby lymph nodes",
"      </li>",
"      <li>",
"       Signs of cancer in other organs (liver, bone)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, the PSA (prostate-specific antigen) level and the Gleason grade are used to gauge how aggressive the tumor is and what treatment options are available.",
"    </p>",
"    <p>",
"     In general, lower-stage cancers are less aggressive and less likely to come back after treatment compared with higher-stage cancers. Stage I and II prostate cancer are referred to as localized prostate cancer, stage III is locally advanced, and stage IV is referred to as advanced or metastatic prostate cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Further testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other tests, such as MRI, ultrasound, or bone scan, may be done before treatment begins to determine whether the cancer has spread beyond the prostate.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      STAGE I TO II (LOCALIZED) PROSTATE CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Localized prostate cancer is cancer that has not spread to the lymph nodes or distant organs. There are three standard ways to treat localized prostate cancer:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Surgery to remove the prostate gland (called radical prostatectomy)",
"      </li>",
"      <li>",
"       Radiation therapy (external beam or brachytherapy), sometimes combined with androgen deprivation therapy",
"      </li>",
"      <li>",
"       Active surveillance, also called \"watch and wait\"",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The best treatment depends upon your age and health, your preferences, and the stage of your cancer. (See",
"     <a class=\"local\" href=\"#H21\">",
"      'Which treatment is right for me?'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Radical prostatectomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical prostatectomy (also called prostatectomy) is a surgery done to remove the prostate gland and then reconnect the urethra and bladder (",
"     <a class=\"graphic graphic_figure graphicRef65675 \" href=\"mobipreview.htm?36/32/37382\">",
"      figure 1",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24313?source=see_link\">",
"      \"Radical prostatectomy for localized prostate cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The most common complications of prostatectomy are:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Urinary incontinence (leakage of urine)",
"      </li>",
"      <li>",
"       Erectile dysfunction (ED, difficulty having an erection)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There are two ways to perform prostatectomy: open and robotic.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Open prostatectomy requires an up-and-down incision (cut) that is three to four inches (7.5 to 10 cm) long, beginning from the top of the pubic bone.",
"      </li>",
"      <li>",
"       Robotic prostatectomy is done through several small incisions. Small instruments and a camera are placed through the incisions. The surgeon operates while looking at a monitor, which displays what is seen through the camera.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The likelihood of curing your cancer and having as few postsurgery complications as possible depends on the skill and experience of the surgeon, not whether the surgery is done open or with a robot. In experienced hands, issues like needing a blood transfusion, pain, time in the hospital, and return to full activity (about three weeks) are similar with both approaches. Asking about your surgeon's experience is important in getting a good result.",
"    </p>",
"    <p>",
"     Talk to your surgeon about the potential risks and benefits of all types of prostatectomies to determine which is right for you.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Radiation therapy (RT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Two forms of RT are used to treat prostate cancer: external beam RT and brachytherapy. These are sometimes used together.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      External beam radiation",
"     </span>",
"     &nbsp;&mdash;&nbsp;External beam RT (EBRT) uses a machine that moves around you, directing X-rays at the pelvis. EBRT is typically done daily five days per week, for five to eight weeks. Each treatment takes just a few minutes, and you can usually continue your normal activities during treatment. EBRT is sometimes used in combination with androgen deprivation therapy (see",
"     <a class=\"local\" href=\"#H19\">",
"      'Androgen deprivation therapy'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Possible side effects of EBRT include needing to run to the bathroom frequently to urinate, bladder pain, erectile dysfunction, and swelling and pain in the rectum (called proctitis). These symptoms are usually temporary. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=see_link\">",
"      \"External beam radiation therapy for localized prostate cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Brachytherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In brachytherapy, a doctor places a radioactive source directly into the prostate gland. There are two types of brachytherapy, both of which are done under anesthesia. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32824?source=see_link\">",
"      \"Brachytherapy for localized prostate cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       One type of brachytherapy, called low-dose rate, involves placing rice-size seeds, which emit radiation, into the prostate. The seeds gradually lose their radioactivity over time and are not removed.",
"      </li>",
"      <li>",
"       The second type of brachytherapy, called high-dose rate, involves temporarily implanting a radioactive source into the prostate gland, then removing it after one or two days. This treatment is done while you stay in the hospital and is usually combined with EBRT.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Men who undergo brachytherapy usually develop inflammation and swelling of the prostate gland, which can lead to urinary urgency and frequency (needing to rush to the bathroom to urinate frequently), burning with urination, and occasionally retention of urine (being unable to empty the bladder completely, which requires temporary use of a catheter). Less commonly, some men experience bowel urgency and frequency, rectal bleeding, and rectal ulcers. These problems usually resolve within a few weeks to months.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Active surveillance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some men choose to delay prostate cancer treatment, a strategy called active surveillance. During active surveillance, you may require one or more additional prostate biopsies, and you will be monitored carefully for signs of cancer growth with an exam and blood tests every three to six months. Your doctor may recommend that you begin treatment (surgery or radiation therapy) if the cancer begins to grow. Using this approach, you may be able to avoid or postpone treatment for long periods of time. Active surveillance may be a reasonable option if your cancer is very small and unlikely to grow quickly.",
"    </p>",
"    <p>",
"     Active surveillance is not generally recommended if you have a high-grade tumor or if your tumor has other features that make it likely to behave aggressively, making it hard to cure later. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13288?source=see_link\">",
"      \"Active surveillance for men with early prostate cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Androgen deprivation therapy (ADT)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Male hormones (androgens, the most common of which is testosterone) fuel the growth of prostate cancer. Treatments that decrease the body's levels of androgens (called androgen deprivation therapy, or ADT) decrease the size and slow the growth of prostate cancer. ADT can be done by taking medicines that interfere with androgens or by having surgery to remove the testicles (called an orchiectomy).",
"    </p>",
"    <p>",
"     ADT is not needed for men with small tumors that are unlikely to grow quickly. ADT might be recommended, in addition to external beam radiation therapy (EBRT), for men with intermediate and high-risk prostate cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Side effects of ADT",
"     </span>",
"     &nbsp;&mdash;&nbsp;The side effects of ADT are related to the lowered levels of male hormones and include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Decreased libido (sex drive) and difficulties with erection (erectile dysfunction)",
"      </li>",
"      <li>",
"       Hot flashes",
"      </li>",
"      <li>",
"       Enlargement of the breasts (called gynecomastia) (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/47/41713?source=see_link\">",
"        \"Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Loss of muscle and increase in body fat",
"      </li>",
"      <li>",
"       Thinning and weakening of the bones (called osteoporosis), which can increase the risk of bone fractures (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"        \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       An increased risk of developing type 2 diabetes",
"      </li>",
"      <li>",
"       Loss of muscle mass",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Many of these side effects are serious, and they might seem frightening. Not all men have these side effects. In addition, it is important to balance the risk of side effects with the risk of not using androgen deprivation, which could allow your cancer to grow or spread. In addition, there are ways to prevent or treat many of these side effects. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link\">",
"      \"Side effects of androgen deprivation therapy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      STAGE III (LOCALLY ADVANCED) PROSTATE CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Locally advanced prostate cancer has spread outside the prostate gland, to areas such as the seminal vesicles (",
"     <a class=\"graphic graphic_figure graphicRef65675 \" href=\"mobipreview.htm?36/32/37382\">",
"      figure 1",
"     </a>",
"     ). There is no one \"best\" treatment for locally advanced prostate cancer. Treatment often includes a combination of two approaches:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Radiation therapy with ADT",
"      </li>",
"      <li>",
"       Radical prostatectomy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link\">",
"      \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Radiation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radiation therapy involves the use of X-rays to destroy cancer cells. There are two forms of radiation therapy used to treat prostate cancer: external beam radiation therapy (EBRT) (see",
"     <a class=\"local\" href=\"#H11\">",
"      'External beam radiation'",
"     </a>",
"     above) and brachytherapy (see",
"     <a class=\"local\" href=\"#H12\">",
"      'Brachytherapy'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     Most men who have radiation therapy for locally advanced prostate cancer are also given androgen deprivation therapy (ADT) (see",
"     <a class=\"local\" href=\"#H19\">",
"      'Androgen deprivation therapy'",
"     </a>",
"     below). Having both treatments helps to control the cancer and improves the chance of survival. Most experts recommend treatment with ADT for at least two years after the radiation therapy is completed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Radical prostatectomy is a surgery that completely removes the prostate gland (see",
"     <a class=\"local\" href=\"#H9\">",
"      'Radical prostatectomy'",
"     </a>",
"     above) and has become more popular in recent years for stage III disease. After surgery, some men are treated with adjuvant radiotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Androgen deprivation therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Androgen deprivation therapy starves the cancer cells and causes the prostate gland to shrink. In men with locally advanced prostate cancer, ADT is usually given in combination with radiation therapy. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Androgen deprivation therapy (ADT)'",
"     </a>",
"     above.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      TREATMENT OF RISING PSA",
"     </span>",
"    </p>",
"    <p>",
"     After treatment for localized prostate cancer, experts advise follow-up testing to monitor for signs that the cancer has returned. This follow-up testing usually includes a blood test called PSA (prostate-specific antigen). The PSA test is very sensitive, meaning that the PSA may begin to rise well before you can see or feel that the cancer has returned. Many men with a rising PSA will not have any sign that the cancer has come back for many years (even 15 or more). Thus, not all men with a rising PSA need immediate treatment.",
"    </p>",
"    <p>",
"     However, in some men with a rising PSA, treatment is recommended to reduce the chance that the cancer will continue to grow or spread. Talk to your doctor or nurse to discuss your options. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link\">",
"      \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The best treatment for a rising PSA depends upon what treatment you had before.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Men who had radiation therapy initially are usually advised to have a prostate biopsy and imaging studies. If those tests show cancer has not grown beyond the prostate, surgery (salvage prostatectomy) or cryotherapy is advised. Cryotherapy is a treatment that freezes the tissue to destroy cancer cells. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1656?source=see_link\">",
"        \"Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Men who initially had prostate surgery are usually treated with radiation therapy. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"        \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Men who cannot have radiation therapy, surgery, or cryotherapy can be treated with androgen deprivation therapy. (See",
"       <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link\">",
"        \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHICH TREATMENT IS RIGHT FOR ME?",
"     </span>",
"    </p>",
"    <p>",
"     For men with early-stage (localized) prostate cancer, the decision between radiation therapy (RT) and surgery is largely a matter of preference. The choice also depends on the risk that the cancer will grow quickly or come back after treatment.",
"    </p>",
"    <p>",
"     The potential risks and complications of surgery, radiation therapy, and active surveillance are unique. The following tables list the advantages and disadvantages of each type of treatment (",
"     <a class=\"graphic graphic_table graphicRef77851 \" href=\"mobipreview.htm?22/54/23404\">",
"      table 1",
"     </a>",
"     and",
"     <a class=\"graphic graphic_table graphicRef60321 \" href=\"mobipreview.htm?6/60/7116\">",
"      table 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Localized (stage I to II) prostate cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Men who have small tumors that are unlikely to grow quickly have the option to have treatment (with surgery or radiation) or delay treatment (active surveillance). Men who are older or who have other serious illnesses might prefer active surveillance to surgery or radiation.",
"    </p>",
"    <p>",
"     Men who have moderate to large tumors or any size of tumor that could behave aggressively, making it hard to cure later, are usually encouraged to have treatment (surgery or radiation). Some men who have radiation therapy will also need androgen deprivation therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Locally advanced (stage III) prostate cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is no single best treatment for men with locally advanced prostate cancer. Most experts recommend a combination of either androgen deprivation therapy plus radiation therapy or surgery plus adjuvant radiotherapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Advanced prostate cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Treatment for advanced (stage IV) prostate cancer is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"      \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating prostate cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learning/\">",
"        www.cancer.gov/clinicaltrials/learning/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287462035\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292593480\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/3/2099?source=see_link\">",
"      Patient information: Prostate cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/27/32176?source=see_link\">",
"      Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/5/37970?source=see_link\">",
"      Patient information: Hydronephrosis in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/15/3315?source=see_link\">",
"      Patient information: Choosing treatment for low-risk localized prostate cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H292593542\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/55/38770?source=see_link\">",
"      Patient information: Prostate cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/51/28467?source=see_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/47/41713?source=see_link\">",
"      Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13288?source=see_link\">",
"      Active surveillance for men with early prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32824?source=see_link\">",
"      Brachytherapy for localized prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41736?source=see_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/63/43000?source=see_link\">",
"      Cryotherapy and other ablative techniques for the initial treatment of prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9704?source=see_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23290?source=see_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=see_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/52/24394?source=see_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/2/41001?source=see_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20405?source=see_link\">",
"      Investigational approaches for the treatment of advanced prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16969?source=see_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24313?source=see_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/39/1656?source=see_link\">",
"      Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/48/30470?source=see_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33544?source=see_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20983?source=see_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/types/prostate\">",
"      www.cancer.gov/cancertopics/types/prostate",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.org/index.asp\">",
"      file://www.nccn.org/index.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/prostatecancer.html\">",
"      www.nlm.nih.gov/medlineplus/prostatecancer.html",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where you can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     ) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/39/40565/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 6, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/39/40565?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40565/abstract/1\">",
"      Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40565/abstract/2\">",
"      Koch MO. Focal prostate therapy. J Urol 2008; 179:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40565/abstract/3\">",
"      Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25:1596.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f39_39_40565=[""].join("\n");
var outline_f39_39_40565=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PROSTATE CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PROSTATE CANCER DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           STAGE I TO II (LOCALIZED) PROSTATE CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           STAGE III (LOCALLY ADVANCED) PROSTATE CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           TREATMENT OF RISING PSA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHICH TREATMENT IS RIGHT FOR ME?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/32/37382\" title=\"figure 1\">",
"           Prostate anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/54/23404\" title=\"table 1\">",
"           Disadv prostate ca treat",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/60/7116\" title=\"table 2\">",
"           Adv prostate ca treat",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f39_39_40566="Candida endocarditis";
var content_f39_39_40566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Candida endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40566/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40566/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40566/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40566/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40566/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40566/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/39/40566/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida endocarditis is one of the most serious manifestations of candidiasis and is the most common cause of fungal endocarditis, causing over half of all cases. In a 2001 review of 270 cases of fungal endocarditis in the world literature, the following distribution of organisms was noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Candida albicans &mdash; 24 percent",
"     </li>",
"     <li>",
"      Non-albicans species of Candida &mdash; 28 percent",
"     </li>",
"     <li>",
"      Aspergillus species &mdash; 24 percent",
"     </li>",
"     <li>",
"      Histoplasma capsulatum &mdash; 6 percent",
"     </li>",
"     <li>",
"      Other &mdash; 17 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Candida endocarditis will be reviewed here. An overview of Candida infections, Candida pericarditis, and fungal endocarditis due to Aspergillus spp are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/40/18055?source=see_link&amp;anchor=H10#H10\">",
"     \"Candida infections of the abdomen and thorax\", section on 'Pericarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of Candida pericarditis, myocarditis, and suppurative thrombophlebitis are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef87681 \" href=\"mobipreview.htm?38/10/39084\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida endocarditis results from candidemia.",
"   </p>",
"   <p>",
"    Risk factors include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1-11\">",
"     1-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prosthetic heart valves or other valvular disease",
"     </li>",
"     <li>",
"      Intravenous drug use",
"     </li>",
"     <li>",
"      Indwelling central venous catheters",
"     </li>",
"     <li>",
"      Low birth weight in neonates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the International Collaboration on Endocarditis Prospective Cohort Study, 49 percent of cases of Candida endocarditis were in patients with prosthetic heart valves, compared with only 20 percent of cases of non-fungal endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/11\">",
"     11",
"    </a>",
"    ]. Additionally, Candida endocarditis, compared with non-fungal endocarditis, occurred significantly more often in patients who had a history of prior endocarditis (21 versus 8 percent), and in patients with healthcare associated infection (52 versus 26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/11\">",
"     11",
"    </a>",
"    ]. Prosthetic valve infection can occur at the time of surgery or later during an episode of candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/4\">",
"     4",
"    </a>",
"    ]. Contamination of an aortic valve allograft has been reported as the source for Candida prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Candida species vary in part with the population at risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida infection of a prosthetic valve usually occurs early in the postoperative period. C. albicans is the most common pathogen, with C. parapsilosis a distant second [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drug users most often have endocarditis due to C. albicans or C. parapsilosis. Those who use Iranian brown heroin and develop endocarditis almost always have C. albicans because the organism grows abundantly in the lemon juice that is used to cut the heroin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/7,9\">",
"       7,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The magnitude of risk of endocarditis in patients with candidemia who have prosthetic heart valves was illustrated in a review of 44 patients on a cardiothoracic surgery service who developed nosocomial candidemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/13\">",
"     13",
"    </a>",
"    ]. Seven patients were diagnosed with prosthetic valve endocarditis at the time of candidemia; among the remaining 37 patients, four (11 percent) developed endocarditis at a mean of 232 days (range 26 to 390 days) after candidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of Candida endocarditis include symptoms and signs of cardiac involvement (dyspnea, edema, chest pain, and new or changing murmurs on examination); embolic phenomena, often involving major vessels supplying the brain, extremities, and the gastrointestinal tract; and systemic symptoms of fever, night sweats, malaise, and weight loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arterial embolization is more common in fungal endocarditis than in bacterial endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], likely a reflection of the larger size of the vegetations associated with fungal endocarditis. The most common sites are the cerebral circulation, extremities, and the gastrointestinal tract. Classic signs of endocarditis, such as Osler's nodes, Roth's spots, and Janeway's lesions are infrequently noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with Candida endocarditis can develop other complications of candidemia, including endophthalmitis, vertebral osteomyelitis, and meningitis. Thus, all patients should be questioned about and examined for signs of other complications of candidemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of Candida endocarditis is often delayed. In one review, fungal endocarditis was characterized by a long duration of symptoms before hospitalization (mean 32 days), extracardiac manifestations, and delayed or missed diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for Candida endocarditis are similar to those for bacterial endocarditis. Blood cultures usually show persistent candidemia, and echocardiography frequently reveals valvular vegetations that are often large. Although transthoracic echocardiography can show vegetations, transesophageal echocardiography is more sensitive and especially useful in patients with prosthetic valve Candida endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of vegetations or an embolus by histopathology shows yeast forms and by culture yields Candida species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combined medical and surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon case reports, case series, and clinical experience, a combined approach that utilizes both antifungal agents and valve replacement is recommended in the 2009 Infectious Diseases Society of America guidelines for treatment of native and prosthetic valve Candida endocarditis (",
"    <a class=\"graphic graphic_table graphicRef87681 \" href=\"mobipreview.htm?38/10/39084\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/6,17-28\">",
"     6,17-28",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    There are conflicting data about the mortality rate associated with a combined medical and surgical approach compared with antifungal therapy alone. In a review of cases of fungal endocarditis that occurred between 1965 and 1995, the mortality rate of Candida endocarditis was 59 percent among those who received antifungal therapy alone and 42 percent among those who received combined surgical and antifungal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1\">",
"     1",
"    </a>",
"    ]. A subsequent meta-analysis of 72 of 163 patients who had Candida endocarditis between 1980 and 2002, also revealed that better outcomes were associated with a combined surgical and medical therapy approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/29\">",
"     29",
"    </a>",
"    ]. A subsequent series of 33 cases between 2001 and 2005 found that the mortality rate was similar in patients who received combined medical-surgical therapy and those who received antifungal therapy alone (33 versus 28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/11\">",
"     11",
"    </a>",
"    ]. The authors postulated that one explanation for the lack of improved outcomes in patients who underwent valve replacement was that they may have been more ill, thus biasing the results against surgical intervention.",
"   </p>",
"   <p>",
"    In a review of 64 reported cases of Candida endocarditis that were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    alone or combined with another antifungal agent but without surgical intervention, 4 relapses and 11 failures (26 percent) occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/30\">",
"     30",
"    </a>",
"    ]. Failures were higher in the 19 patients who received only fluconazole (42 percent) than in the group of 45 patients who received fluconazole plus another antifungal agent, usually an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation (16 percent). Outcomes were better in a comparison group of historical controls that had undergone valve replacement in addition to antifungal therapy (9 percent mortality). However, this comparison appears to be flawed, since the matching method and analysis were not presented in detail and the historical cohort consisted of only 23 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic regimen used most frequently is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    . Even though almost all of the reported experience is with amphotericin B deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily), most patients are now treated with a lipid formulation of amphotericin B at a dose of 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in order to reduce nephrotoxicity, and lipid formulations are preferred in the IDSA Candida guidelines.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally daily in four divided doses in patients with normal renal function) can be added for synergistic activity, but caution must be used to avoid dose-related bone marrow toxicity. Serum flucytosine levels should be monitored routinely, especially if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    -associated nephrotoxicity occurs, to keep peak serum drug levels &lt;75",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    If flucytosine levels cannot be obtained in a timely fashion and if the patient has renal failure, then the risks of using this agent may outweigh the benefits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used as monotherapy for Candida endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are case reports of successful treatment of Candida endocarditis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    , either alone or combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/27,28,31\">",
"     27,28,31",
"    </a>",
"    ]. Failure with development of resistance to caspofungin and other antifungal agents has also been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/32\">",
"     32",
"    </a>",
"    ]. The role of the echinocandins has not yet been clarified, but it seems reasonable that these agents, which are fungicidal against many species of Candida, could be used for endocarditis. The most appropriate dosage has not been studied, but higher dosages than normally used for candidemia have been suggested: caspofungin (up to 150 mg intravenously daily);",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/31/44532?source=see_link\">",
"     micafungin",
"    </a>",
"    (up to 150 mg intravenously daily); and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    (up to 200 mg intravenously daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resection of the valve and any associated abscesses is essential for cure in most, but not all, patients. Following surgery, antifungal therapy should be continued for at least six weeks. The preferred regimen is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef87681 \" href=\"mobipreview.htm?38/10/39084\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/2-6,16\">",
"     2-6,16",
"    </a>",
"    ]. After the patient's condition has stabilized and the blood cultures remain negative, therapy can be changed to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 to 800 mg [6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily) if the organism is susceptible to complete the course of therapy. Because of the high rates of relapse, many clinicians will treat for longer than six weeks. A total course longer than six weeks is particularly important in patients with perivalvular abscesses and other complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who cannot undergo surgical resection of the affected valve, initial treatment with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    formulation plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    followed by life-long suppression with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 to 800 mg [6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily) is recommended in the 2009 Infectious Diseases Society of America guidelines (",
"    <a class=\"graphic graphic_table graphicRef87681 \" href=\"mobipreview.htm?38/10/39084\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic suppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, all patients who cannot undergo surgical resection of the affected valve should receive life-long suppression with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 to 800 mg [6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    daily). Some clinicians will use long-term suppressive fluconazole therapy for months and even life-long (400 to 800 mg [6 to 12",
"    <span class=\"nowrap\">",
"     mg/kg]",
"    </span>",
"    orally daily) even when surgical resection has been performed because of the high relapse rate, especially in patients with complications of endocarditis, such as perivalvular abscesses, and those with Candida prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/4-6,33\">",
"     4-6,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with C. glabrata endocarditis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    should be used for chronic suppressive therapy if the organism is susceptible, and an echinocandin should be used if the organism is resistant to all oral agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A unique group in which antifungal therapy alone may be effective is that of neonates who have disseminated candidiasis with cardiac thrombi and vegetations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. The rate of success reported in a review of 30 neonates was 60 percent among the 20 patients treated with medical therapy alone, compared with 60 percent among the 10 patients treated with combined medical and surgical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In neonates with Candida endocarditis, we suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/16\">",
"     16",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     Flucytosine",
"    </a>",
"    may be added. Because there are few data about the safety and efficacy of flucytosine in neonates, a strong recommendation cannot be made to use this agent for this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/34\">",
"     34",
"    </a>",
"    ]. As with adults, after the patient has stabilized and the blood cultures are negative, one could change to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for susceptible organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses are common, even with surgical resection and treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1,2,4,5,33\">",
"     1,2,4,5,33",
"    </a>",
"    ]. For example, in one small case series, four of ten patients had a late relapse (mean 25 months) despite a combined therapy approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/4\">",
"     4",
"    </a>",
"    ]. Because of the risk of relapse, careful follow-up is essential, even after apparently successful therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an international multicenter prospective cohort study that included 33 cases of Candida endocarditis that were treated between 2000 and 2005, the mortality rate was 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/11\">",
"     11",
"    </a>",
"    ]. This is substantially lower than earlier mortality estimates of approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida endocarditis is one of the most serious manifestations of candidiasis and is the most common cause of fungal endocarditis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candida endocarditis results from candidemia. Risk factors include prosthetic heart valves or other valvular disease, intravenous drug use, indwelling central venous catheters, and low birth weight in neonates. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of Candida endocarditis include symptoms and signs of cardiac involvement (dyspnea, edema, chest pain, and new or changing murmurs on examination); embolic phenomena, often involving major vessels supplying the brain, extremities, and the gastrointestinal tract; and systemic symptoms of fever, night sweats, malaise, and weight loss. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic criteria for Candida endocarditis are similar to those for bacterial endocarditis. Blood cultures usually show persistent candidemia, and echocardiography frequently reveals valvular vegetations that are often large. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with native or prosthetic valve Candida endocarditis, we suggest a combined approach that utilizes both antifungal agents and valve replacement rather than antifungal therapy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Combined medical and surgical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For initial antifungal therapy of Candida endocarditis, we suggest a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      at a dose of 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally daily in four divided doses in patients with normal renal function) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Amphotericin B deoxycholate (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) can be used as an alternative to a lipid formulation of amphotericin B in patients if a lipid formulation is not available. Monotherapy with an echinocandin at a higher than usual dose is another acceptable alternative. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest step-down therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily) for patients who are infected with susceptible Candida spp and who are clinically stable and have cleared Candida from the bloodstream (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Treatment should be continued for at least six weeks following surgery. However, due to the high rates of relapse, especially in those who have a complication, such as a perivalvular abscess, many clinicians prefer to extend treatment longer than six weeks and follow clinical and laboratory parameters to decide on the total length of therapy. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial antifungal therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who cannot undergo surgical resection of the affected valve, initial treatment with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulation plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      should be followed by life-long suppression with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Chronic suppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neonates with candida endocarditis, in the absence of another indication for surgery we suggest antifungal therapy without valve replacement (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) is the drug of choice in neonates. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neonates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/1\">",
"      Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001; 32:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/2\">",
"      Pierrotti LC, Baddour LM. Fungal endocarditis, 1995-2000. Chest 2002; 122:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/3\">",
"      Mayayo E, Moralejo J, Camps J, Guarro J. Fungal endocarditis in premature infants: case report and review. Clin Infect Dis 1996; 22:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/4\">",
"      Muehrcke DD, Lytle BW, Cosgrove DM 3rd. Surgical and long-term antifungal therapy for fungal prosthetic valve endocarditis. Ann Thorac Surg 1995; 60:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/5\">",
"      Melgar GR, Nasser RM, Gordon SM, et al. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore) 1997; 76:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/6\">",
"      Nguyen MH, Nguyen ML, Yu VL, et al. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis 1996; 22:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/7\">",
"      Mir&oacute; JM, Puig de la Bellacasa J, Odds FC, et al. Systemic candidiasis in Spanish heroin addicts: a possible source of infection. J Infect Dis 1987; 156:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/8\">",
"      Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001; 32:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/9\">",
"      Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/10\">",
"      Levy I, Shalit I, Birk E, et al. Candida endocarditis in neonates: report of five cases and review of the literature. Mycoses 2006; 49:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/11\">",
"      Baddley JW, Benjamin DK Jr, Patel M, et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/12\">",
"      Kuehnert MJ, Clark E, Lockhart SR, et al. Candida albicans endocarditis associated with a contaminated aortic valve allograft: implications for regulation of allograft processing. Clin Infect Dis 1998; 27:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/13\">",
"      Nasser RM, Melgar GR, Longworth DL, Gordon SM. Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 1997; 103:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/14\">",
"      Rubinstein E, Noriega ER, Simberkoff MS, et al. Fungal endocarditis: analysis of 24 cases and review of the literature. Medicine (Baltimore) 1975; 54:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/15\">",
"      Ellis M. Fungal endocarditis. J Infect 1997; 35:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/16\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/17\">",
"      Melamed R, Leibovitz E, Abramson O, et al. Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome). Scand J Infect Dis 2000; 32:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/18\">",
"      Czwerwiec FS, Bilsker MS, Kamerman ML, Bisno AL. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am J Med 1993; 94:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/19\">",
"      Lejko-Zupanc T, Kozelj M. A case of recurrent Candida parapsilosis prosthetic valve endocarditis: cure by medical treatment alone. J Infect 1997; 35:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/20\">",
"      Aaron L, Therby A, Viard JP, et al. Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis. Scand J Infect Dis 2003; 35:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/21\">",
"      Zahid MA, Klotz SA, Hinthorn DR. Medical treatment of recurrent candidemia in a patient with probable Candida parapsilosis prosthetic valve endocarditis. Chest 1994; 105:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/22\">",
"      Castiglia, M, Smego, RA Jr, Sames, EL. Candida endocarditis and amphotericin B intolerance: potential role for fluconazole. Infect Dis Clin Pract 1994; 3:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/23\">",
"      Wells CJ, Leech GJ, Lever AM, Wansbrough-Jones MH. Treatment of native valve Candida endocarditis with fluconazole. J Infect 1995; 31:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/24\">",
"      Venditti M, De Bernardis F, Micozzi A, et al. Fluconazole treatment of catheter-related right-sided endocarditis caused by Candida albicans and associated with endophthalmitis and folliculitis. Clin Infect Dis 1992; 14:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/25\">",
"      Mayrer AR, Brown A, Weintraub RA, et al. Successful medical therapy for endocarditis due to Candida parapsilosis. A clinical and epidemiologic study. Chest 1978; 73:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/26\">",
"      Westling K, Thalme A, Julander I. Candida albicans tricuspid valve endocarditis in an intravenous drug addict: successful treatment with fluconazole. Scand J Infect Dis 2005; 37:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/27\">",
"      Jim&eacute;nez-Exp&oacute;sito MJ, Torres G, Barald&eacute;s A, et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004; 39:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/28\">",
"      Rajendram R, Alp NJ, Mitchell AR, et al. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis 2005; 40:e72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/29\">",
"      Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 2005; 51:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/30\">",
"      Smego RA Jr, Ahmad H. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis. Medicine (Baltimore) 2011; 90:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/31\">",
"      Talarmin JP, Boutoille D, Tattevin P, et al. Candida endocarditis: role of new antifungal agents. Mycoses 2009; 52:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/32\">",
"      Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005; 49:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/33\">",
"      Gilbert HM, Peters ED, Lang SJ, Hartman BJ. Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin Infect Dis 1996; 22:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40566/abstract/34\">",
"      Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990; 116:791.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2423 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40566=[""].join("\n");
var outline_f39_39_40566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combined medical and surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic suppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2423|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/10/39084\" title=\"table 1\">",
"      Treatment of Candida cardiovascular infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/40/18055?source=related_link\">",
"      Candida infections of the abdomen and thorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_39_40567="Calcium and phosphorus requirements of newborn infants";
var content_f39_39_40567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Calcium and phosphorus requirements of newborn infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40567/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40567/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40567/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40567/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40567/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40567/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/39/40567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium (Ca) and phosphorus (P) are essential minerals for two reasons: they are critical for the structural integrity of bone; and calcium and inorganic phosphorus ions in the cellular and extracellular fluid play an important role in many biochemical processes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=see_link\">",
"     \"Etiology of hypocalcemia in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CALCIUM HOMEOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium homeostasis is a function of dietary intake, intestinal absorption, skeletal accretion and resorption, and urinary excretion. Most of the body calcium and much of the phosphate exist as hydroxyapatite, Ca10(PO4)6(OH)2, the main mineral component of bone.",
"   </p>",
"   <p>",
"    Within the plasma, both Ca and P circulate in different forms. Of the plasma Ca, for example, roughly 40 percent is bound to serum proteins, principally albumin; 10 percent is complexed with citrate, bicarbonate, sulfate, or phosphate; and 50 percent exists as the physiologically important ionized (or free) calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although only a small fraction of the total body Ca and P is located in the plasma, the plasma concentrations of ionized Ca and inorganic P are the ones under hormonal control. This function is mediated primarily by parathyroid hormone (PTH) and vitamin D metabolites, which affect intestinal absorption, bone formation and resorption, and urinary excretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the effects of PTH and vitamin D, bone resorption of Ca is affected by certain medications. As an example, vitamin A and synthetic retinoids increase bone resorption.",
"   </p>",
"   <p>",
"    The primary function of renal excretion of Ca is the maintenance of overall Ca balance, not the plasma calcium concentration, which is regulated by changes in bone resorption via the effects of PTH and vitamin D. Parathyroid hormone reduces urinary Ca excretion, an appropriate response if hypocalcemia has stimulated parathyroid hormone secretion. Diuretics also affect Ca excretion, which is increased by loop diuretics and reduced by thiazide diuretics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CALCIUM AND PHOSPHORUS IN HUMAN MILK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human milk has slightly greater concentrations of minerals after a term birth than after a preterm birth. Compared to preterm human milk, term human milk contains more Ca (7 versus 6.25",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [280 versus 250",
"    <span class=\"nowrap\">",
"     mg/L])",
"    </span>",
"    and P (4.8 versus 4.5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    [150 versus 140",
"    <span class=\"nowrap\">",
"     mg/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/5\">",
"     5",
"    </a>",
"    ]. The Ca and P exist in ionized and complexed forms that are readily absorbed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Estimation of dietary calcium requirement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factorial method is used to determine the appropriate intake for a particular nutrient, such as calcium. This approach includes a summary of the nutrients provided and an estimate of nutrient losses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/6\">",
"     6",
"    </a>",
"    ]. It also accounts for the bioavailability of the particular nutrient, which may be affected by incomplete absorption.",
"   </p>",
"   <p>",
"    In the following example, the factorial approach is used to estimate Ca intake in formula typical for very low-birth-weight (VLBW) infants.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Net Ca deposition &mdash; 105",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Urinary losses &mdash; 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Cutaneous losses &mdash; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Subtotal net Ca requirement &mdash; 112",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"     <li>",
"      Interindividual variability &mdash; 10 percent",
"     </li>",
"     <li>",
"      Net absorption of dietary Ca &mdash; 50 percent",
"     </li>",
"     <li>",
"      Total calcium intake to meet requirement &mdash; 246",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REQUIREMENTS IN PRETERM INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accretion of Ca and P rises exponentially during the third trimester because of the high rate of intrauterine growth. Chemical analyses of fetal cadavers during the last trimester of pregnancy have been used to estimate the rate of nutrient accretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These data have been computed on a daily basis per kilogram body weight. The estimated intrauterine accretion rates for Ca and P are 105",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and 70",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    The requirements for Ca and P intake in preterm infants attempt to meet the rate of intrauterine accretion and account for nutrient losses. Preterm infants who have inadequate mineral intake develop metabolic bone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Osteopenia of prematurity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mineral inadequacy of human milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The content of Ca and P in human milk is insufficient for VLBW infants to achieve intrauterine accretion rates or normal bone mineralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/6,9-12\">",
"     6,9-12",
"    </a>",
"    ]. This condition was illustrated in a study of extremely low-birth-weight infants fed human milk; bone mineralization measured by photon absorptiometry was reduced, and one-third of the infants had rickets or fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/13\">",
"     13",
"    </a>",
"    ]. Biochemical markers of deficient mineral intake included low serum and urine phosphorus concentrations, elevated serum alkaline phosphatase activity, and elevated serum and urine calcium concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/10,11,14-16\">",
"     10,11,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most VLBW infants fed unsupplemented human milk have elevated serum alkaline phosphatase activity, indicating stimulation of bone resorption to normalize the serum Ca concentration. In one study of 865 preterm infants, infants fed unsupplemented human milk had elevated serum alkaline phosphatase activity, indicating stimulation of bone resorption to normalize the serum Ca concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/15\">",
"     15",
"    </a>",
"    ]. In this series, newborns with peak alkaline phosphatase activity &gt;1200",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    had 1.6 cm less linear growth at 18 months and shorter stature at 9 to 12 years of age than those with lower levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Supplementation of human milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplementation of human milk with Ca and P improves linear growth; increases bone mineralization during hospitalization and after discharge; and normalizes serum calcium, phosphorus, and alkaline phosphatase activity and urinary excretion calcium and phosphorus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/15,16,18,19\">",
"     15,16,18,19",
"    </a>",
"    ]. Net mineral retention and bone mineral content are improved with increased intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/20\">",
"     20",
"    </a>",
"    ]. Bone mineral content was similar when Ca and P were added to a multinutrient fortifier or given alone, although the multinutrient formulation resulted in better linear growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For VLBW infants, we recommend the addition of elemental Ca (2 to 3",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    per day",
"    <strong>",
"     or",
"    </strong>",
"    80 to 120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and P (1.5 to 2",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    per day",
"    <strong>",
"     or",
"    </strong>",
"    45 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) to human milk, so that infants receive the recommended intake of 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of calcium and 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    after enteral feeding is established. Current commercial human milk fortifiers provide stable suspensions of these minerals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/458?source=see_link&amp;anchor=H14#H14\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\", section on 'Calcium and phosphorus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23655?source=see_link&amp;anchor=H15#H15\">",
"     \"Human milk feeding and fortification of human milk for premature infants\", section on 'Commercial fortifiers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Premature formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature formulas currently available in the United States administered to provide",
"    <span class=\"nowrap\">",
"     120kcal/kg",
"    </span>",
"    per day provide daily intakes of approximately 5",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    Ca and 3",
"    <span class=\"nowrap\">",
"     mmol/kg",
"    </span>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    P. Absorption of these minerals allows the infant to accrete minerals at the approximate intrauterine accretion levels&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/22\">",
"     22",
"    </a>",
"    ]. However, quantities of Ca and P in formulas for term infants and other specialized (not premature) formulas are generally not adequate to meet the mineral needs of VLBW infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absorption of Ca from human milk or commercial formula is approximately 60 percent of intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/22\">",
"     22",
"    </a>",
"    ], whereas the absorption of P is greater in human milk than in commercial formula (90 versus 80 percent). P retention is improved when the ratio of Ca to P intake is 1.6:1 to 1.8:1 compared to 2:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/23\">",
"     23",
"    </a>",
"    ]. Absorption of both minerals is affected by postnatal age and the intake of Ca, P, lactose, fat, and vitamin D&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/24\">",
"     24",
"    </a>",
"    ]. However, vitamin D may contribute little to Ca absorption in premature infants in the first weeks of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Parenteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mineral accretion is inadequate in VLBW infants who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    for more than two weeks. This is related in part to the need to limit mineral concentrations because of their solubility in parenteral nutrition solutions. However, increased administration of Ca and P improves mineral retention. As an example, in a study of 24 VLBW infants receiving total parenteral nutrition, administration of 17",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (680",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    Ca and 20",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (660",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    P resulted in net retention of 70 to 80",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day Ca and P [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended mineral concentrations for parenteral nutrition solutions depend upon the duration of therapy. When parenteral nutrition is given to VLBW infants for less than two weeks, solutions should contain Ca 15",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (600",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    and P 15",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (465",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    and be given at rates of 120 to 130",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/22\">",
"     22",
"    </a>",
"    ]. Mineral concentrations are increased to Ca 20",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (800",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    and P 20",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (620",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    when parenteral nutrition is given at 120 to 130",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day for more than two weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/50/27434?source=see_link&amp;anchor=H17#H17\">",
"     \"Parenteral nutrition in premature infants\", section on 'Calcium, phosphorus, and magnesium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     After discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sufficient Ca and P must be provided for premature infants during hospitalization to maintain adequate bone mineral content. After discharge, continued supplementation may be needed. In a randomized trial, 59 premature infants who received formula with calcium content of 545, 660, or 1290",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    for eight weeks after discharge had greater gains in weight and length and lower serum alkaline phosphatase values than did those fed human milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/27\">",
"     27",
"    </a>",
"    ]. Infants who received the formula with the highest calcium concentration had the highest bone mineral density. Infants who received human milk had the lowest bone mineral content. In another study, bone mineral content was greater at nine months corrected age in preterm infants taking formula with a Ca concentration of 700",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    compared to 350",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of formula feeding on mineral status appears to dissipate over time, with a catch-up in bone mineral density by two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/29\">",
"     29",
"    </a>",
"    ]. However, a mineral-enriched formula may be indicated after discharge in selected patients with elevated alkaline phosphatase and low serum phosphorus, especially in infants with birth weights &lt;1500 g [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growth is closely monitored in VLBW infants who are discharged feeding human milk exclusively. Possible mineral deficiency is assessed after four to eight weeks by measuring serum phosphorus concentration and alkaline phosphatase activity. If these values are abnormal, a radiograph of the long bones is obtained to assess mineralization. Mineral supplementation is provided if osteopenia is detected on the bone films. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Osteopenia of prematurity'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Supplemental minerals can be provided by several methods. One approach is to give formula with a high mineral content instead of human milk for multiple feedings each day. Typically, this is done for two to three feedings, but no studies have been done to evaluate different approaches. As an alternative, a human milk fortifier is added to the breast milk, which is given by bottle; this method has not been studied in infants after discharge. The last approach is less preferable because of concerns about the use of powdered infant formula and difficulties in accurately fortifying milk. In rare circumstances, such as cow milk protein allergy, use of special formulas or human milk fortifier is not feasible; in this setting, calcium and phosphorus supplements can be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OSTEOPENIA OF PREMATURITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia of prematurity, also called metabolic bone disease of prematurity, is defined as postnatal bone mineralization that is less than intrauterine bone density at a comparable gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/22,33,34\">",
"     22,33,34",
"    </a>",
"    ]. Osteopenia occurs commonly in preterm infants; the incidence and severity increase with decreasing birth weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/35\">",
"     35",
"    </a>",
"    ]. Characteristic radiographic changes are seen in 55 percent of infants with birth weight &lt;1000 g [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/34\">",
"     34",
"    </a>",
"    ]. High bone turnover appears to be more important than decreased bone formation in the pathogenesis of this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to immaturity, the major predisposing factor is deficiency of Ca and P because of inadequate intake. Other risk factors include prolonged parenteral nutrition and medications that affect mineral metabolism, such as caffeine, loop diuretics, and corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/38\">",
"     38",
"    </a>",
"    ]. Decreased bone mineralization also occurs in infants who are small-for-gestational age or are born to diabetic mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia typically develops in premature infants at 3 to 12 weeks of age. The condition is not clinically apparent and is detected by routine laboratory monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Laboratory features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest indications of osteopenia are decreased serum phosphorus concentration, typically less than 3.5 to 4.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1 to 1.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and increased alkaline phosphatase activity. Alkaline phosphatase values &gt;800",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    are worrisome, especially if combined with serum phosphorus values less than 4.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    However, distinguishing the normal rise in alkaline phosphatase activity associated with rapid bone mineralization from the pathologic increase related to early osteopenia often is difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/41\">",
"     41",
"    </a>",
"    ]. In this circumstance, decreased bone mineralization observed on a radiograph confirms the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Radiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic feature characteristic of osteopenia is decreased lucency of the cortical bone with or without epiphyseal changes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52881 \" href=\"mobipreview.htm?18/32/18959\">",
"     image 1",
"    </a>",
"    ). Although most infants with decreased bone mineralization do not have fractures even when osteopenia is severe, in some cases, a fracture can be the earliest sign. In a multicenter retrospective study of chest radiographs of infants born at &lt;37 weeks gestation, rib fractures were identified in 26 of 1446 infants (1.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/42\">",
"     42",
"    </a>",
"    ]. The median age at the time of detection was 14 weeks, and the median corrected gestational age was 39 weeks. The median number of fractures per infant was two and about one-third of the fractures were located posteriorly (27 of 62 fractures). Rib fractures were attributed to osteopenia of prematurity in two-thirds of the patients (n = 17 patients), of whom 15 had posterior rib fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend routine monitoring of the serum phosphorus concentration and alkaline phosphatase activity in all infants with birth weight &lt;1500 g. Studies are obtained at two week intervals until full feeds are achieved and stable values are demonstrated. Infants with additional risk factors for osteopenia, such as prolonged parenteral nutrition or inadequate enteral intake of Ca and P, are tested weekly. If these laboratory values are abnormal, we obtain radiographs of the wrist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    knees to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia of prematurity is treated by providing adequate Ca and P for bone mineralization through feeding fortified human milk or premature formula (see above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/20,39\">",
"     20,39",
"    </a>",
"    ]. Infants who do not tolerate human milk fortifiers or premature formula because of lactose intolerance or cow's milk protein allergy should be given supplements of calcium and phosphorus. The maximum allowable parenteral mineral concentrations should be provided to infants not receiving enteral feeding. Vitamin D supplementation is rarely indicated for this condition. Total daily doses of 200 to 400",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    are adequate, although some (especially European centers) prefer a higher dose of 800 to 1000",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/43\">",
"     43",
"    </a>",
"    ]. We recommend providing a dose of 400",
"    <span class=\"nowrap\">",
"     IU/day",
"    </span>",
"    to a preterm infant when",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    reaches a body weight of 2000 g.",
"   </p>",
"   <p>",
"    Infants with severe cholestasis or other chronic illnesses may need prolonged supplementation with high doses of Ca, P and vitamin D. Vitamin D may need to be given as the active form, calcitriol (1,25 dihydroxy vitamin D), with appropriate monitoring of serum calcium to avoid hypercalcemia. Premature infants with fractures resulting from osteopenia are managed conservatively with supplemental minerals and vitamin D, but not with surgical intervention.",
"   </p>",
"   <p>",
"    Most infants who receive increased enteral or parenteral mineral supplementation have improved radiographic findings after several weeks. Serum P concentration and alkaline phosphatase activity also become normal during this period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CALCIUM REQUIREMENTS IN TERM INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk from their own mothers is the optimal nutritional source for term infants during the first year after birth and provides adequate amounts of Ca and P. The amounts of Ca and P retained by the term infant who is exclusively breastfed during the first six months and is supplemented with solid foods during the second six months result in appropriate bone mineralization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Need for vitamin D supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the amounts of Ca and P are adequate, human milk is not a primary source of vitamin D for infants. Rather, sunlight exposure is needed to provide for the cutaneous formation of vitamin D. As a result, rickets can occur in breastfed infants who have inadequate exposure to sunlight or are deeply pigmented.",
"   </p>",
"   <p>",
"    Thus, the American Academy of Pediatrics recommends that breastfed infants receive supplementation of vitamin D in a dose of 400 IU per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/44\">",
"     44",
"    </a>",
"    ]. Although infant formula is supplemented with vitamin D (400",
"    <span class=\"nowrap\">",
"     IU/L),",
"    </span>",
"    infants who ingest less than 1000 mL of vitamin D fortified formula also require supplementation in order to reach the recommended daily vitamin D dose of 400 IU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/45\">",
"     45",
"    </a>",
"    ]. In the United States, compliance with these vitamin D supplementation guidelines is poor and less than 15 percent of breastfed infants receive appropriate amounts of vitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=see_link&amp;anchor=H723639#H723639\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\", section on 'Vitamin D supplementation for infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ca and P in formula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentrations of Ca and P in infant formulas are greater than in human milk to compensate for the possibility of reduced absorption of these minerals with formula feeding. Infants fed cow's milk-based formulas may have calcium retention, which considerably exceeds that of breast-fed infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/47\">",
"     47",
"    </a>",
"    ]. The potential benefits of high levels of minerals in infant formulas on short and long-term bone mineralization are uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40567/abstract/14\">",
"     14",
"    </a>",
"    ]. There are no proven advantages to increasing bone mineralization or calcium retention in full-term infants relative to that achieved by breast-fed infants.",
"   </p>",
"   <p>",
"    The bioavailability of Ca and P in the specialized formulas that contain soy or casein hydrolysates is less than in standard formulas. Thus, these special preparations have even greater concentrations of Ca and P.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H644081\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium (Ca) and phosphorus (P) are essential minerals as they play critical roles in the structural integrity of bone and growth, and in cellular and extracellular biochemical processes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ca homeostasis is based upon the net effects of dietary intake, intestinal absorption, skeletal accretion and resorption, and urinary excretion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Calcium homeostasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Ca concentration is greater in human milk from mothers after term delivery compared with preterm delivery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Calcium and phosphorus in human milk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The requirement of both Ca and P is greater in preterm infants compared with term infants because of the high rate of accretion needed for growth. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Requirements in preterm infants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In preterm infants who are breastfed, Ca and P supplementation is required because preterm human milk is inadequate to meet the needs of these infants. We recommend the addition of elemental Ca (2 to 3",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      per day or 80 to 120",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and P (1.5 to 2",
"      <span class=\"nowrap\">",
"       mmol/kg",
"      </span>",
"      per day or 45 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) to human milk after enteral feeding is established. Current commercial human milk fortifiers provide stable suspensions of these minerals. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Supplementation of human milk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In preterm infants who are formula-fed, preterm formula in a volume of 120 to 150",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      provide adequate Ca and P intake. However, formulas for term infants do not adequately meet the mineral needs of premature infants. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Premature formula'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In preterm infants who receive parenteral nutrition, the requirement of Ca and P is dependent upon the length of parenteral nutrition. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Parenteral nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After discharge, Ca and P supplementation may still be required. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'After discharge'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inadequate Ca and P intake increases the risk of osteopenia of prematurity (ie, postnatal bone mineralization that is less than intrauterine bone density at a comparable gestational age). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Osteopenia of prematurity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Term human milk and term formula has adequate concentrations of Ca and P to meet the needs of term infants. However, in exclusively breast-fed infants, vitamin D supplementation (dose of 400 IU per day) is recommended because of the concern of inadequate vitamin D intake. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Calcium requirements in term infants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Marx, SJ, Bourdeau, JE. Calcium metabolism. In: Clinical Disorders of Fluid and Electrolyte Metabolism, 4th ed, Maxwell, MH, Kleeman, CR, Narins, RG (Eds), McGraw-Hill, New York 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/2\">",
"      Holick MF. Vitamin D and the kidney. Kidney Int 1987; 32:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/3\">",
"      Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/4\">",
"      Salle BL, Delvin EE, Lapillonne A, et al. Perinatal metabolism of vitamin D. Am J Clin Nutr 2000; 71:1317S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/5\">",
"      Butte NF, Garza C, Johnson CA, et al. Longitudinal changes in milk composition of mothers delivering preterm and term infants. Early Hum Dev 1984; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     Ziegler EE, Biga RL, Fomon SJ. Nutritional requirements of the premature infant. In: Textbook of Pediatric Nutrition, Suskind RM (Ed), Raven Press, New York 1981. p.29.",
"    </li>",
"    <li>",
"     Widdowson EM. Importance of nutrition in development, with special reference to feeding low-birth-weight infants. In: Meeting Nutritional Goals for Low-Birth-Weight Infants, Sauls HS, Bachhuber WL, Lewis LA (Eds), Ross Laboratories, Columbus 1982. p.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/8\">",
"      Ziegler EE, O'Donnell AM, Nelson SE, Fomon SJ. Body composition of the reference fetus. Growth 1976; 40:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/9\">",
"      Schanler RJ, Oh W. Composition of breast milk obtained from mothers of premature infants as compared to breast milk obtained from donors. J Pediatr 1980; 96:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/10\">",
"      Atkinson SA, Radde IC, Anderson GH. Macromineral balances in premature infants fed their own mothers' milk or formula. J Pediatr 1983; 102:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/11\">",
"      Schanler, RJ. Calcium and phosphorus absorption and retention in preterm infants. Exp Med 1991; 2:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/12\">",
"      Butte NF, Garza C, Smith EO, Nichols BL. Human milk intake and growth in exclusively breast-fed infants. J Pediatr 1984; 104:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/13\">",
"      Koo WW, Sherman R, Succop P, et al. Sequential bone mineral content in small preterm infants with and without fractures and rickets. J Bone Miner Res 1988; 3:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/14\">",
"      Specker BL, Beck A, Kalkwarf H, Ho M. Randomized trial of varying mineral intake on total body bone mineral accretion during the first year of life. Pediatrics 1997; 99:E12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/15\">",
"      Lucas A, Brooke OG, Baker BA, et al. High alkaline phosphatase activity and growth in preterm neonates. Arch Dis Child 1989; 64:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/16\">",
"      Rowe JC, Wood DH, Rowe DW, Raisz LG. Nutritional hypophosphatemic rickets in a premature infant fed breast milk. N Engl J Med 1979; 300:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/17\">",
"      Fewtrell MS, Cole TJ, Bishop NJ, Lucas A. Neonatal factors predicting childhood height in preterm infants: evidence for a persisting effect of early metabolic bone disease? J Pediatr 2000; 137:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/18\">",
"      Abrams SA, Schanler RJ, Tsang RC, Garza C. Bone mineralization in former very low birth weight infants fed either human milk or commercial formula: one-year follow-up observation. J Pediatr 1989; 114:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/19\">",
"      Abrams SA, Schanler RJ, Garza C. Bone mineralization in former very low birth weight infants fed either human milk or commercial formula. J Pediatr 1988; 112:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/20\">",
"      Schanler RJ, Abrams SA. Postnatal attainment of intrauterine macromineral accretion rates in low birth weight infants fed fortified human milk. J Pediatr 1995; 126:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/21\">",
"      Wauben IP, Atkinson SA, Grad TL, et al. Moderate nutrient supplementation of mother's milk for preterm infants supports adequate bone mass and short-term growth: a randomized, controlled trial. Am J Clin Nutr 1998; 67:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/22\">",
"      Schanler RJ, Rifka M. Calcium, phosphorus and magnesium needs for the low-birth-weight infant. Acta Paediatr Suppl 1994; 405:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/23\">",
"      Mize CE, Uauy R, Waidelich D, et al. Effect of phosphorus supply on mineral balance at high calcium intakes in very low birth weight infants. Am J Clin Nutr 1995; 62:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/24\">",
"      Abrams SA, Esteban NV, Vieira NE, Yergey AL. Dual tracer stable isotopic assessment of calcium absorption and endogenous fecal excretion in low birth weight infants. Pediatr Res 1991; 29:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/25\">",
"      Bronner F, Salle BL, Putet G, et al. Net calcium absorption in premature infants: results of 103 metabolic balance studies. Am J Clin Nutr 1992; 56:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/26\">",
"      Prestridge LL, Schanler RJ, Shulman RJ, et al. Effect of parenteral calcium and phosphorus therapy on mineral retention and bone mineral content in very low birth weight infants. J Pediatr 1993; 122:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/27\">",
"      Chan GM. Growth and bone mineral status of discharged very low birth weight infants fed different formulas or human milk. J Pediatr 1993; 123:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/28\">",
"      Bishop NJ, King FJ, Lucas A. Increased bone mineral content of preterm infants fed with a nutrient enriched formula after discharge from hospital. Arch Dis Child 1993; 68:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/29\">",
"      Schanler RJ, Burns PA, Abrams SA, Garza C. Bone mineralization outcomes in human milk-fed preterm infants. Pediatr Res 1992; 31:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/30\">",
"      Cooke RJ, Embleton ND, Griffin IJ, et al. Feeding preterm infants after hospital discharge: growth and development at 18 months of age. Pediatr Res 2001; 49:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/31\">",
"      Carver JD, Wu PY, Hall RT, et al. Growth of preterm infants fed nutrient-enriched or term formula after hospital discharge. Pediatrics 2001; 107:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/32\">",
"      Lucas A, Fewtrell MS, Morley R, et al. Randomized trial of nutrient-enriched formula versus standard formula for postdischarge preterm infants. Pediatrics 2001; 108:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/33\">",
"      Steichen JJ, Gratton TL, Tsang RC. Osteopenia of prematurity: the cause and possible treatment. J Pediatr 1980; 96:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/34\">",
"      Backstr&ouml;m MC, Kuusela AL, M&auml;ki R. Metabolic bone disease of prematurity. Ann Med 1996; 28:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/35\">",
"      Rigo J, De Curtis M, Pieltain C, et al. Bone mineral metabolism in the micropremie. Clin Perinatol 2000; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/36\">",
"      Tsukahara H, Takeuchi M, Fujisawa K, et al. High-turnover osteopenia in preterm infants: determination of urinary pyridinium cross-links of collagen. Metabolism 1998; 47:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/37\">",
"      Naylor KE, Eastell R, Shattuck KE, et al. Bone turnover in preterm infants. Pediatr Res 1999; 45:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/38\">",
"      Atkinson SA. Calcium and phosphorus needs of premature infants. Nutrition 1994; 10:66.",
"     </a>",
"    </li>",
"    <li>",
"     Abrams, SA. Enteral feeding of the preterm infant: An update of recent findings. In: Baillieres Clinical Paediatrics: Nutritional Support, Ryan, S (Ed), Bailliere Tindall, London, 1997, p. 305.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/40\">",
"      Palacios J, Rodr&iacute;guez S, Rodr&iacute;guez JI. Intra-uterine long bone growth in small-for-gestational-age infants. Eur J Pediatr 1992; 151:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/41\">",
"      Walters EG, Murphy JF, Henry P, et al. Plasma alkaline phosphatase activity and its relation to rickets in pre-term infants. Ann Clin Biochem 1986; 23 ( Pt 6):652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/42\">",
"      Lucas-Herald A, Butler S, Mactier H, et al. Prevalence and characteristics of rib fractures in ex-preterm infants. Pediatrics 2012; 130:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/43\">",
"      Rigo J, Pieltain C, Salle B, Senterre J. Enteral calcium, phosphate and vitamin D requirements and bone mineralization in preterm infants. Acta Paediatr 2007; 96:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/44\">",
"      Dietary reference intakes for calcium and vitamin d. Pediatrics 2012; 130:e1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/45\">",
"      Abrams SA. Dietary guidelines for calcium and vitamin D: a new era. Pediatrics 2011; 127:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/46\">",
"      Perrine CG, Sharma AJ, Jefferds ME, et al. Adherence to vitamin D recommendations among US infants. Pediatrics 2010; 125:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40567/abstract/47\">",
"      Abrams SA, Griffin IJ, Davila PM. Calcium and zinc absorption from lactose-containing and lactose-free infant formulas. Am J Clin Nutr 2002; 76:442.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5056 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40567=[""].join("\n");
var outline_f39_39_40567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H644081\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CALCIUM HOMEOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CALCIUM AND PHOSPHORUS IN HUMAN MILK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Estimation of dietary calcium requirement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REQUIREMENTS IN PRETERM INFANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mineral inadequacy of human milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Supplementation of human milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Premature formula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Parenteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      After discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OSTEOPENIA OF PREMATURITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Laboratory features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Radiographic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CALCIUM REQUIREMENTS IN TERM INFANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Need for vitamin D supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ca and P in formula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H644081\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5056|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?18/32/18959\" title=\"diagnostic image 1\">",
"      Osteopenia of prematurity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35209?source=related_link\">",
"      Etiology of hypocalcemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/6/23655?source=related_link\">",
"      Human milk feeding and fortification of human milk for premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/458?source=related_link\">",
"      Nutritional composition of human milk and preterm formula for the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/50/27434?source=related_link\">",
"      Parenteral nutrition in premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_39_40568="Epidemiology and pathogenesis of the polycystic ovary syndrome in adults";
var content_f39_39_40568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40568/contributors\">",
"     Ricardo Azziz, MD, MBA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40568/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40568/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/39/40568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS), a heterogeneous disorder of unclear etiology, is an important cause of both ovulatory and menstrual irregularity and androgen excess in women. When fully expressed, the manifestations include ovulatory dysfunction, androgen excess, and polycystic ovaries. It is recognized as one of the most common",
"    <span class=\"nowrap\">",
"     endocrine/metabolic",
"    </span>",
"    disorders of women. This syndrome was first described by Stein and Leventhal in 1935 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/1\">",
"     1",
"    </a>",
"    ], although the presence of sclerocystic ovaries had been recognized for at least 90 years prior to their report.",
"   </p>",
"   <p>",
"    The definition, pathogenesis, and etiology of PCOS will be reviewed here. The clinical manifestations, diagnosis, and treatment of PCOS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal features of PCOS include androgen excess, ovulatory dysfunction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polycystic ovaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/2\">",
"     2",
"    </a>",
"    ]. There are several proposed diagnostic criteria for PCOS that are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is recognized as one of the most common",
"    <span class=\"nowrap\">",
"     endocrine/metabolic",
"    </span>",
"    disorders of women. Its prevalence depends in part upon the diagnostic criteria used to define the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, in a report of 827 women with World Health Organization class II oligoovulation (euestrogenic normogonadotropic ovulatory dysfunction), 456 (55 percent) were classified as having PCOS by the National Institutes of Health (NIH) 1990 criteria (irregular menses, biochemical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical hyperandrogenism, and other causes of hyperandrogenism excluded). In contrast, 754 (91 percent) women were considered to have PCOS using the Rotterdam 2003 criteria (which requires two out of three of the following: oligo-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anovulation, clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical signs of hyperandrogenism, and polycystic ovaries [by ultrasound]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/4\">",
"     4",
"    </a>",
"    ]. Other causes of hyperandrogenism must also be excluded for the Rotterdam criteria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, the prevalence of PCOS has been determined primarily using the NIH 1990 criteria. A similar prevalence between 6 and 12 percent has been reported in the following populations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An unselected population of obese and non-obese black and white women who were undergoing a pre-employment physical in the southeastern United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Women seeking a medical exam on the Island of Lesbos in Greece [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Women volunteering to donate blood in Madrid, Spain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Female university students and patients of health clinics in Oxford, UK [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A community birth cohort of women in Adelaide, Australia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A community sample of unselected women in Iran [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     High-risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions are associated with an increased prevalence of PCOS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with oligoovulatory infertility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/4,11-13\">",
"       4,11-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obesity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      insulin resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/14-17\">",
"       14-17",
"      </a>",
"      ], although the impact of obesity appears to be relatively modest [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Weight and energy regulation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Type 1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/18,19\">",
"       18,19",
"      </a>",
"      ], type 2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/20,21\">",
"       20,21",
"      </a>",
"      ], or gestational diabetes mellitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Type 2 diabetes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of premature adrenarche [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      First-degree relatives with PCOS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mexican-American women compared with Caucasian or African-American women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/28,29\">",
"       28,29",
"      </a>",
"      ], although this observation remains to be confirmed in larger and more diverse populations.",
"     </li>",
"     <li>",
"      Women using antiepileptic drugs &mdash; Women with epilepsy receiving antiepileptic drugs have an increased frequency of polycystic ovary syndrome. While some studies suggest that the association is independent of antiepileptic medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/30\">",
"       30",
"      </a>",
"      ], most available data now report that the increased rate of PCOS in these women is due to antiepileptic drug use, in particular,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/31-33\">",
"       31-33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In one prospective study of women starting valproic acid for bipolar disorder, oligomenorrhea with hyperandrogenism developed in 9 (10.5 percent) of 86 women on valproate compared with 2 (1.4 percent) of 144 women on a non-valproate anticonvulsant or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/34\">",
"       34",
"      </a>",
"      ]. A follow-up study in a subgroup of these women suggested that menstrual cycle irregularities and clinical hyperandrogenism improved after stopping valproate, but weight and polycystic ovarian morphology on ultrasound did not change [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/35\">",
"       35",
"      </a>",
"      ]. The best evidence comes from a meta-analysis of 11 studies demonstrating a twofold excess risk of developing PCOS in 556 women treated with valproate compared with 593 women treated with other antiepileptic drugs. Of note, valproic acid appears to potentiate androgen biosynthesis in theca cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Historical perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is a functional disorder of unclear etiology. Prior to the description of Stein and Leventhal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/1\">",
"     1",
"    </a>",
"    ], the presence of sclerocystic ovaries was felt to be due to a number of disparate etiologies. In 1910, Fogue and Massabuau described three potential mechanisms: inflammation, congestion, and dystrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/37\">",
"     37",
"    </a>",
"    ]. The inflammation theory proposed that the microcystic ovary was the result of infection either of internal or external provenance. The congestion theory suggested that the lesion was the result of pressure, partial torsion, or other interruption in circulatory flow to the ovary. Finally, the dystrophy theory proposed that the abnormalities were caused by modifications or abnormalities in the nutrition of the ovary.",
"   </p>",
"   <p>",
"    Others suggested that the development of polycystic ovaries was due to the morphological changes observed in the ovaries, including a thickened tunica albuginea that impeded normal ovulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/38\">",
"     38",
"    </a>",
"    ]; however, these anatomic changes appear to primarily reflect the endocrine milieu, and effective ovulation is achievable by modulating the endocrine environment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    , gonadotropins, or insulin sensitizers.",
"   </p>",
"   <p>",
"    Some investigators proposed an adrenal etiology for PCOS, based upon observations in patients with congenital adrenal hyperplasia or adrenal neoplasms (both of whom often present with irregular menses and hyperandrogenism), and the response of the patients to cortisone therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Today, while an adrenal component is observed in many women with PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/41\">",
"     41",
"    </a>",
"    ], it is known that the ovaries are the predominant source of excess androgens in PCOS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Current perspective",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polycystic ovary syndrome (PCOS) is now thought to be a complex genetic trait, similar to cardiovascular disease, type 2 diabetes mellitus, and the metabolic syndrome, where multiple genetic variants and environmental factors interact to foster the development of the disorder. The inherited basis of PCOS was established by twin studies and reports demonstrating an increased prevalence of PCOS in female first degree relatives of affected women. The largest twin study documented monozygotic correlation of 71 percent and a dizygotic correlation of 38 percent; the authors estimated that genetic influences account for as much as 70 percent of the variance in the pathogenesis of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/42\">",
"     42",
"    </a>",
"    ]. The prevalence of PCOS in mothers and sisters of PCOS women is 20 to 40 percent, considerably higher than that seen in the general population, strongly supporting a genetic basis of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Principal genetic targets for the responsible variants proposed include genes regulating gonadotropin secretion and action, insulin secretion and action, weight and energy regulation, and androgen biosynthesis and action (",
"    <a class=\"graphic graphic_figure graphicRef64337 \" href=\"mobipreview.htm?22/62/23535\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef59649 \" href=\"mobipreview.htm?13/52/14156\">",
"     table 1",
"    </a>",
"    ).",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H185346940\">",
"    <span class=\"h3\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many candidate genes have demonstrated some evidence of linkage or association with PCOS, but follow-up studies have often failed to replicate results on the same candidate gene in different populations. Of over 100 candidate genes examined, the table lists genes with supporting evidence from multiple reports or evidence of replication (",
"    <a class=\"graphic graphic_table graphicRef59649 \" href=\"mobipreview.htm?13/52/14156\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the first genome-wide association and replication studies of PCOS, conducted in Chinese Han individuals, three loci were identified that were significantly associated with PCOS: two loci on chromosome 2, and a third locus on chromosome 9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/43\">",
"     43",
"    </a>",
"    ]. One of these loci, on chromosome 2p16.3, contains the gene for the",
"    <span class=\"nowrap\">",
"     LH/hCG",
"    </span>",
"    receptor (LHCGR), a logical susceptibility gene for PCOS. Two of the three, 2p21 and 9p33.3, contained multiple SNPs that appeared to be independently associated with PCOS. The chromosome 2p21 locus contained SNPs in THADA, a gene that codes for a thyroid adenoma-associated protein, while the 9p33.3 locus included variants in DENND1A, a gene coding for a protein that binds endoplasmic reticulum aminopeptidase 1 (ERAP1); increased ERAP1 serum levels have been associated with PCOS accompanied by obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/44\">",
"     44",
"    </a>",
"    ]. A report in patients with type 2 diabetes suggests that the THADA gene variant is associated with impaired beta-cell function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study observed that several of the same variants in DENND1A and THADA associated with PCOS in the Chinese population also affected the odds of PCOS in individuals of European origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/46\">",
"     46",
"    </a>",
"    ]. The observation that the same genes influence PCOS risk in diverse ethnic groups supports the hypothesis that PCOS is an ancient disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/47\">",
"     47",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gonadotropin secretion and action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stein and Leventhal, in their original report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/1\">",
"     1",
"    </a>",
"    ], observed that \"bilateral polycystic ovaries are most probably a result of some hormonal stimulation and very likely relates to the anterior lobe of the pituitary gland,\" noting that other investigators achieved similar polycystic ovaries when injecting \"Antuitrin-S,\" a urinary extract of anterior pituitary hormones, notably human chorionic gonadotropin (hCG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/48\">",
"     48",
"    </a>",
"    ]. Others subsequently observed excess LH activity in the urine of women with the Stein-Leventhal syndrome, determined using a bioassay (ie, the ovarian response of immature female rats or the prostatic response of hypophysectomized male rats to urinary extracts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. This was later confirmed by plasma levels determined by radioimmunoassay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Altered LH action may be involved in the pathogenesis of PCOS, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCOS patients often have higher serum LH concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/54,55\">",
"       54,55",
"      </a>",
"      ] and increased LH pulse frequency and amplitude [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/56\">",
"       56",
"      </a>",
"      ] than matched controls. However, serum LH tends to be lower in obese women with PCOS compared with their lean counterparts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LH action at the ovarian level may be enhanced in PCOS, as the LH receptor is overexpressed in thecal and granulosa cells from polycystic ovaries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic variants of the LH beta-subunit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/57,59\">",
"       57,59",
"      </a>",
"      ] have been reported in patients with PCOS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, elevated LH levels are not required for increased ovarian androgen secretion or polycystic ovarian morphology. As an example, in a study of 45 women with regular ovulatory cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/60\">",
"     60",
"    </a>",
"    ], women with polycystic ovaries on ultrasound (n = 21) had higher serum androgens when compared with women with normal ovarian morphology (n = 24), although the two groups had identical mean LH concentrations on daily and frequent sampling studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Insulin secretion and action",
"    </span>",
"    &nbsp;&mdash;&nbsp;It was first observed that patients with polycystic ovary syndrome (PCOS) were hyperinsulinemic in response to an oral glucose tolerance test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/61\">",
"     61",
"    </a>",
"    ]. It is now known that insulin resistance, and the development of compensatory hyperinsulinemia, is a frequent finding in PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. The insulin resistance of PCOS patients that underlies many of the features of this disorder is highlighted by the finding that the administration of insulin-sensitizing agents, principally",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , thiazolidinediones, and d-chiro-inositol, have been found to improve these features in many patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, 50 to 70 percent of women with PCOS demonstrate clinically measurable insulin resistance in vivo, above and beyond that determined by their body weight (ie, degree of obesity). Insulin stimulates theca cell secretion of androgens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/70,71\">",
"     70,71",
"    </a>",
"    ] and inhibits hepatic sex-hormone binding globulin (SHBG) production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], resulting in an increase in free androgens.",
"   </p>",
"   <p>",
"    In addition, the theca cells in PCOS women are hyper-responsive to the stimulatory effects of insulin on androgen secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/71\">",
"     71",
"    </a>",
"    ]. A number of variants of genes related to insulin action have been reported to be associated with PCOS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Weight and energy regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of obesity worsens insulin resistance, the degree of hyperinsulinemia, the severity of ovulatory and menstrual dysfunction, and pregnancy outcome in polycystic ovary syndrome (PCOS), and is associated with an increasing prevalence of metabolic syndrome, glucose intolerance, cardiovascular risk factors, and sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/74-78\">",
"     74-78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the fact that the risk of PCOS increases modestly with the degree of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], and that the metabolic features of PCOS are worsened by the concomitant presence of obesity, it is still unclear whether obesity itself is causative. In a 2004 study from the United States, 60 percent of women with PCOS were obese [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/79\">",
"     79",
"    </a>",
"    ], about twice the rate seen in the general adult population at that time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/80\">",
"     80",
"    </a>",
"    ]. However, the prevalence of obesity in PCOS varies widely with the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/81\">",
"     81",
"    </a>",
"    ], suggesting that environmental factors play a significant role in determining the presence of obesity in PCOS. Likewise, while the prevalence of obesity in the population varies widely throughout the world, the prevalence of PCOS appears to be relatively uniform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. This was illustrated in a study of 675 unselected women seeking an employment history; the prevalence rates of PCOS in underweight, normal weight, overweight, and obese women were 8.2, 9.8, 9.9, and 9.0 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/17\">",
"     17",
"    </a>",
"    ]. Although body mass index (BMI) may not have an important impact on the prevalence of PCOS, the mean BMI of women with PCOS has been gradually increasing; the change parallels the increase in BMI seen in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these data suggest that obesity in PCOS primarily reflects environmental factors, it is also possible that PCOS is associated with a greater propensity for obesity and weight gain, and genes relating to weight and energy regulation have been studied. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link&amp;anchor=H25#H25\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Factors affecting phenotype'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Androgen biosynthesis and action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperandrogenism is a central feature of polycystic ovary syndrome (PCOS). The androgens are secreted primarily by the ovaries and secondarily by the adrenals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/41\">",
"     41",
"    </a>",
"    ]. Although hyperinsulinism is associated with hyperandrogenism in PCOS, insulin resistance alone is not sufficient for the development of PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/15\">",
"     15",
"    </a>",
"    ], suggesting that an underlying (genetic) predisposition to hyperandrogenism must also be present. Variants of a number of genes involved in the regulation of androgen biosynthesis or action have been described in PCOS. Additional information on the disturbances of androgen biosynthesis observed in PCOS is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/12?source=see_link\">",
"     \"Steroid hormone metabolism in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most clearly defined environmental factor likely affecting the development of PCOS is diet and its association with obesity. Nonetheless, as noted above, despite wide variations in the prevalence of obesity and type of diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/82\">",
"     82",
"    </a>",
"    ], the prevalence of PCOS appears to be relatively uniform [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40568/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Weight and energy regulation'",
"    </a>",
"    above.) Other potential factors may include as yet undetermined androgen-mimicking environmental toxins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The polycystic ovary syndrome (PCOS) is a heterogeneous disorder of functional androgen excess, detectable either by laboratory analysis or by clinical exam, with ovulatory dysfunction and polycystic ovarian morphology also affecting a large proportion of these patients. The definitions and diagnostic criteria for PCOS are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=see_link\">",
"       \"Diagnosis of polycystic ovary syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevalence of PCOS depends to a degree upon the criteria used to define this disorder. Using the original National Institutes of Health 1990 criteria, most studies have observed a 6 to 12 percent prevalence in unselected reproductive-aged women. The prevalence of PCOS is increased in the presence of obesity, insulin resistance, type 1, type 2, or gestational diabetes mellitus, oligoovulatory infertility, premature adrenarche, and a positive family history for PCOS among first-degree relatives.",
"     </li>",
"     <li>",
"      PCOS is a complex genetic trait whose development is likely influenced to some degree by environmental factors (eg, diet and the development of obesity) and more significantly by a number of different genetic variants. A susceptible genotype may stem from the inheritance of variants in genes regulating gonadotropin secretion and action, insulin secretion and action, weight and energy regulation, and androgen biosynthesis and action. Further studies of well-defined patients are necessary to develop an understanding of the etiology(s) of this highly prevalent and morbid disorder.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/1\">",
"      Stein, IF, Leventhal, NL. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935; 29:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/2\">",
"      Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007; 370:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/3\">",
"      March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/4\">",
"      Broekmans FJ, Knauff EA, Valkenburg O, et al. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 2006; 113:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/5\">",
"      Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83:3078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/6\">",
"      Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89:2745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/7\">",
"      Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84:4006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/8\">",
"      Asunci&oacute;n M, Calvo RM, San Mill&aacute;n JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/9\">",
"      Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999; 51:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/10\">",
"      Tehrani FR, Simbar M, Tohidi M, et al. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol 2011; 9:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/11\">",
"      Kousta E, White DM, Cela E, et al. The prevalence of polycystic ovaries in women with infertility. Hum Reprod 1999; 14:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/12\">",
"      Hull MG. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987; 1:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/13\">",
"      Allen SE, Potter HD, Azziz R. Prevalence of hyperandrogenemia among nonhirsute oligo-ovulatory women. Fertil Steril 1997; 67:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/14\">",
"      Hartz AJ, Barboriak PN, Wong A, et al. The association of obesity with infertility and related menstural abnormalities in women. Int J Obes 1979; 3:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/15\">",
"      Korhonen S, Hippel&auml;inen M, Niskanen L, et al. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol 2001; 184:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/16\">",
"      Alvarez-Blasco F, Botella-Carretero JI, San Mill&aacute;n JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/17\">",
"      Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/18\">",
"      Escobar-Morreale HF, Rold&aacute;n B, Barrio R, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2000; 85:4182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/19\">",
"      Codner E, Soto N, Lopez P, et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/20\">",
"      Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/21\">",
"      Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001; 24:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/22\">",
"      Holte J, Gennarelli G, Wide L, et al. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998; 83:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/23\">",
"      Anttila L, Karjala K, Penttil&auml; RA, et al. Polycystic ovaries in women with gestational diabetes. Obstet Gynecol 1998; 92:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/24\">",
"      Ib&aacute;&ntilde;ez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche--normal variant or forerunner of adult disease? Endocr Rev 2000; 21:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/25\">",
"      Rosenfield RL. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/26\">",
"      Legro RS, Driscoll D, Strauss JF 3rd, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95:14956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/27\">",
"      Kahsar-Miller MD, Nixon C, Boots LR, et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril 2001; 75:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/28\">",
"      Goodarzi MO, Qui&ntilde;ones MJ, Azziz R, et al. Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance. Fertil Steril 2005; 84:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/29\">",
"      Kauffman RP, Baker VM, Dimarino P, et al. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. Am J Obstet Gynecol 2002; 187:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/30\">",
"      Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001; 86:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/31\">",
"      Joffe H, Taylor AE, Hall JE. Polycystic ovarian syndrome--relationship to epilepsy and antiepileptic drug therapy. J Clin Endocrinol Metab 2001; 86:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/32\">",
"      Isoj&auml;rvi JI, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/33\">",
"      Mikkonen K, Vainionp&auml;&auml; LK, Pakarinen AJ, et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004; 62:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/34\">",
"      Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/35\">",
"      Joffe H, Cohen LS, Suppes T, et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: A preliminary report. Biol Psychiatry 2006; 60:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/36\">",
"      Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/37\">",
"      Forgue, E, Massabuau, G. L'ovaire a petits kystes (cont.). Revue de Gyn&eacute;cologie et de Chirurgie Abdminale 1910; 14:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/38\">",
"      Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called \"hyperthecosis\". Obstet Gynecol Surv 1982; 37:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/39\">",
"      JONES GE, HOWARD JE, LANGFORD H. The use of cortisone in follicular phase disturbances. Fertil Steril 1953; 4:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/40\">",
"      GREENBLATT RB. Cortisone in treatment of the hirsute woman. Am J Obstet Gynecol 1953; 66:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/41\">",
"      Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2005; 62:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/42\">",
"      Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006; 91:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/43\">",
"      Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/44\">",
"      Olszanecka-Glinianowicz M, Bana M, Zahorska-Markiewicz B, et al. Is the polycystic ovary syndrome associated with chronic inflammation per se? Eur J Obstet Gynecol Reprod Biol 2007; 133:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/45\">",
"      Simonis-Bik AM, Nijpels G, van Haeften TW, et al. Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes 2010; 59:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/46\">",
"      Goodarzi MO, Jones MR, Li X, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet 2012; 49:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/47\">",
"      Azziz R, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? Fertil Steril 2011; 95:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/48\">",
"      Geist, SH. Reaction of the mature human ovary to antuitrin-S. Am J Obstet Gynecol 1933; 26:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/49\">",
"      KEETTEL WC, BRADBURY JT, STODDARD FJ. Observations on the polycystic ovary syndrome. Am J Obstet Gynecol 1957; 73:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/50\">",
"      McARTHUR JW, INGERSOLL FM, WORCESTER J. The urinary excretion of interstitial-cell and follicle-stimulating hormone activity by women with diseases of the reproductive system. J Clin Endocrinol Metab 1958; 18:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/51\">",
"      INGERSOLL FM, McARTHUR JW. Longitudinal studies of gonadotropin excretion in the Stein-Leventhal syndrome. Am J Obstet Gynecol 1959; 77:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/52\">",
"      TAYMOR ML, BARNARD R. Luteinizing hormone excretion in the polycystic ovary syndrome. Fertil Steril 1962; 13:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/53\">",
"      Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970; 30:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/54\">",
"      Rebar R, Judd HL, Yen SS, et al. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976; 57:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/55\">",
"      Balen AH. Hypersecretion of luteinizing hormone and the polycystic ovary syndrome. Hum Reprod 1993; 8 Suppl 2:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/56\">",
"      Waldstreicher J, Santoro NF, Hall JE, et al. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988; 66:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/57\">",
"      Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/58\">",
"      Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab 2001; 86:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/59\">",
"      Nilsson C, Jiang M, Pettersson K, et al. Determination of a common genetic variant of luteinizing hormone using DNA hybridization and immunoassays. Clin Endocrinol (Oxf) 1998; 49:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/60\">",
"      Adams JM, Taylor AE, Crowley WF Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab 2004; 89:4343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/61\">",
"      Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/62\">",
"      Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/63\">",
"      Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/64\">",
"      Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83:2694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/65\">",
"      DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005; 83:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/66\">",
"      Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/67\">",
"      Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/68\">",
"      Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/69\">",
"      Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; :CD003053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/70\">",
"      Barbieri RL, Makris A, Ryan KJ. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol 1984; 64:73S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/71\">",
"      Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/72\">",
"      Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab 1988; 67:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/73\">",
"      Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/74\">",
"      Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/75\">",
"      Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/76\">",
"      Dokras A, Jagasia DH, Maifeld M, et al. Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. Fertil Steril 2006; 86:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/77\">",
"      Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/78\">",
"      Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update 2006; 12:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/79\">",
"      Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004; 89:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/80\">",
"      Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004; 291:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/81\">",
"      Carmina E, Rosato F, Jann&igrave; A, et al. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40568/abstract/82\">",
"      Carmina E, Legro RS, Stamets K, et al. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003; 18:2289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7430 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40568=[""].join("\n");
var outline_f39_39_40568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      High-risk groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Historical perspective",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Current perspective",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H185346940\">",
"      - Genetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gonadotropin secretion and action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Insulin secretion and action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Weight and energy regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Androgen biosynthesis and action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7430|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/62/23535\" title=\"figure 1\">",
"      Pathogenesis PCOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/52/14156\" title=\"table 1\">",
"      Genes associated with PCOS or component traits of PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/12?source=related_link\">",
"      Steroid hormone metabolism in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_39_40569="Evaluation of dysphagia in children";
var content_f39_39_40569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of dysphagia in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40569/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40569/contributors\">",
"     Ronald A Furnival, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40569/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40569/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40569/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/39/40569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary function of swallowing is the ingestion, preparation, and transport of nutrients to the digestive tract. Secondary functions of swallowing are the control of secretions, clearance of respiratory contaminants, protection of the upper airway, and equalization of pressure across the tympanic membrane through the eustachian tube. Dysphagia is defined as any difficulty or abnormality of swallowing.",
"   </p>",
"   <p>",
"    The differential diagnosis and evaluation of dysphagia in children are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysphagia &ndash; Dysphagia is defined as any difficulty or abnormality of swallowing. Dysphagia is not a specific disease entity but is a symptom of other conditions and may be life-threatening.",
"     </li>",
"     <li>",
"      Odynophagia &ndash; Odynophagia refers to pain on swallowing and may also be present in the dysphagic child.",
"     </li>",
"     <li>",
"      Sialorrhea &ndash; Sialorrhea (drooling) may accompany dysphagia and often indicates oropharyngeal, upper airway,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      esophageal infection or obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table provides a listing of life-threatening, common, and other conditions associated with dysphagia in children (",
"    <a class=\"graphic graphic_table graphicRef73934 \" href=\"mobipreview.htm?38/9/39067\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening etiologies of dysphagia may cause airway compromise, pulmonary aspiration, serious local or systemic infection, and inflammatory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Esophageal foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients of any age with an esophageal foreign body may present with inability or refusal of oral fluids or solids (dysphagia), drooling, or respiratory symptoms, including wheezing, stridor, or choking. The majority of foreign body ingestions occur in children between the ages of six months and three years. Most children with esophageal foreign bodies are brought to medical attention by their parents because the ingestion was witnessed or reported to them.",
"   </p>",
"   <p>",
"    When symptoms do occur, they are often related to the location of the foreign body. Older children may localize the sensation of something \"stuck\" in the neck or lower chest, suggesting irritation in the upper or lower esophagus, respectively. Foreign bodies lodged in the esophagus at the cricoid cartilage or the tracheal bifurcation can compress the airway causing partial airway obstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76887 \" href=\"mobipreview.htm?14/15/14578\">",
"     image 1",
"    </a>",
"    ). It is also possible that an esophageal foreign body will become dislodged into the upper airway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal perforation from ingested sharp objects or erosion from retained smooth foreign bodies, particularly \"button\" batteries, may cause serious sequelae, including death (",
"    <a class=\"graphic graphic_picture graphicRef74761 \" href=\"mobipreview.htm?42/53/43871\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54791 \" href=\"mobipreview.htm?17/47/18175\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=see_link\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15337?source=see_link&amp;anchor=H17#H17\">",
"     \"Button and cylindrical battery ingestion\", section on 'Esophageal position'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impacted meat or other food bolus is the most common esophageal foreign body in adults, but is relatively rare in children. It usually presents as dysphagia beginning acutely while eating. In children presenting with a food impaction, there is a higher incidence of underlying esophageal pathology (strictures, achalasia, or esophageal motility disorders) as compared to children with other esophageal foreign bodies. Children who are in acute distress or unable to swallow oral secretions following food impaction require immediate attention and removal of the impaction. If the patient is comfortable and able to handle oral secretions, endoscopic intervention can be delayed, as many food impactions will pass spontaneously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=see_link&amp;anchor=H19#H19\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\", section on 'Food bolus impaction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Stevens-Johnson syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    overlap syndrome represent disorders of uncertain etiology that are characterized by desquamative lesions of the skin and mucous membranes (",
"    <a class=\"graphic graphic_picture graphicRef73805 \" href=\"mobipreview.htm?30/7/30836\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67632 \" href=\"mobipreview.htm?24/48/25345\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76141 \" href=\"mobipreview.htm?26/25/27030\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef66134 \" href=\"mobipreview.htm?17/63/18419\">",
"     picture 6",
"    </a>",
"    ). Drooling and dysphagia commonly accompany severe oropharyngeal mucosal sloughing. Cases with less than 10 percent epidermal involvement are classified as SJS; those with 30 percent or more involvement are classified as TEN; cases with between 10 and 30 percent involvement are considered overlap",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"   </p>",
"   <p>",
"    TEN",
"    is almost invariably drug-induced, while SJS is associated with infections, as well as drug administration. SJS and TEN begin with a prodrome of fever and influenza-like symptoms one to three days before the development of mucocutaneous and skin lesions. Characteristic vesicular and bullous skin lesions then appear and progress over several days, followed by sloughing (",
"    <a class=\"graphic graphic_picture graphicRef82150 \" href=\"mobipreview.htm?34/18/35106\">",
"     picture 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68458 \" href=\"mobipreview.htm?39/1/39953\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59418 \" href=\"mobipreview.htm?13/27/13747\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef73805 \" href=\"mobipreview.htm?30/7/30836\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76141 \" href=\"mobipreview.htm?26/25/27030\">",
"     picture 5",
"    </a>",
"    ). Multiorgan involvement, including tracheobronchitis, may occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Caustic ingestion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia is the most common symptom of caustic oropharyngeal and esophageal injury (",
"    <a class=\"graphic graphic_picture graphicRef53496 \" href=\"mobipreview.htm?3/6/3168\">",
"     picture 10",
"    </a>",
"    ). Patients may also present with drooling, oral burns, retrosternal or abdominal pain, hematemesis, and features suggesting upper airway injury, such as stridor, hoarseness, nasal flaring, and retractions. Caustic ingestion may also cause a chemical epiglottitis or an esophageal perforation with mediastinitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4473?source=see_link\">",
"     \"Caustic esophageal injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12553?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Treatment and prevention\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Esophageal perforation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Retropharyngeal abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retropharyngeal abscess occurs most commonly in children between the ages of two and four years. Retropharyngeal abscess often is a polymicrobial infection. The predominant bacterial species are Streptococcus pyogenes (group A streptococcus), Staphylococcus aureus (including methicillin-resistant S. aureus), and respiratory anaerobes (including Fusobacteria, Prevotella, and Veillonella species).",
"   </p>",
"   <p>",
"    Early in the disease process, the findings may be indistinguishable from those of uncomplicated pharyngitis. With disease progression, symptoms related to inflammation and obstruction of the upper aerodigestive tract develop. Children with retropharyngeal abscess eventually appear ill with moderate fever. Symptoms may include dysphagia, odynophagia, drooling, pain on neck extension, torticollis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muffled or \"hot potato\" voice. In addition, respiratory distress, stridor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck swelling, mass, or lymphadenopathy may be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Epiglottitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suspected epiglottitis, which occurs rarely among children immunized against Haemophilus influenza, type B, is a medical emergency. To minimize morbidity and mortality, prompt recognition and treatment is critical (",
"    <a class=\"graphic graphic_table graphicRef80169 \" href=\"mobipreview.htm?25/10/25773\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12553?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abrupt onset and rapid progression (within hours) of dysphagia, drooling, and distress (\"the three D's\") are hallmarks of epiglottitis in children. Sudden onset of high fever (between 38.8&ordm; and 40.0&ordm;C), odynophagia, and severe sore throat are also characteristic of infectious epiglottitis. Non-infectious epiglottitis may also occur in children who ingest caustic substances or hot liquids.",
"   </p>",
"   <p>",
"    Children with epiglottitis usually appear \"toxic\" (",
"    <a class=\"graphic graphic_picture graphicRef76538 \" href=\"mobipreview.htm?8/0/8197\">",
"     picture 11",
"    </a>",
"    ) and may assume a sitting position with the trunk leaning forward, neck hyperextended, and chin thrust forward in an effort to maximize the diameter of the obstructed airway (the \"tripod\" posture) (",
"    <a class=\"graphic graphic_picture graphicRef79826 \" href=\"mobipreview.htm?25/54/26465\">",
"     picture 12",
"    </a>",
"    ). They may be reluctant to lie down. Although many patients have minor antecedent upper respiratory tract symptoms, the usual duration of notable illness before hospitalization is &lt;24 hours and frequently &lt;12 hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Central nervous system infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with meningitis, encephalitis, or cerebral abscess may have impaired consciousness (lethargy, obtundation, or coma) with loss of the gag reflex and dysphagia. They may also rarely exhibit bulbar signs with difficulty swallowing due to infection of the components of the swallowing pathway (eg, cortical motor stripe, vagus nerve nucleus). Fever is usually present and may be of variable elevation.",
"   </p>",
"   <p>",
"    Most patients with bacterial meningitis also present with fever and with clinical findings of meningeal inflammation (nausea, vomiting, irritability, anorexia, headache, confusion, back pain, and nuchal rigidity). However, the clinical manifestations of bacterial meningitis are variable and nonspecific; no single sign is pathognomonic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with encephalitis often have fever, altered mental status, seizures,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    focal neurologic signs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21769?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Impairment of swallowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diverse group of conditions associated with poor coordination of swallowing may lead to dysphagia with pulmonary aspiration of saliva or food. Etiologies include cerebral palsy, traumatic brain injury, demyelinating diseases (eg, Guillain-Barr&eacute; syndrome with bulbar weakness [Miller Fisher syndrome]), botulism, congenital myopathies, mitochondrial myopathies, spinal muscular atrophy, and neurodegenerative diseases (eg, metachromatic leukodystrophy, Alexander disease, Krabbe disease, juvenile amyotrophic lateral sclerosis). (See separate topic reviews).",
"   </p>",
"   <p>",
"    These patients often present with respiratory distress and clinical findings of aspiration pneumonia (eg, hypoxia, fever, tachypnea, cyanosis, rales). Empiric treatment of aspiration pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25354?source=see_link&amp;anchor=H23#H23\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Aspiration pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tetanus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus is a nervous system disorder characterized by muscle spasms that is caused by the toxin-producing anaerobe, Clostridium tetani. While tetanus is now rare in the developed world, the disease remains a threat in developing countries. Dysphagia and trismus are common presenting symptoms in patients with generalized tetanus. Other clinical findings may include stiff neck, opisthotonos, and risus sardonicus (sardonic smile). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with generalized tetanus characteristically have tonic contraction of their skeletal muscles and intermittent intense muscular spasms. Since patients with tetanus have no impairment of consciousness or awareness, both the tonic contractions and spasms are intensely painful. Tetanic spasms may be triggered by loud noises or other sensory stimuli, such as physical contact or light.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diphtheria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diphtheria occurs rarely in developed countries but remains a serious disease throughout much of the world. It is an acute, communicable disease caused by the Gram-positive bacillus, Corynebacterium diphtheriae. Respiratory diphtheria has a gradual onset of symptoms with sore throat, odynophagia, malaise, and low grade fever being the most common. In a significant percentage of patients, toxin elaborated locally induces the formation of a coalescing pseudomembrane which can extend to any portion of the respiratory tract from the nasal passages to the tracheobronchial tree and cause odynophagia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\", section on 'Respiratory diphtheria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic toxicity with uncoordinated swallowing, dysphagia, upper airway obstruction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary aspiration is unusual in mild disease but develops in up to three-fourths of patients with severe diphtheria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology, pathophysiology and clinical manifestations of diphtheria\", section on 'Systemic manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Poliomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although polio no longer poses the public health threat in the United States that it once did, areas of endemic wild-type poliovirus still exist in other areas of the world. Up to one-third of patients may develop bulbar involvement with dysphagia, dysarthria, and difficulty handling secretions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/44/36553?source=see_link\">",
"     \"Polio and infectious diseases of the anterior horn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Central nervous system tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial neuropathies with drooling, dysphagia, diplopia, impairment of ocular movements,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    facial palsy, suggest underlying brainstem pathology. These findings represent common localizing signs of central nervous system tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/56/13192?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\", section on 'Localizing symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Esophageal perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal perforation and mediastinitis occur rarely in children. Caustic ingestions, erosive esophageal foreign bodies (ie, button batteries), and esophageal procedures (eg, endoscopy, dilation of esophageal strictures) are the most frequent causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clinical findings of esophageal perforation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysphagia",
"     </li>",
"     <li>",
"      Neck pain (cervical esophageal perforation)",
"     </li>",
"     <li>",
"      Chest pain (thoracic esophageal perforation)",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, hematemesis may occur if the foreign body erodes into adjacent vascular structures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15337?source=see_link&amp;anchor=H17#H17\">",
"     \"Button and cylindrical battery ingestion\", section on 'Esophageal position'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal perforation progresses to mediastinitis when oral and gastric fluids contaminate the mediastinal space. Mediastinitis typically presents with fever and subcutaneous emphysema and rapidly progresses to septic shock within hours if not rapidly detected and treated. This infection is usually polymicrobial and is caused by mouth flora, including Staphylococcus species, Streptococcus species, anaerobic bacteria, and Gram-negative bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory evaluation of these patients should include a complete blood count, blood culture, electrolytes, and type and screen.",
"   </p>",
"   <p>",
"    Plain radiographs of the chest (AP and lateral) and neck (soft tissue lateral and AP) will detect esophageal perforation in 90 to 95 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/1\">",
"     1",
"    </a>",
"    ]. Findings depend on the location of the perforation. Neck films demonstrate air in the prevertebral fascial planes of the retropharynx and subcutaneous emphysema in patients with cervical esophageal perforations. Findings associated with more distal esophageal perforations on chest radiograph include pneumomediastinum, subcutaneous emphysema, pleural effusion, hydrothorax, hydropneumothorax, and subdiaphragmatic air (upright film).",
"   </p>",
"   <p>",
"    When suspected, esophageal perforation warrants emergent consultation with a surgeon with pediatric thoracic surgery expertise.",
"   </p>",
"   <p>",
"    Contrast esophagography or computed tomography may identify the specific site of esophageal perforation and are confirmatory studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/1\">",
"     1",
"    </a>",
"    ]. The choice of confirmatory test is best guided by a surgical consultant.",
"   </p>",
"   <p>",
"    Management priorities are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive treatment of hypovolemia and shock as determined by the patient's circulatory status (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"mobipreview.htm?41/12/42178\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"       \"Initial management of shock in children\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Administration of a broad spectrum antibiotic regimen that provides coverage for Gram-positive cocci (including methicillin-resistant Staphylococcus aureus), anaerobic bacteria, and Gram-negative bacteria (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Surgical drainage, ideally within 24 hours of esophageal perforation",
"     </li>",
"     <li>",
"      In patients with active bleeding, endotracheal intubation, hemodynamic stabilization, and emergent thoracotomy in the operating room.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality from esophageal perforation varies from approximately 0 to 10 percent in patients who undergo drainage procedures within 24 hours to as high as 31 percent in patients where definitive drainage is delayed beyond 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Stomatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stomatitis, the inflammation of the mucous lining of the mouth and throat, is one of the most common causes of dysphagia in children and is typically associated with viral infection (eg, enterovirus or herpesvirus infection).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteroviruses cause the hand, foot, and mouth syndrome which is characterized by fever, oral vesicles on the buccal mucosa and tongue, and peripherally distributed small, tender cutaneous lesions on the hands, feet, buttocks, and (less commonly) genitalia.",
"     </li>",
"     <li>",
"      The enterovirus, Coxsackie A virus, is also the etiologic agent of herpangina, a vesicular enanthem of the tonsillar fauces and soft palate that principally affects children 3 to 10 years of age. Oropharyngeal symptoms of sore throat are accompanied by fever and odynophagia. Most disease occurs during summer outbreaks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Hand, foot, and mouth syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Herpangina'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Herpetic gingivostomatitis is caused by herpes simplex virus type 1 and typically occurs in children between six months and five years of age. Clinical features of HSV-1 stomatitis include a prodrome of fever and constitutional symptoms, followed by oral and extraoral lesions. The lesions begin as vesicles, which coalesce to form painful ulcers (",
"      <a class=\"graphic graphic_picture graphicRef58542 \" href=\"mobipreview.htm?27/3/27702\">",
"       picture 13",
"      </a>",
"      ). Associated findings include fever, bad breath, odynophagia, anorexia, and submandibular or cervical lymphadenitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of viral stomatitis caused by enterovirus is primarily supportive and consists of administration of appropriate oral pain medications (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every six hours as needed) and encouragement of adequate fluid intake. Topical therapy (eg, equal parts of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/36/21062?source=see_link\">",
"     aluminum hydroxide",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/59/29622?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    [eg, Maalox&reg;]) and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    may be effective in some patients. Topical viscous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/19/11574?source=see_link\">",
"     benzocaine",
"    </a>",
"    should be avoided in young children because of the risk for toxicity from mucosal absorption or ingestion. In severe cases, oral opiates may be required for pain control. On occasion, children will refuse to drink and require intravenous treatment for dehydration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of herpetic gingivostomatitis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=see_link&amp;anchor=H11#H11\">",
"     \"Herpetic gingivostomatitis in young children\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Infectious pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dysphagia and clinical evidence of infectious pharyngitis are managed according to the infectious etiology (",
"    <a class=\"graphic graphic_algorithm graphicRef64820 \" href=\"mobipreview.htm?30/37/31327\">",
"     algorithm 2",
"    </a>",
"    ). Common pathogens include enterovirus, adenovirus, Epstein-Barr virus, Group A Streptococcus, and Neisseria gonorrhoeae. On occasion, children with pharyngitis have such severe pain with swallowing that they refuse fluid intake and become dehydrated. The approach to the diagnosis of infectious pharyngitis and the treatment of dehydration in children is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=see_link\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Peritonsillar abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with peritonsillar abscess (PTA) have a severe sore throat (usually unilateral), fever, and a \"hot potato\" or muffled voice. Pooling of saliva or drooling may be present. Trismus, related to irritation and reflex spasm of the internal pterygoid muscle, occurs in nearly two-thirds of patients and helps to distinguish PTA from severe pharyngitis or tonsillitis. Although most children with PTA are adolescents, at times, it may present in younger children and be difficult to differentiate from retropharyngeal abscess or epiglottitis, especially if drooling and trismus are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link&amp;anchor=H6#H6\">",
"     \"Peritonsillar cellulitis and abscess\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination findings consistent with PTA include an extremely swollen and fluctuant tonsil often with deviation of the uvula to the opposite side (",
"    <a class=\"graphic graphic_picture graphicRef69943 \" href=\"mobipreview.htm?29/54/30575\">",
"     picture 14",
"    </a>",
"    ). Alternatively, there may be visible swelling or bulging of the posterior soft palate near the tonsil, with palpable fullness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluctuance.",
"   </p>",
"   <p>",
"    Drainage, antimicrobial therapy, and supportive care are the cornerstones of management for peritonsillar abscess. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link&amp;anchor=H13#H13\">",
"     \"Peritonsillar cellulitis and abscess\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Esophagitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal injury with inflammation and dysphagia most commonly occurs as a complication of gastroesophageal reflux (",
"    <a class=\"graphic graphic_picture graphicRef59503 \" href=\"mobipreview.htm?25/53/26449\">",
"     picture 15",
"    </a>",
"    ). Medication-induced esophagitis (or \"pill esophagitis\"), esophageal infection, and eosinophilic esophagitis (",
"    <a class=\"graphic graphic_picture graphicRef74737 \" href=\"mobipreview.htm?22/23/22896\">",
"     picture 16",
"    </a>",
"    ) are additional etiologies to consider and are more likely in children with dysphagia and odynophagia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical patient with medication-induced esophagitis does not have a history of prior esophageal disease. Patients will often present with the sudden onset of odynophagia and retrosternal pain; the pain may be so severe that swallowing saliva is difficult. An adolescent with acute onset of heartburn or odynophagia in association with ingestion of tetracyclines (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/54/12136?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/20/43334?source=see_link\">",
"     minocycline",
"    </a>",
"    ) that are frequently used for treatment of acne is a common scenario. In such cases, a clinical diagnosis may be made without the requirement for confirmatory endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=see_link\">",
"     \"Medication-induced esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious esophagitis is most commonly found in immunocompromised patients with human immunodeficiency virus or hematologic malignancies, although it may occasionally occur in immunocompetent hosts. Candidal esophagitis is most frequently identified. Other etiologies include Herpes simplex virus (type 1), Mycobacterium tuberculosis, Cryptosporidium, and Pneumocystis carinii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of Candida infections in children\", section on 'Esophagitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6647?source=see_link\">",
"     \"Herpes simplex virus infection of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper endoscopy provides the best means to definitely diagnose children with suspected esophagitis other than those with uncomplicated medication-induced esophagitis. Unlike esophageal pH monitoring studies, endoscopy permits visualization of the esophageal epithelium, histologic evaluation to establish the presence of other disorders (eg, allergic or infectious esophagitis), and identification of the presence and severity of esophagitis as well as complications, such as strictures (",
"    <a class=\"graphic graphic_picture graphicRef64024 \" href=\"mobipreview.htm?36/9/37023\">",
"     picture 17",
"    </a>",
"    ) or Barrett's esophagus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dystonic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia may occur as part of a dystonic reaction to certain medications, including typical antipsychotics (eg, Thorazine,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/51/38711?source=see_link\">",
"     haloperidol",
"    </a>",
"    ), anticonvulsants (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    ), and antiemetics (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/27/2487?source=see_link\">",
"     promethazine",
"    </a>",
"    ). The reaction causes acute spasm of multiple muscle groups, including oropharyngeal muscle spasm. Patients may also manifest a fixed upper gaze (oculogyric crisis), neck twisting, grimace, clenched jaw, and dysarthria. Dystonic reactions that are drug-induced can be treated with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/45/36563?source=see_link\">",
"     benztropine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4600?source=see_link&amp;anchor=H13#H13\">",
"     \"First generation (Typical) antipsychotic medication poisoning\", section on 'Acute extrapyramidal syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Oropharyngeal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating oropharyngeal wounds in children typically result from low force mechanisms and usually heal spontaneously with no sequelae. Rarely, internal carotid artery (ICA) injury with neurologic deficit or deep space neck infection with drooling and dysphagia may complicate oropharyngeal trauma involving the lateral aspect of the palate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23016?source=see_link\">",
"     \"Oropharyngeal trauma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intentional trauma to the posterior oropharynx of a nonverbal child by the caregiver to induce hematemesis has been described as a form of Munchausen syndrome by proxy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=see_link&amp;anchor=H2#H2\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Achalasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysphagia for solids (91 percent) and liquids (85 percent) is the primary clinical feature of achalasia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53672 \" href=\"mobipreview.htm?23/55/24446\">",
"     image 2",
"    </a>",
"    ). An association with adrenal glucocorticoid deficiency and alacrima (triple A syndrome or Allgrove syndrome) has been described in children with achalasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link&amp;anchor=H26#H26\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Triple A syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A contrast swallow is the primary screening test when achalasia is suspected on clinical grounds. The diagnostic accuracy of contrast swallow for achalasia is approximately 95 percent. Patients who have clinical and radiographic findings suggestive of achalasia require manometric and endoscopic evaluation to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14759?source=see_link\">",
"     \"Clinical manifestations and diagnosis of achalasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rheumatic disease",
"      </strong>",
"      &ndash; Gastrointestinal involvement is found in 30 to 74 percent of children with juvenile systemic sclerosis (scleroderma [JSSc]). Radiological and functional studies of the GI tract often demonstrate abnormalities, such as gastroesophageal reflux and esophageal dysmotility, even in the absence of symptoms. Manometry and intraesophageal 24-hour pH monitoring are sensitive indicators of diminished lower esophageal sphincter tone and gastroesophageal reflux. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=see_link&amp;anchor=H10#H10\">",
"       \"Juvenile systemic sclerosis (scleroderma)\", section on 'Other organ involvement'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/35/41529?source=see_link\">",
"       \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In children with juvenile dermatomyositis, weakness of the palate and cricopharyngeal muscle may result in dysphagia, a nasal voice, tracheal aspiration, and reflux of food into the nasopharynx. Involvement of the upper esophagus can lead to dysphagia for solids and liquids. Dysphagia may also result from weakness of striated muscle in the lower third of the esophagus with esophageal reflux and esophageal dysmotility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\", section on 'Muscle weakness'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Children with juvenile idiopathic arthritis may rarely develop dysphagia caused by cricoarytenoid arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Myasthenia gravis",
"      </strong>",
"      &ndash; Myasthenia gravis occurs very rarely in older children and adolescents. Although most patients with myasthenia gravis present with ocular symptoms of ptosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diplopia, about 15 percent of patients demonstrate bulbar symptoms, including dysphagia. Imminent risk of aspiration may produce a \"myasthenic crisis.\" Nasal regurgitation, particularly of liquids, may occur due to palatal weakness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=see_link\">",
"       \"Myasthenic crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Crohns disease",
"      </strong>",
"      &ndash; In children with Crohn s disease, esophageal involvement is present histologically in 18 to 43 percent of patients and may cause dysphagia and odynophagia. This condition is primarily seen in children with advanced ileocolonic disease. Acid suppression therapy (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/23/24952?source=see_link\">",
"       omeprazole",
"      </a>",
"      ) may provide symptomatic relief. Corticosteroid therapy may temporarily resolve inflammation. However, recurrence of disease after tapering of corticosteroid therapy commonly occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Thyroid enlargement",
"      </strong>",
"      &ndash; Enlarging thyroid lobes usually grow outward because of their location in the anterior neck in front of the trachea, covered only by thin muscles, subcutaneous tissue, and skin. As a result of this outward growth, even very large goiters may not compress the trachea or impinge on the great vessels lateral to the lobes. However, in patients with substantial enlargement of one lobe or asymmetric enlargement of both lobes, the trachea, esophagus, or blood vessels may be displaced or, less often, compressed. Bilateral lobar enlargement, especially if the goiter extends posterior to the trachea, may cause either compression or concentric narrowing of the trachea or compression of the esophagus or jugular veins. Dysphagia is less common than respiratory distress because of the posterior position of the esophagus relative to the trachea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/46?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and evaluation of obstructive or substernal goiter\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Among the various causes of thyroid enlargement in children, acute suppurative thyroiditis is most commonly associated with dysphagia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24280?source=see_link&amp;anchor=H17#H17\">",
"       \"Congenital and acquired goiter in children\", section on 'Acute suppurative thyroiditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Esophageal tumor",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Adenocarcinoma or leiomyoma of the esophagus are extremely rare causes of dysphagia for solids greater than liquids in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40569/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Vascular ring or extrinsic compression",
"      </strong>",
"      &ndash; Vascular anomalies of the aortic arch with an encircling ring around the esophagus may rarely cause dysphagia in children. These anatomic anomalies usually present as respiratory distress in an infant less than one year of age. Dysphagia, vomiting, and feeding difficulty are also common. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=see_link&amp;anchor=H11#H11\">",
"       \"Vascular rings\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Extrinsic compression from mediastinal or chest tumors (eg, lymphoma) may rarely compromise esophageal motility. However, these tumors are most notable for causing respiratory distress, stridor, wheezing,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anxiety, especially when the patient is in a supine position, and for complicating airway management in patients with respiratory failure. Patients with stridor, obstructive upper airway swelling, or cerebral edema caused by superior vena cava syndrome warrant emergency radiotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vascular stenting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=see_link&amp;anchor=H18#H18\">",
"       \"Malignancy-related superior vena cava syndrome\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Globus sensation",
"      </strong>",
"      &ndash; Globus sensation is defined as an intermittent feeling of a lump or foreign body in the throat that occurs between meals, has lasted for at least six months, and is not associated with gastroesophageal reflux or esophageal motility disorders. In addition, patients with globus sensation do not have true dysphagia. Although common in adults, globus sensation is rare in children and warrants appropriate diagnostic evaluation to exclude the presence of a true foreign body or other esophageal pathology. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21814?source=see_link&amp;anchor=H9#H9\">",
"       \"Globus sensation\", section on 'Evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of children with signs and symptoms of dysphagia must begin with a rapid assessment of respiratory status to identify those who need resuscitation. Conditions that require immediate intervention include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete upper airway obstruction",
"     </li>",
"     <li>",
"      Rapidly progressing partial airway obstruction",
"     </li>",
"     <li>",
"      Respiratory failure",
"     </li>",
"     <li>",
"      Mediastinal mass with tracheal impingement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Priorities for these patients include providing supplemental oxygen, support of breathing, and definitive airway management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate and complete history should suggest the diagnosis in the majority of patients. Key historical information includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Witnessed foreign body ingestion (or missing small foreign bodies or button batteries)Known or suspected caustic ingestion",
"     </li>",
"     <li>",
"      Aphonia",
"     </li>",
"     <li>",
"      Presence of fever, especially with oral lesions, drooling, sore throat, trismus, or stiff neck",
"     </li>",
"     <li>",
"      Erythema multiforme rash or desquamation with mucous membrane changes in patients with risk factors for Stevens-Johnson syndrome or toxic epidermal necrolysis (",
"      <a class=\"graphic graphic_picture graphicRef73805 \" href=\"mobipreview.htm?30/7/30836\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef67632 \" href=\"mobipreview.htm?24/48/25345\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef76141 \" href=\"mobipreview.htm?26/25/27030\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef66134 \" href=\"mobipreview.htm?17/63/18419\">",
"       picture 6",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H6\">",
"       'Stevens-Johnson syndrome'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Type of dysphagia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dysphagia for solids more than liquids suggests some degree of esophageal obstruction (eg, foreign body, food bolus, esophageal tumor [rare], vascular ring [rare])",
"     </li>",
"     <li>",
"      Dysphagia that is equal for solids and liquids suggests esophageal dysmotility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain exacerbated by eating suggesting gastroesophageal reflux",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      esophagitis",
"     </li>",
"     <li>",
"      Substernal pain after taking an oral medication, especially",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/38/28262?source=see_link\">",
"       tetracycline",
"      </a>",
"      antibiotics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/54/12136?source=see_link\">",
"       doxycycline",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Symptoms of cranial nerve weakness, including vision changes, ptosis, nasal regurgitation of food or liquid with swallowing",
"     </li>",
"     <li>",
"      Prior history of rheumatic disease, Crohn's disease, or chronic neurologic impairment (eg, cerebral palsy, traumatic brain injury)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with dysphagia should undergo a thorough general physical examination, initially focusing on the patient's cardiopulmonary status. Signs suggesting upper airway obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serious respiratory distress include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      New onset of drooling",
"     </li>",
"     <li>",
"      Stridor",
"     </li>",
"     <li>",
"      Suprasternal retractions",
"     </li>",
"     <li>",
"      Inability to speak (aphonia)",
"     </li>",
"     <li>",
"      Hot potato voice",
"     </li>",
"     <li>",
"      Tachypnea",
"     </li>",
"     <li>",
"      Cyanosis or low oxygen saturation by pulse oximetry",
"     </li>",
"     <li>",
"      Worsening respiratory status in the supine position indicating a mediastinal mass",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of respiratory distress should be treated promptly. Assurance of a secure and stable airway should precede attempts to examine the oropharynx or to remove a foreign body (",
"    <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"mobipreview.htm?22/48/23296\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef54996 \" href=\"mobipreview.htm?9/37/9810\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the stable dysphagic patient, inspection of the oral cavity, pharynx, and neck may reveal a cyst, mass, localized infection, or inflammatory cause for dysphagia. Specific findings are discussed in the conditions described above.",
"   </p>",
"   <p>",
"    The pulmonary examination may also detect signs of aspiration, including rales, rhonchi, decreased breath sounds, expiratory wheezing, or hoarse voice.",
"   </p>",
"   <p>",
"    Neurologic examination may reveal an altered level of arousal from an underlying brain injury or depressed sensorium from drugs or infection that may limit effective swallowing. Examination of the cranial nerves, particularly V, VII, IX, X, and XII, may reveal deficits that negatively impact swallowing.",
"   </p>",
"   <p>",
"    Evaluation of muscle tone, strength, and reflexes is important to identify other neuromuscular causes of dysphagia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Ancillary studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The older child with an acute onset of dysphagia requires an urgent approach to diagnosis. In most patients, a history and physical examination will identify the most likely etiology. Additional studies provide confirmation of the clinical diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should obtain a complete blood count and appropriate cultures based on the suspected infectious etiology in the febrile child with dysphagia.",
"   </p>",
"   <p>",
"    Whether or not to obtain other studies (eg, electrolytes, blood gas measurements) depends on the respiratory and hydration status of the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic evaluation of the dysphagic child typically includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AP and lateral plain films of the airway and soft tissues of the neck, looking for evidence of a foreign body, mass, airway impingement, air in the retropharyngeal region or subcutaneous tissues, epiglottitis, tracheitis, or other abnormality.",
"     </li>",
"     <li>",
"      AP and lateral chest radiograph to identify signs of aspiration pneumonia, congenital heart disease, subcutaneous air from mediastinitis, mediastinal mass, or, as in the patient with achalasia, dilated esophagus with air-fluid levels.",
"     </li>",
"     <li>",
"      In addition to plain radiographs, children with witnessed or highly suspected radiolucent foreign bodies and dysphagia should undergo fluoroscopic contrast studies (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow) or endoscopy. Once identified, timing of esophageal foreign body removal depends on the location of obstruction and degree of symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=see_link&amp;anchor=H15#H15\">",
"       \"Foreign bodies of the esophagus and gastrointestinal tract in children\", section on 'Approaches for specific types of foreign bodies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link&amp;anchor=H35#H35\">",
"       \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Algorithmic approach'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computed tomography (CT) scan of the neck or chest provides confirmation of diseases, such as retropharyngeal abscess and mediastinitis, suggested by clinical evaluation and plain radiographs.",
"   </p>",
"   <p>",
"    Patients with evidence of increased intracranial pressure or focal neurologic signs suggesting a brain abscess or tumor should receive a head CT.",
"   </p>",
"   <p>",
"    Although cervical ultrasonography has been used to identify abnormalities with the tissues and function of the palate, tongue, and floor of the mouth, it is less useful than contrast studies for assessing airway problems and aspiration.",
"   </p>",
"   <p>",
"    Ultrasound of the chest in an upright position can identify whether a mediastinal mass is solid or liquid and avoids patient decompensation associated with the supine position necessary for chest CT in patients with superior cava syndrome. However, US often does not provide a definitive diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Other diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy is an essential procedure in patients who have ingested a caustic agent or have evidence of an obstructing foreign body. Optimal timing of endoscopy depends on the clinical setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4473?source=see_link&amp;anchor=H8#H8\">",
"     \"Caustic esophageal injury in children\", section on 'Diagnostic evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link&amp;anchor=H9#H9\">",
"     \"Airway foreign bodies in children\", section on 'Diagnosis and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Upper endoscopy and bronchoscopy are emergently indicated in patients with mediastinitis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Esophageal perforation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Elective upper gastrointestinal endoscopy and manometry are typically performed to confirm achalasia and esophagitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to children with dysphagia is provided in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef75648 \" href=\"mobipreview.htm?4/25/4497\">",
"     algorithm 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef63998 \" href=\"mobipreview.htm?40/13/41169\">",
"     algorithm 6",
"    </a>",
"    ). Evaluation and management is strongly determined by the presence of respiratory compromise, fever, and clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Respiratory compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with cyanosis or respiratory distress should receive 100 percent oxygen, and receive no oral intake until fully evaluated and clinically stable.",
"   </p>",
"   <p>",
"    Children with life-threatening upper airway obstruction require assessment and treatment as presented in the algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef55990 \" href=\"mobipreview.htm?22/48/23296\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef54996 \" href=\"mobipreview.htm?9/37/9810\">",
"     algorithm 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Children with evidence of respiratory failure should receive support of breathing with bag-valve-mask ventilation and undergo endotracheal intubation (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"mobipreview.htm?17/26/17837\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Dysphagia with fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should evaluate these patients for oropharyngeal, parapharyngeal, and upper airway infection, in particular (",
"    <a class=\"graphic graphic_algorithm graphicRef75648 \" href=\"mobipreview.htm?4/25/4497\">",
"     algorithm 5",
"    </a>",
"    ). Other diagnoses, such as mediastinitis, are also possible.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epiglottitis manifests as aphonia, drooling, and severe respiratory distress with signs of upper airway obstruction.",
"     </li>",
"     <li>",
"      Trismus and unilateral peritonsillar swelling with a hot potato (muffled, hypernasal) voice identifies peritonsillar abscess.",
"     </li>",
"     <li>",
"      Drooling, lateral neck pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pain with neck extension suggests retropharyngeal or parapharyngeal infection.",
"     </li>",
"     <li>",
"      Fever, severe substernal pain, crepitus,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shock after a caustic ingestion, chronic esophageal foreign body, or esophageal procedure are manifestations of esophageal perforation with mediastinitis.",
"     </li>",
"     <li>",
"      Severe trismus, opisthotonos, and myotonia worsened by loud noise in an unimmunized or underimmunized child is diagnostic for tetanus. The presence of fever may be variable.",
"     </li>",
"     <li>",
"      The presence of a pseudomembrane on oropharyngeal examination suggests diphtheria.",
"     </li>",
"     <li>",
"      Exudative tonsillitis with pain on swallowing indicates acute pharyngitis.",
"     </li>",
"     <li>",
"      Painful mucosal ulcers are characteristic for stomatitis or Stevens-Johnson syndrome. The presence of fever may be variable.",
"     </li>",
"     <li>",
"      Acute thyroid enlargement with respiratory compromise is seen in patients with acute suppurative thyroiditis. The presence of fever may be variable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infections, such as poliomyelitis, meningitis, encephalitis, or cerebral abscess, may cause neurologic dysfunction (cranial nerve palsy or altered mental status) with impairment of swallowing.",
"   </p>",
"   <p>",
"    Patients with impaired swallowing from a chronic neurologic disorder (eg, cerebral palsy, traumatic brain injury) require assessment for aspiration pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Dysphagia without fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although typically evident from the history, an acute onset of dysphagia in an otherwise healthy child should raise suspicion for an esophageal foreign body, caustic ingestion, or thermal esophageal burn (",
"    <a class=\"graphic graphic_algorithm graphicRef63998 \" href=\"mobipreview.htm?40/13/41169\">",
"     algorithm 6",
"    </a>",
"    ). Clinical features that identify other etiologies in the afebrile child with dysphagia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral bleeding, puncture wound, or laceration (oropharyngeal trauma).",
"     </li>",
"     <li>",
"      Intermittent dysphagia in association with oculogyric crisis, dysarthria, trismus, or torticollis (dystonic reaction).",
"     </li>",
"     <li>",
"      Odynophagia exacerbated by eating or certain oral medications (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/54/12136?source=see_link\">",
"       doxycycline",
"      </a>",
"      ) (esophagitis).",
"     </li>",
"     <li>",
"      Skin changes, arthritis, and rash characteristic of rheumatic disease (juvenile systemic sclerosis, dermatomyositis).",
"     </li>",
"     <li>",
"      Ptosis, bulbar weakness exacerbated by eating (eg, botulism, myasthenia gravis).",
"     </li>",
"     <li>",
"      Cranial nerve dysfunction in association with visual disturbance, ataxia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      headache (central nervous system tumor).",
"     </li>",
"     <li>",
"      Dysphagia for solids more than liquids in association with an esophageal obstruction (eg, foreign body, food bolus, esophageal tumor [rare], vascular ring [rare]).",
"     </li>",
"     <li>",
"      Dysphagia for solids and liquids in association with abnormal esophageal motility on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      manometry (achalasia).",
"     </li>",
"     <li>",
"      Dysphagia with no apparent anatomic or physiologic cause (globus sensation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table summarizes the important etiologies to consider in the child with dysphagia (",
"    <a class=\"graphic graphic_table graphicRef73934 \" href=\"mobipreview.htm?38/9/39067\">",
"     table 1",
"    </a>",
"    ). Evaluation and management is strongly determined by the presence of respiratory compromise, fever, and clinical findings (",
"    <a class=\"graphic graphic_algorithm graphicRef75648 \" href=\"mobipreview.htm?4/25/4497\">",
"     algorithm 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef63998 \" href=\"mobipreview.htm?40/13/41169\">",
"     algorithm 6",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/1\">",
"      Brinster CJ, Singhal S, Lee L, et al. Evolving options in the management of esophageal perforation. Ann Thorac Surg 2004; 77:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/2\">",
"      Peng L, Quan X, Zongzheng J, et al. Videothoracoscopic drainage for esophageal perforation with mediastinitis in children. J Pediatr Surg 2006; 41:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/3\">",
"      White RK, Morris DM. Diagnosis and management of esophageal perforations. Am Surg 1992; 58:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/4\">",
"      Wright CD, Mathisen DJ, Wain JC, et al. Reinforced primary repair of thoracic esophageal perforation. Ann Thorac Surg 1995; 60:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/5\">",
"      Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol 2008; 24:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/6\">",
"      McCann LJ, Garay SM, Ryan MM, et al. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology (Oxford) 2007; 46:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/7\">",
"      Rudolph CD, Link DT. Feeding disorders in infants and children. Pediatr Clin North Am 2002; 49:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/8\">",
"      Ramaswamy K, Jacobson K, Jevon G, Israel D. Esophageal Crohn disease in children: a clinical spectrum. J Pediatr Gastroenterol Nutr 2003; 36:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/9\">",
"      Gangopadhyay AN, Mohanty PK, Gopal SC, et al. Adenocarcinoma of the esophagus in an 8-year-old boy. J Pediatr Surg 1997; 32:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40569/abstract/10\">",
"      Federici S, Ceccarelli PL, Bernardi F, et al. Esophageal leiomyomatosis in children: report of a case and review of the literature. Eur J Pediatr Surg 1998; 8:358.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6445 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-DB96A30595-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40569=[""].join("\n");
var outline_f39_39_40569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Esophageal foreign body",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Caustic ingestion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Retropharyngeal abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Epiglottitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Central nervous system infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Impairment of swallowing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tetanus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diphtheria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Poliomyelitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Central nervous system tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Esophageal perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Stomatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Infectious pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Peritonsillar abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Esophagitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dystonic reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Oropharyngeal trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Achalasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Ancillary studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Other diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Respiratory compromise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Dysphagia with fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Dysphagia without fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6445|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?41/12/42178\" title=\"algorithm 1\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?30/37/31327\" title=\"algorithm 2\">",
"      Suspected infectious pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?22/48/23296\" title=\"algorithm 3\">",
"      Complete airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?9/37/9810\" title=\"algorithm 4\">",
"      Severe upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/25/4497\" title=\"algorithm 5\">",
"      Acute dysphagia child fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?40/13/41169\" title=\"algorithm 6\">",
"      Acute dysphagia child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6445|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/15/14578\" title=\"diagnostic image 1\">",
"      Esophageal foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/55/24446\" title=\"diagnostic image 2\">",
"      Achalasia barium swallow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6445|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/53/43871\" title=\"picture 1\">",
"      Esophageal coin erosion 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/47/18175\" title=\"picture 2\">",
"      Esophageal coin erosion 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/7/30836\" title=\"picture 3\">",
"      Mucosal changes in Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/48/25345\" title=\"picture 4\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/25/27030\" title=\"picture 5\">",
"      Cutaneous findings of Stevens Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/63/18419\" title=\"picture 6\">",
"      Toxic epidermal necrolysis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/18/35106\" title=\"picture 7\">",
"      Toxic epidermal necrolysis - bullae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/1/39953\" title=\"picture 8\">",
"      Toxic epidermal necrolysis - back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/27/13747\" title=\"picture 9\">",
"      Toxic epidermal necrolysis - abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/6/3168\" title=\"picture 10\">",
"      Caustic stricture esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/0/8197\" title=\"picture 11\">",
"      Epiglottitis classic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/54/26465\" title=\"picture 12\">",
"      Epiglottitis tripod posture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/3/27702\" title=\"picture 13\">",
"      Herpetic stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/54/30575\" title=\"picture 14\">",
"      Peritonsillar abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/53/26449\" title=\"picture 15\">",
"      Reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/23/22896\" title=\"picture 16\">",
"      Eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/9/37023\" title=\"picture 17\">",
"      Esophagitis stricture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6445|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/9/39067\" title=\"table 1\">",
"      Dysphagia child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/10/25773\" title=\"table 2\">",
"      Epiglottitis in children &ndash; Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/26/17837\" title=\"table 3\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21769?source=related_link\">",
"      Acute viral encephalitis in children and adolescents: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15337?source=related_link\">",
"      Button and cylindrical battery ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4473?source=related_link\">",
"      Caustic esophageal injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/26/14759?source=related_link\">",
"      Clinical manifestations and diagnosis of achalasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/56/13192?source=related_link\">",
"      Clinical manifestations and diagnosis of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/46?source=related_link\">",
"      Clinical manifestations and evaluation of obstructive or substernal goiter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24280?source=related_link\">",
"      Congenital and acquired goiter in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29287?source=related_link\">",
"      Epidemiology, pathophysiology and clinical manifestations of diphtheria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/16/12553?source=related_link\">",
"      Epiglottitis (supraglottitis): Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4600?source=related_link\">",
"      First generation (Typical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21814?source=related_link\">",
"      Globus sensation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/31/6647?source=related_link\">",
"      Herpes simplex virus infection of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/27/31160?source=related_link\">",
"      Herpetic gingivostomatitis in young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39433?source=related_link\">",
"      Juvenile systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37078?source=related_link\">",
"      Medication-induced esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23016?source=related_link\">",
"      Oropharyngeal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31481?source=related_link\">",
"      Overview of Candida infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_39_40570="Overview of the management of epilepsy in adults";
var content_f39_39_40570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the management of epilepsy in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40570/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40570/contributors\">",
"     Steven C Schachter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40570/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/39/40570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/39/40570/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/39/40570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with epilepsy is focused on three main goals: controlling seizures, avoiding treatment side effects, and maintaining or restoring quality of life. Physicians should assist in empowering patients with epilepsy to lead lifestyles consistent with their capabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal treatment plan is derived following an accurate diagnosis of the patient's seizure type(s), an objective measure of the intensity and frequency of the seizures, awareness of medication side effects, and an evaluation of disease-related psychosocial problems. A working knowledge of available antiepileptic drugs (AEDs), including their mechanisms of action, pharmacokinetics, drug-drug interactions, and adverse effects is essential.",
"   </p>",
"   <p>",
"    It is usually appropriate to refer the patient to a neurologist, when establishing a diagnosis and formulating a course of treatment. Referral to an epilepsy specialist may be necessary if there is doubt about the diagnosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if the patient continues to have seizures.",
"   </p>",
"   <p>",
"    The overall approach to management of a patient with seizures is reviewed here. Evaluation of the patient who has had a first seizure and the pharmacology of specific AEDs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in designing a treatment plan is to classify the patient's seizure type(s) using the framework of the International League Against Epilepsy (",
"    <a class=\"graphic graphic_table graphicRef53661 \" href=\"mobipreview.htm?0/60/973\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Seizure types and epilepsy syndromes are classified primarily upon clinical grounds, assisted by laboratory, neurophysiologic, and radiographic studies. Seizure type has important implications in the choice of antiepileptic drugs (AEDs). Accurate classification requires a full history from the patient and reports from observers who have witnessed actual seizures.",
"   </p>",
"   <p>",
"    Patients may be better able to describe their seizure symptoms after reading published seizure descriptions, which in turn may improve the clinician's ability to categorize the seizure type and to plan a successful therapeutic approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/5\">",
"     5",
"    </a>",
"    ]. Many patients experience more than one type of seizure (eg, complex partial and secondarily generalized seizures).",
"   </p>",
"   <p>",
"    Pointed questions may be necessary to reveal behaviors or environmental factors that contribute to the incidence of seizures. These \"seizure triggers,\" such as sleep deprivation, alcohol intake, and stress, may be modifiable. Thus, taking steps that limit exposure to these triggers usually enhances the benefits of AED therapy.",
"   </p>",
"   <p>",
"    There are two broad categories of seizures: partial (or focal) and generalized (",
"    <a class=\"graphic graphic_table graphicRef53661 \" href=\"mobipreview.htm?0/60/973\">",
"     table 1",
"    </a>",
"    ). Partial seizures involve only a portion of the brain, typically part of one lobe of one hemisphere. A complex partial seizure (CPS) implies that consciousness is impaired, while simple partial seizures (SPS) are not associated with altered consciousness. A partial seizure can evolve over seconds into a tonic-clonic convulsion, referred to as a secondarily generalized seizure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Partial seizures. SPS can present in a variety of ways; however, within an individual patient, the seizures are usually stereotyped. Common SPS include both visible manifestations, such as jerking of a limb as well as subjective experiences perceived only by the patient, such as epigastric discomfort, fear, or an unpleasant smell. Such subjective feelings are commonly referred to as auras. SPS may be immediately followed by CPS; these are usually manifested by a clouding of consciousness, staring, and repetitive motor behaviors, termed automatisms, such as swallowing, chewing, or lip smacking. After a CPS, the patient may experience confusion, fatigue, and a throbbing headache. When individuals are told of their behavior during CPS, they often express disbelief, as they have no recollection. In fact, some patients are completely unaware of all of their seizures.",
"     </li>",
"     <li>",
"      Generalized seizures. Generalized seizures are those in which the first clinical and electroencephalographic changes indicate that large parts of both hemispheres of the brain are involved at the onset of the seizure. There is nearly always impaired consciousness except for the very brief myoclonic seizures. The most common subtypes of generalized seizures are tonic-clonic seizures (grand mal), absence seizures (petit mal), and myoclonic seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIEPILEPTIC DRUG THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     When to start AED therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate antiepileptic drug (AED) therapy is usually not necessary in individuals after a single seizure, particularly if a first seizure is provoked by factors that resolve. AED therapy should be started in patients who are at significant risk for recurrent seizures, such as those with remote symptomatic seizures. AED treatment is generally started after two or more unprovoked seizures, because the recurrence proves that the patient has a substantially increased risk for repeated seizures, well above 50 percent.",
"   </p>",
"   <p>",
"    The issues to be considered in deciding when to start AED therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial treatment of epilepsy in adults\", section on 'When to start AED therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AED therapy is not necessarily life-long. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Discontinuing AED therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choosing an AED",
"    </span>",
"    &nbsp;&mdash;&nbsp;About half of patients with a new diagnosis of epilepsy will become seizure free with the first AED prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Tolerability of side effects is as important as efficacy in determining the overall effectiveness of treatment. No single AED is optimal for every patient or even most patients. The selection of a specific AED for treating seizures must be individualized considering:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Drug effectiveness for the seizure type or types (",
"      <a class=\"graphic graphic_table graphicRef78021 \" href=\"mobipreview.htm?19/32/19979\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Potential adverse effects of the drug (",
"      <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Interactions with other medications (",
"      <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Comorbid medical conditions, especially but not limited to hepatic and renal disease",
"     </li>",
"     <li>",
"      Age and gender, including childbearing plans",
"     </li>",
"     <li>",
"      Lifestyle and patient preferences",
"     </li>",
"     <li>",
"      Cost",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, enzyme-inducing AEDs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    ; and less so,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ) are the most problematic for drug interactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and oral contraceptive therapy, as well as certain anti-cancer and anti-infective drugs (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Issues to consider in selecting a specific AED are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial treatment of epilepsy in adults\", section on 'Selection of an AED'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Subsequent drug trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;About half of patients with a new diagnosis of epilepsy are successfully treated with the first AED prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Treatment failure may result from breakthrough seizures or drug intolerance. In one study of 138 newly treated patients with epilepsy, breakthrough seizures (that were not explained by medical noncompliance or significant provoking factor) occurred in 45 patients during the first year and were more common in patients with pretreatment neuropsychiatric symptoms and those with MRI abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/8\">",
"     8",
"    </a>",
"    ]. Multivariate analysis also identified genomic factors as a risk of recurrent seizures. At this point, a second drug trial should be attempted. When the initial drug failure is due to adverse effects, the second drug trial will be successful in half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/9\">",
"     9",
"    </a>",
"    ]. Substantially fewer patients (about 10 to 20 percent) will have a successful second drug trial if the initial failure was due to lack of efficacy.",
"   </p>",
"   <p>",
"    Similar factors are considered when a second AED is chosen as when the first was selected. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Choosing an AED'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    .) However, the clinician may also choose to select an AED with a somewhat different mechanism of action (",
"    <a class=\"graphic graphic_table graphicRef71274 \" href=\"mobipreview.htm?30/0/30733\">",
"     table 7",
"    </a>",
"    ) in hopes that efficacy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tolerance will be improved compared with the first drug used. It remains important to choose a drug with demonstrated efficacy for the patient's seizure type (",
"    <a class=\"graphic graphic_table graphicRef78021 \" href=\"mobipreview.htm?19/32/19979\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Except in the case of a serious adverse event, the second medication is typically increased to therapeutic levels before the first agent is reduced in order to prevent a flurry of seizures or status epilepticus during the switch-over period. The second antiepileptic medication is gradually titrated up slowly to effect (control of seizures) or to toxicity (side effects). However, patients should expect a temporary increase in side effects during the overlap period that will likely abate when the first AED is subsequently tapered off.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, it is preferable to maintain a patient on a single AED. This increases the probability of compliance, provides a wider therapeutic index, and is more cost-effective than combination drug treatment. Monotherapy is also associated with fewer idiosyncratic reactions and a lower incidence of teratogenic effects. Combination therapy can be associated with drug interactions between AEDs (",
"    <a class=\"graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463 \" href=\"mobipreview.htm?0/4/72\">",
"     table 8A-C",
"    </a>",
"    ), making it difficult to dose and monitor patients.",
"   </p>",
"   <p>",
"    This conventional wisdom is only partly supported by published data, which give conflicting information regarding the risks and benefits of mono- versus polytherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one large case series of 809 patients with refractory epilepsy, rates of adverse events did not differ between patients on poly- versus monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In one clinical trial, rates of adverse events were similar among 157 patients randomized to adjunctive treatment versus alternative monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A randomized, double-blind study that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      monotherapy to combination therapy with carbamazepine and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      found no significant difference in neurotoxicity between the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In one epidemiologic survey, polytherapy was associated with lower quality of life and lower rates of employment compared with patients on monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no controlled studies comparing different drug combinations, and virtually every possible combination of AEDs has been tried. An analysis of 70 randomized controlled trials of AEDs administered as add-on therapy in patients with refractory partial epilepsy found that differences in efficacy were of too small magnitude to allow a conclusion about which AED is more effective as adjunctive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/15\">",
"     15",
"    </a>",
"    ]. A retrospective chart review of 148 developmentally disabled adults with drug-resistant epilepsy suggested that the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    may have superior efficacy over other combinations, but this was a nonrandomized study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/16\">",
"     16",
"    </a>",
"    ]. In the absence of data from clinical trials, it makes sense to choose an add-on drug that has a different mechanism of action (",
"    <a class=\"graphic graphic_table graphicRef71274 \" href=\"mobipreview.htm?30/0/30733\">",
"     table 7",
"    </a>",
"    ) and a different side-effect profile than the first AED (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. In this way, it is hoped that efficacy can be maximized and side effects minimized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/11\">",
"     11",
"    </a>",
"    ]. The benefit of this approach is largely theoretical, and one study found that patients randomized to an adjunctive treatment had similar rates of seizure remission compared with those randomized to alternative monotherapy (16 versus 14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/12\">",
"     12",
"    </a>",
"    ]. However, there is some anecdotal evidence that synergism between AEDs can occur. As an example, the combination of lamotrigine and valproate has been reported in some cases to have dramatic efficacy even when patients had previously failed treatment with one or both drugs in monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizure remission is achieved with combination therapy in only a small percentage (10 to 15 percent) of patients who have failed monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/9,23,24\">",
"     9,23,24",
"    </a>",
"    ]. One retrospective chart review suggested that while two concurrent AEDs might provide efficacy over monotherapy, use of three AEDs did not provide further benefit over two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the chances of treatment success diminish incrementally with each successive drug trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/25\">",
"     25",
"    </a>",
"    ], two studies suggest a value in pursuing further drug trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In one center, 15 percent of patients who had failed at least two prior AED trials subsequently became seizure free with AED therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/24\">",
"     24",
"    </a>",
"    ]. In another, 28 percent of patients with a history of uncontrolled seizures for five or more years were subsequently controlled on AED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/23\">",
"     23",
"    </a>",
"    ]. In some cases, response to treatment occurred with a fourth or fifth drug trial. Both studies found that the number of previous failed trials was a negative prognostic indicator, and a history of status epilepticus, younger age at intractability, underlying mental retardation, longer duration of epilepsy, and symptomatic epilepsy were each negative predictors in one of the two studies.",
"   </p>",
"   <p>",
"    Overall, up to 80 percent of patients can become seizure free on AED treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Side effects of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first six months of treatment, systemic toxicity and neurotoxicity cause AED failure to the same degree as lack of efficacy against seizures (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"     table 4",
"    </a>",
"    ). Serum levels that are associated with neurotoxicity vary from patient to patient, and toxicity can occur even when measured levels are considered to be within the appropriate therapeutic range.",
"   </p>",
"   <p>",
"    The usual strategy in patients experiencing peak-level side effects from a specific drug is to alter the medication regimen or treatment schedule to minimize side effects; one alteration may be to spread the medication over more doses throughout the day. The physician should attempt to correlate serum drug concentrations with the patient's side effects before abandoning that medication. Specifically, levels should be obtained when a patient is experiencing side effects compared with levels when the patient is free from symptoms can be helpful in the management of some patients.",
"   </p>",
"   <p>",
"    I find it helpful to refer to the patient's seizure calendar in planning the timing of drug levels in an attempt to prove a cause-and-effect relationship between peak levels and side effects. As an example, in a patient who experiences seizures only at night but who has side effects in the afternoon from his or her morning dose of antiepileptic, shifting part of the morning dose to the bedtime dose may eliminate these side effects while improving seizure control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Specific adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many side effects of AEDs specific to individual medications are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .) Some severe reactions that are common to more than one medication include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased risk of suicidality has been linked to several AEDs in randomized placebo-controlled studies of patients with epilepsy, according to a January 2008 United States Food and Drug Administration (FDA) report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/26\">",
"       26",
"      </a>",
"      ]. The elevated risk (0.43 versus 0.22 percent) was observed as early as one week after starting medication and continued though the 24 weeks of study observation. The effect was consistent in the 11 AEDs studied, and the FDA considers this risk likely to be shared by all AEDs. A literature review estimated that the overall standardized mortality ratio for suicide was 3.3; and that this increased risk appeared to be present among most subgroups of individuals with epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      While observational studies have challenged these findings, these studies are not sufficiently rigorous to refute them. A case-control study found that only some of the newer AEDs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"       vigabatrin",
"      </a>",
"      ) were associated with a risk of self-harm or suicide, while older and other newer AEDS were not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/28\">",
"       28",
"      </a>",
"      ]. Another study based in the United Kingdom found that the magnitude of suicide risk associated with AED use varied according to the underlying etiology and was not elevated in patients with epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/29\">",
"       29",
"      </a>",
"      ]. However, the clinical studies evaluated by the FDA that led to the original warning were performed in patients with epilepsy.",
"      <br/>",
"      <br/>",
"      While this clinical advisory is somewhat controversial, clinicians prescribing AEDs should identify a current or past history of depression, anxiety, and suicidal ideation or behavior in their patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Patients taking AEDs should be monitored for emergence or worsening of suicidal ideation or depression. Patients and families should be encouraged to call their physician if they experience any symptoms of depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/30,32\">",
"       30,32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H669264\">",
"       'Depression and psychiatric disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) are rare but severe idiosyncratic reactions, characterized by fever and mucocutaneous lesions that have been associated with the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"       zonisamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , and (less commonly) other AEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/33-36\">",
"       33-36",
"      </a>",
"      ]. The period of highest risk is within the first two months of use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/37\">",
"       37",
"      </a>",
"      ]. The risk may be higher in patients with HLA-B*1502 allele, which occurs almost exclusively in patients of Asian ancestry, including South Asian Indians. The FDA recommends screening such patients for this allele prior to starting carbamazepine and possibly phenytoin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/38\">",
"       38",
"      </a>",
"      ]. Because cross-hypersensitivity to other AEDs is common, patients who experience this reaction should subsequently be treated with nonaromatic AEDs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ) which have a lower risk of this reaction. In one case series, the latter medications were well-tolerated when prescribed as alternative AEDs to patients who experienced SJS or TEN in association with an aromatic AED [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/36\">",
"       36",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"       \"Pharmacology of antiepileptic drugs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduced vitamin levels have also been described in patients taking AEDs. In one study, subnormal folate levels were reported in 16 percent of patients on AEDs (primarily in patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"       primidone",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/39\">",
"       39",
"      </a>",
"      ]. While vitamin B12 levels were lower on average in patients taking AEDs (particularly in patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      , primidone, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ), the frequency of subnormal B12 levels was not significantly different in patients compared with controls. Vitamin supplementation yielded normal levels in patients with subnormal levels within three months.",
"     </li>",
"     <li>",
"      Bone loss has also been described in patients receiving long-term AEDs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36969?source=see_link\">",
"       \"Antiepileptic drugs and bone disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Maximizing the likelihood of a successful outcome",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Titration and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some general principles to consider when starting an AED include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment should be started with a single drug (monotherapy).",
"     </li>",
"     <li>",
"      In general, the strategy is to gradually titrate the dosage to that which is maximally tolerated",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      produces seizure freedom (start low and go slow).",
"     </li>",
"     <li>",
"      Treatment should be monitored regularly. At regular office visits, physicians should ask and record seizure frequency and medication side effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The recommended initial dose for individual AEDs and a potential titration schedule are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular follow-up visits should be scheduled to check drug concentrations, blood counts, and hepatic and renal function, when indicated. These visits are also used to address concerns the patient may have about taking the medication and possible side effects, or psychosocial aspects of their disorder. It may be useful to obtain drug levels at least yearly, including in patients who are not having seizures and not undergoing medication dose changes.",
"   </p>",
"   <p>",
"    Drug levels can be helpful in the management of AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To establish an individual therapeutic concentration range when a patient is in remission",
"     </li>",
"     <li>",
"      To assist in the diagnosis of clinical AED toxicity (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Side effects of therapy'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      To assess compliance (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Noncompliance with AED therapy'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      To guide dose adjustments, particularly in the setting of drug formulation changes, breakthrough seizures, when an interacting medication is added to or removed from a patient's regimen, or during pregnancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total serum levels alone should not necessarily be taken at face value. As an example, unbound (\"free\") serum levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , must be checked in patients who have low albumin levels or who are taking other drugs that are tightly protein-bound; free levels should be multiplied by 10 to approximate the desired total serum level for agents that are typically about 90 percent protein bound. It is also important to measure free drug levels in pregnant women taking AEDs that are bound significantly to serum proteins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of epilepsy and pregnancy\", section on 'Drug levels and dose adjustment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum drug concentrations may fluctuate in compliant patients due to laboratory error, change in drug formulation (generic to brand, reverse, or generic to generic switch), drug interactions, variable absorption, and variable pill potency (eg, some pills stored in warm, humid places may have reduced effectiveness). Fluctuating AED levels at different points in the menstrual cycle may play a role in breakthrough seizures in women with catamenial epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23480?source=see_link\">",
"     \"Catamenial epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before treatment is initiated, the physician needs to begin a dialogue with the patient and family to increase their understanding of epilepsy and their ability to report necessary and relevant information. Epilepsy affects each patient in a unique way, and patients differ in their capacity to understand various aspects of the disorder. As a result, physicians must tailor discussions to clarify the impact of the condition on the specific patient's quality of life and expectations of the treatment plan. These discussions will improve the likelihood that the patient will comply with the plan of treatment.",
"   </p>",
"   <p>",
"    The physician should impress upon the patient, family, and patient's friends the critical need to follow the prescribed drug regimen. Nonadherence to AED treatment regimen is associated with increased risk of mortality, as well as hospitalization and injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Complications of epilepsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Written instructions on how and when to take the drugs should be provided and should explain the dosing regimen and any potential adverse effects (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"     table 4",
"    </a>",
"    ). The patient must also be warned not to stop taking an AED and not to allow a prescription to run out or expire.",
"   </p>",
"   <p>",
"    Patients should be urged not to start any other prescription, over-the-counter medications, dietary supplements, or herbal remedies without first contacting their physician because these might affect serum concentrations of their AEDs (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial treatment of epilepsy in adults\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Seizure calendar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and family members should be asked to record seizures and AED doses on a calendar or diary, which can then be brought or sent to the physician for review. Seizure triggers should be indicated. The patient and family should note on the calendar the hour at which any symptoms occur. Electronic seizure diaries are also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The seizure calendar helps to monitor and encourage compliance. The seizure calendar also may be used to track the patient's response to drug therapy, including possible side effects. Seizure calendars can help identify seizure triggers. In one study of 71 patients completing daily seizure diaries, both lack of sleep and higher self-reported stress and anxiety were associated with seizure occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/49\">",
"     49",
"    </a>",
"    ]. Seizures were also associated with the patients' own prediction of the likelihood of seizure occurrence. Other reported seizure triggers include visual, olfactory, and auditory stimuli, alcohol consumption, missed meals, and hormone fluctuations related to the menstrual cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23480?source=see_link\">",
"     \"Catamenial epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physicians should be aware that patients are often unaware of their seizures and may significantly underestimate the number of seizures that occur, especially those that occur during sleep or that disrupt consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/51\">",
"     51",
"    </a>",
"    ]. Prolonged EEG recordings may be helpful in such patients, either ambulatory or in a video-EEG monitoring unit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Generic substitution",
"    </span>",
"    &nbsp;&mdash;&nbsp;While definitive studies have not been performed, anecdotal reports, small case series, and patient surveys suggest that generic substitution of AEDs may be problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Using pharmacokinetic data submitted to the FDA, one group of investigators found that most generic AEDs provide total drug delivery similar to the reference product [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/56\">",
"     56",
"    </a>",
"    ]. Differences in peak concentrations occurred but were more common, with switches between generic products causing greater changes in plasma drug concentrations than generic substitution of the reference product. It is possible that the small, FDA-allowed variations in pharmacokinetics between a name brand and its generic equivalent (and between generic equivalents) can lead to either toxicity or seizures in some patients who, for unknown reasons, are particularly vulnerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/57-61\">",
"     57-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of published reports with indirect evidence that this is a potential problem include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three large case-control studies have found that changes in AED formulation involving generics was a risk factor for emergency or hospital-level treatment of epilepsy (OR: 1.78 to 1.81) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/62-64\">",
"       62-64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Many, but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/65\">",
"       65",
"      </a>",
"      ], studies using medical and pharmacy claims databases have found that generic switching of AEDs is associated with higher epilepsy-related medical utilization rates (eg, hospitalizations) and seizure-related injuries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/66-69\">",
"       66-69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A retrospective study of breakthrough seizures that occurred in association with generic substitution found that AED blood levels at the time of the seizure were on average 33 percent lower than previous levels obtained when the patient was using branded AEDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a systematic review and meta-analysis of seven trials in which the frequency of seizures were compared between a brand name AED and a generic alternative found no difference in the odds of seizures between treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/71\">",
"     71",
"    </a>",
"    ]. The FDA also maintains that there is no convincing evidence that people with epilepsy have lessened seizure control when taking generic medications.",
"   </p>",
"   <p>",
"    Patients should be aware that pharmacists or mail-order pharmacies sometimes make generic substitutions at the point of sale, and that they should check with their physician prior to accepting this substitution. Additional clinical and laboratory monitoring with plasma drug levels may be advisable with changes in drug formulation. Clinicians should consider the possibility of change in drug formulation as a cause of unexpected break-through seizures or toxicity along with other possible explanations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol consumption in small amounts (one to two drinks per day) may not affect seizure frequency or serum levels of AEDs in patients with well-controlled epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/72\">",
"     72",
"    </a>",
"    ]. Heavier alcohol intake (three or more drinks per day) increases the risk of seizures, particularly during the withdrawal period (7 to 48 hours after the last drink), and this practice should be strongly discouraged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an effort to enable people with epilepsy to live as normal a life as possible, it may be reasonable to advise that limited alcohol intake is acceptable, provided there is no history of alcohol or substance abuse or a history of alcohol-related seizures. However, patients should be aware that the data are not definitive at this time. Driving or other high-risk activities should be avoided for 24 to 48 hours after heavy alcohol intake due to the higher risk of seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Noncompliance with AED therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 50 percent of patients with epilepsy may fail to take their medications as directed; over one-half of those evaluated in emergency departments for recurrent seizures have been noncompliant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/74\">",
"     74",
"    </a>",
"    ]. Nonadherence to AED treatment regimen is not only associated with increased seizures, but also with increased risk of mortality, as well as hospitalization and injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/44,75\">",
"     44,75",
"    </a>",
"    ]. Clinicians should suspect noncompliance if a patient denies the diagnosis of epilepsy, has limited financial means to pay for AEDs, has difficulty tolerating side effects, or forgets when or how to take medication because of memory impairment. An unexpected increase in the number or severity of seizures, or either subtherapeutic or supratherapeutic serum drug concentrations, also suggests noncompliance. However, serum levels can fluctuate due to a number of factors; thus, they should be interpreted with some caution.",
"   </p>",
"   <p>",
"    Compliance diminishes when intervals between office visits grow longer and when medication regimens grow increasingly complex. Noncompliance also often results from a failure to communicate. Thus, improving the patient's understanding of his or her disorder and the need for regular intake of medications usually improves compliance. Some of the guidelines proposed to improve patient adherence to antihypertensive therapy may also be relevant to the patient with epilepsy (",
"    <a class=\"graphic graphic_table graphicRef77847 \" href=\"mobipreview.htm?34/12/35020\">",
"     table 9",
"    </a>",
"    ). One randomized study showed that at least short-term compliance was improved with an intervention that linked intake of medication with a particular time, place, or activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DRUG-RESISTANT EPILEPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standardized definition of medically intractable epilepsy. A task force of the International League Against Epilepsy proposed that drug-resistant epilepsy may be defined as failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2890?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation and management of drug-resistant epilepsy\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis and classification of epilepsy should be reconsidered in patients whose seizures do not respond to AED trials. In particular, video-EEG monitoring to confirm the epileptic nature of spells should be considered in anyone still having seizures after two AED trials or more than one year of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Established treatment options for medically refractory epilepsy in adults include epilepsy surgery and vagus nerve stimulation. The ketogenic or modified Atkins diet may be helpful in selected patients. Therapeutic strategies that employ varies forms of brain stimulation are in development. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One published guideline suggests that patients whose seizures are uncontrolled after 12 months should be referred to a specialized epilepsy center when possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and management of patients with medically refractory epilepsy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2890?source=see_link\">",
"     \"Evaluation and management of drug-resistant epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3824319\">",
"    <span class=\"h1\">",
"     ALTERNATIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some herbal medicines and dietary supplements, including melatonin and cannabis, may have anticonvulsant effects, but none has been tested in randomized, blinded, controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/79-82\">",
"     79-82",
"    </a>",
"    ]. Some herbal medicines and dietary supplements may instead be proconvulsant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/83\">",
"     83",
"    </a>",
"    ]. In addition, as with other drugs, alternative medications supplements can affect the metabolism of antiepileptic drugs (AEDs) and can thus alter drug levels. In addition, patients should be asked about their use of alternative medications and supplements, and consideration should be given to additional monitoring of AED levels in such patients.",
"   </p>",
"   <p>",
"    In one trial, acupuncture therapy was compared with a sham procedure in 34 patients with epilepsy and found no benefit for seizure frequency, seizure-free weeks, or quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Women of childbearing age",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of issues are important in women of childbearing age especially if they are considering becoming or are already pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. Clinicians should regularly review these issues with their female patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21131883\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate should be routinely prescribed to all women of childbearing age taking antiepileptic drugs (AEDs). Patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    should receive daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation (4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for one to three months prior to conception. Women who are taking other AEDs should take the more standard lower dose of folic acid (0.4 to 0.8 mg per day). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of epilepsy and pregnancy\", section on 'Folic acid supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancies should be planned and women with epilepsy require close follow-up in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link\">",
"     \"Management of epilepsy and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Oral contraceptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should be educated on the interactions between AED therapies and oral contraceptives (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 5",
"    </a>",
"    ). The expected contraceptive failure rate of 0.7 per 100 woman-years using oral contraceptives is increased to 3.1 per 100 woman-years in patients who concomitantly take AEDs that induce hepatic enzymes that increase the metabolism of oral contraceptives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enzyme induction occurs with all older AEDs (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    ) except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    . It also occurs, but to a lesser extent, with a few of the second generation AEDs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/18/7462?source=see_link\">",
"     perampanel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/94\">",
"     94",
"    </a>",
"    ]. Enzyme-inducing AEDs are also associated with decreased estrogen and progesterone levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/92,95\">",
"     92,95",
"    </a>",
"    ]. While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    is not an enzyme inducer, lower levels of ethinyl estradiol have been reported in volunteers taking this AED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) suggests that women taking enzyme-inducing AEDs use an alternative method of contraception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/97\">",
"     97",
"    </a>",
"    ]. They add, however, that hormonal contraception is reasonable if the patient understands the risks and cannot use other methods. The reported failure rate with oral contraceptives in women taking AEDs may still be comparable with or better than other methods of contraception, such as barrier methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While as yet unconfirmed in systematic studies, the increased failure rate with oral contraceptives may be ameliorated by increasing the dose and using extended cycle regimens with shorter pill-free intervals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Clinicians often recommend that women on enzyme-inducing AEDs who want to take oral contraceptives receive a preparation with at least 50 mcg of the estrogen component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/99\">",
"     99",
"    </a>",
"    ]. It is expected that both the efficacy and the incidence of adverse effects associated with a higher dose of hormones used in conjunction with enzyme-inducing AEDs should be comparable with standard doses when not combined with AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/99\">",
"     99",
"    </a>",
"    ]. However, this is unproven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Shorter pill-free interval'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H30#H30\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Continuous pill'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hormone levels in patients using intrauterine hormone-releasing systems (Mirena&reg;, LNg 20) or depot injections of progesterone are not affected by AEDs; these are effective alternatives to oral contraceptive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/99,101,102\">",
"     99,101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of intrauterine contraception\", section on 'Levonorgestrel-releasing IUD'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of contraception\", section on 'Depot medroxyprogesterone acetate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of the \"morning after pill\" may be similarly affected by enzyme-inducing AEDs. Two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    1.5 mg separated by 12 hours is recommended in these circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/99,103\">",
"     99,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=see_link\">",
"     \"Emergency contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the effect of AEDs on oral contraceptive metabolism, oral contraceptives can increase the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , thereby reducing the plasma drug concentration, typically by about 50 percent. Pregnancy has a similar effect of many other AEDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Lamotrigine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of epilepsy and pregnancy\", section on 'Drug levels and dose adjustment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21131890\">",
"    <span class=\"h3\">",
"     Fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a number of studies have suggested that women with epilepsy have increased rates of infertility, as high as 33 to 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/104,105\">",
"     104,105",
"    </a>",
"    ], other studies have not confirmed this finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/106\">",
"     106",
"    </a>",
"    ]. It is also uncertain whether this association is linked to epilepsy itself or to AED treatment.",
"   </p>",
"   <p>",
"    Potential confounding factors in assessing a possible association include lower marriage rates and a lower rate of planned pregnancies. The latter may result because the woman may be concerned about teratogenicity, her ability to care for a child, and increased risk of epilepsy in her child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that suggests that AED use may affect fertility. In a prospective cohort study of 375 women with epilepsy, infertility was linked to polytherapy, as well as to older age, and lower education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/104\">",
"     104",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     Valproate",
"    </a>",
"    , in particular, has been linked to an increased risk of polycystic ovary disease, a leading cause of infertility in woman [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\", section on 'High-risk groups'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Post-stroke seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke is the most common cause of seizures and epilepsy in population studies of adults over the age of 35 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/109\">",
"     109",
"    </a>",
"    ]. In one of the largest prospective studies, post-stroke seizures occurred in 168 of 1897 patients (8.9 percent) after hemispheric stroke, including 140 of 1632 (8.6 percent) with ischemic stroke and 28 of 265 (10.6 percent) with hemorrhagic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/110\">",
"     110",
"    </a>",
"    ]. However, recurrent seizures were rare during the nine months of follow-up, occurring in only 2.5 percent of patients.",
"   </p>",
"   <p>",
"    Seizures occurred within 24 hours of the stroke in 43 percent of patients in the above report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/110\">",
"     110",
"    </a>",
"    ]. The pathogenesis of these early-onset seizures may be related to local ion shifts and release of high levels of excitotoxic neurotransmitters in the area of ischemic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, an underlying permanent lesion that leads to persistent changes in neuronal excitability appears to be responsible for late-onset seizures after stroke and other brain injuries, and probably accounts for the fact that the risk of chronic epilepsy is higher in patients with late rather than early occurrence of seizures. In one study, for example, 118 patients who had a thrombotic stroke had a bimodal distribution of seizures either within two weeks or from 6 to 12 months after the stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/112\">",
"     112",
"    </a>",
"    ]. Epilepsy developed in more patients with late than early seizures (90 and 35 percent, respectively).",
"   </p>",
"   <p>",
"    Among a wide range of demographic characteristics, medical comorbidities, and stroke characteristics studied, stroke severity and cortical location have been found to be most consistently associated with the risk of acute and late seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/113-115\">",
"     113-115",
"    </a>",
"    ]. Age is not a risk factor. One prospective study found that preexisting dementia was a risk factor for late seizures (OR = 4.66, CI, 1.34-16.21) but not for early seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/116\">",
"     116",
"    </a>",
"    ]. Dementia is a risk factor for epilepsy in patients without stroke as well. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40841?source=see_link\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most seizures following stroke are focal at onset, but secondary generalization is common, particularly in patients with late-onset seizures. Status epilepticus is relatively uncommon, occurring in 9 percent of 180 patients with poststroke seizures in one report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     When to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the relatively low frequency of recurrent seizures after stroke, and an absence of absolute predictors of poststroke epilepsy, the decision of when to treat patients for a poststroke seizure is difficult. Nevertheless, most physicians empirically treat patients who develop late-onset seizures in the setting of a stroke history within the previous two to three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of specific AEDs for poststroke seizures has not been rigorously assessed in controlled trials, although most seizures can be controlled with a single agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/118\">",
"     118",
"    </a>",
"    ]. Several considerations factor into the choice of AED in this population. Studies suggest that newer AEDs have similar efficacy but a more favorable adverse event profile in older patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=see_link\">",
"     \"Treatment of seizures and epilepsy in the elderly patient\"",
"    </a>",
"    .) In one prospective randomized trial, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    treatment arm had a fewer drop-outs due to adverse events than did the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    arm; lamotrigine was also more efficacious, although this did not reach statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/119\">",
"     119",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    has been associated with 80 percent seizure remission in one uncontrolled study of post-stroke epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Older patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;AED use in elderly patients is complicated by several factors, including age-related alterations in protein binding, reduced hepatic metabolism, and diminished renal clearance of medications. In addition, medical comorbidities and polypharmacy are more often a concern in older adults. The selection of AED treatment in the elderly is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=see_link\">",
"     \"Treatment of seizures and epilepsy in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of epilepsy in the setting of brain tumors and head trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link\">",
"     \"Seizures in patients with primary and metastatic brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4935?source=see_link\">",
"     \"Post-traumatic seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF EPILEPSY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates in general are higher in people with chronic epilepsy compared with age- and sex-matched cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/121-124\">",
"     121-124",
"    </a>",
"    ]. In one study, the standardized mortality ratio (SMR) for chronic epilepsy was more than two [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/121\">",
"     121",
"    </a>",
"    ]. The SMR is highest in the initial year after diagnosis and subsequently decreases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/123\">",
"     123",
"    </a>",
"    ]. The greatest excess in mortality is seen in younger patients (&lt;30 years); there is no excess in mortality for older patients (&gt;60 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/121,124\">",
"     121,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Population-based studies have found that the standardized mortality ratios could be stratified according to etiology and are higher for remote symptomatic epilepsy and lower for idiopathic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. Similarly, mortality rates after an incident unprovoked seizure were found to be higher in those with symptomatic versus idiopathic seizures, with the cause of death often attributed to the underlying cause of seizure in those with symptomatic etiologies (eg, malignant neoplasm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accidental death may be the largest contributor to this excess mortality. This observation is supported by epidemiologic studies, which find that death rates for persons with epilepsy are about threefold higher for accidental death compared with persons without epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/124,126\">",
"     124,126",
"    </a>",
"    ]. The risk of a drowning death, in particular, is higher in patients with epilepsy, with an estimated relative risk ranging from 13 to 19-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/124,126,127\">",
"     124,126,127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to accidental deaths, deaths attributed to other causes (eg, respiratory disorders, cancer, cerebrovascular disease) may also be higher in patients with chronic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/121\">",
"     121",
"    </a>",
"    ]. One database study found that patients with epilepsy had high rates of comorbid illness, including pulmonary disease, hypertension, cerebrovascular disease, depression, and alcohol abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/128\">",
"     128",
"    </a>",
"    ]. A comorbidity index score predicted the risk of mortality.",
"   </p>",
"   <p>",
"    Patients with epilepsy have a small risk of sudden unexpected death, a condition referred to as sudden unexpected death in epilepsy (SUDEP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/129\">",
"     129",
"    </a>",
"    ]. Risk factors for SUDEP include early age of epilepsy onset, frequent generalized tonic-clonic seizures, and intractable epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/129-132\">",
"     129-132",
"    </a>",
"    ]. SUDEP is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1128?source=see_link\">",
"     \"Sudden unexpected death in epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Personal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that the risk of seizure-related personal injury, such as falls, bone fractures, drowning, and other accidents is significantly elevated compared with control subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/127,133-138\">",
"     127,133-138",
"    </a>",
"    ]. However, most of these studies selected preferentially for patients with injuries or more severe seizures, as most subjects were evaluated in emergency departments or tertiary centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A population-based study in Europe found that seizure-related accidents occurred in only 6.5 percent of the cohort at two years of follow-up; risk was largely determined by higher seizure frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/90\">",
"     90",
"    </a>",
"    ]. Similarly, a subsequent population-based study in the United States found that the risk of seizure-related injury was low and that most injuries were minor and without adverse social or occupational consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/139\">",
"     139",
"    </a>",
"    ]. Seizure frequency was the only significant risk factor for seizure-related injury.",
"   </p>",
"   <p>",
"    Patients with poorly controlled seizures are at the highest risk for seizure-related injury. However, for most patients with epilepsy, excessive restriction of activities for the purpose of avoiding injury is unnecessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/139\">",
"     139",
"    </a>",
"    ]. Supervision of swimming is a reasonable precaution.",
"   </p>",
"   <p>",
"    A few studies have suggested that people with epilepsy may be at higher risk of violent assault. In one report, death from homicide in the home was more common in patients with epilepsy compared with controls (RR = 2.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/140\">",
"     140",
"    </a>",
"    ]. One population-based study in Canada found that individuals with epilepsy were more likely to suffer assault-related injuries compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is recommended that clinicians regularly review relevant safety issues with their patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Motor vehicle accidents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk of a motor vehicle accident (MVA) in a person with epilepsy compared with other drivers has been variously estimated and may be as high as 2.0. The seizure-free interval (time since last seizure) is believed to be an important factor in assessing the risk of a MVA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32568?source=see_link\">",
"     \"Driving restrictions for patients with seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Driving restrictions",
"    </span>",
"    &nbsp;&mdash;&nbsp;States vary widely in driver licensing requirements for patients with epilepsy. The most common requirements are that patients be free of seizures for a specified period of time and that they submit a physician's evaluation of their ability to drive safely.",
"   </p>",
"   <p>",
"    Physicians should also consider the potential neurotoxic side effects of AEDs (eg, sedation, double vision) (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"     table 3",
"    </a>",
"    ), when counseling patients about driving.",
"   </p>",
"   <p>",
"    A listing of individual state driving requirements can be found on the Epilepsy Foundation Website at",
"    <a class=\"external\" href=\"file://www.epilepsyfoundation.org/resources/drivingandtravel.cfm\">",
"     file://www.epilepsyfoundation.org/resources/drivingandtravel.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Additional details about driving restrictions in patients with epilepsy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32568?source=see_link\">",
"     \"Driving restrictions for patients with seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Psychosocial issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with epilepsy must include consideration of the psychosocial dimensions of the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. Among over 30,000 respondents, the National Health Interview Survey found increased odds of psychological symptoms, medical symptoms and diagnoses, and decreased leisure time physical activity in patients with seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Employment status is often negatively impacted by epilepsy, even when seizures are infrequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/145-147\">",
"     145-147",
"    </a>",
"    ]. In one survey, over 40 percent of college-educated people with \"well-controlled\" seizures were unemployed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newly diagnosed patients with epilepsy are commonly affected by the loss of independence that is most obvious in their inability to drive. They may also have problems obtaining insurance and finding or maintaining suitable employment. Their self-esteem may also suffer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/148\">",
"     148",
"    </a>",
"    ]. As the treatment plan is formulated, psychosocial issues must be systematically explored with patients so that appropriate referrals for additional help and counseling can be initiated.",
"   </p>",
"   <p>",
"    Patients with epilepsy are more likely to have a poor pattern of health-related behaviors (increased smoking, higher alcohol consumption, less physical activity) compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/128,149,150\">",
"     128,149,150",
"    </a>",
"    ]. Counselling regarding these issues may improve health and quality of life.",
"   </p>",
"   <p>",
"    A complete psychosocial history includes inquiries about educational background, employment, driving, insurance, interpersonal relationships, previous psychiatric illness (especially depression), and attitude toward having epilepsy. Questionnaires for this purpose are available, and they provide a measurable way of assessing and following patients as pharmacotherapeutic and psychosocial interventions are implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identifying sources of psychosocial stress should lead to the development of strategies to minimize the impact of those stresses on the patient. Stress reduction can, in turn, help reduce seizure frequency, although this has not been proved definitively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/152\">",
"     152",
"    </a>",
"    ]. Patients are often deeply concerned about health, independence, personal growth, relationships, well-being, and security; those with stress-induced seizures may be candidates for stress reduction, biofeedback, or relaxation training. Many resources are available to help patients. In the absence of a local epilepsy group, patients should be encouraged to call the Epilepsy Foundation at 1-800-EFA-1000 or to visit their website at",
"    <a class=\"external\" href=\"file://www.epilepsyfoundation.org/\">",
"     www.epilepsyfoundation.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H669264\">",
"    <span class=\"h2\">",
"     Depression and psychiatric disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mood disorders, particularly anxiety and depression, are common in patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/128,153-156\">",
"     128,153-156",
"    </a>",
"    ]. In one community health survey, epilepsy was associated with 43 percent higher odds of depression after adjustment for other demographic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/154\">",
"     154",
"    </a>",
"    ]. Results from surveys in Canada and England have also reported higher odds of anxiety, depression, and suicidal ideation among those with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/155,157\">",
"     155,157",
"    </a>",
"    ]. Epilepsy-related disability, including unemployment and activity restriction, along with impaired social support and a perceived stigma associated with the diagnosis are risk factors for depression in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/158\">",
"     158",
"    </a>",
"    ]. Other reports that find a high rate of psychiatric comorbidity (including depression, bipolar disease, psychosis, anxiety, and suicidality) predating seizure onset suggest a bidirectional relationship and perhaps a common underlying mechanism for psychiatric disorders and epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/159,160\">",
"     159,160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mood disturbances are important contributors to decreased health-related quality of life in persons with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/153,161-164\">",
"     153,161-164",
"    </a>",
"    ]. One study&rsquo;s results suggested that the presence of a mood disorder also increases the likelihood of an AED-related adverse event, which may, in turn, contribute to drug intolerance and noncompliance as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/165\">",
"     165",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suicide risk is a particular concern in patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/166\">",
"     166",
"    </a>",
"    ]. A population-based study in Denmark demonstrated a three-time higher risk for suicide in epileptic patients compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/167\">",
"     167",
"    </a>",
"    ]. Similar risk was demonstrated in a separate population-based study both in the three years before and after a diagnosis of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/160\">",
"     160",
"    </a>",
"    ]. Other studies have not found a higher risk of suicide among individuals with epilepsy after adjustment for psychiatric comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/141\">",
"     141",
"    </a>",
"    ]. Suicidality has also been linked to AED treatment. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Side effects of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An international consensus group published guidelines in 2011 for the management of depression and other psychiatric conditions associated with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/168\">",
"     168",
"    </a>",
"    ]. Their recommendations included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for depression at diagnosis of epilepsy and on annual follow-up. The Patient Health Questionnaire (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"       table 10",
"      </a>",
"      ) and Neurologic Disorders Depression Inventory for Epilepsy were suggested tools. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H23#H23\">",
"       \"Clinical manifestations and diagnosis of depression\", section on 'Screening tools'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=see_link\">",
"       \"Using scales to monitor symptoms and treatment of depression (measurement based care)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of the risk of suicide as well as the adverse impact of depression on quality of life and seizure control, they advised against watchful waiting but rather appropriate referral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment of depression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with epilepsy should be advised about the risk of suicide associated with AED therapy. Patients with suicidal ideation should be referred for appropriate intervention. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Side effects of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anxiety is also a common comorbid condition in patients with epilepsy and may benefit from specific treatment. While psychoses and neurobehavioral disorders are less frequent, they can be troublesome and associated with significant risks. Formal psychiatric assessment and treatment should be arranged for such patients as well. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=see_link\">",
"       \"Pharmacotherapy for generalized anxiety disorder\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28583?source=see_link\">",
"       \"Overview of psychosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H669271\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired cognition appears to be a comorbidity of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The causes are likely multifactorial and include the impact of the underlying etiology, side effects of medications or other treatments, the effects of recurrent seizures, as well as psychosocial factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/143,169-171\">",
"     143,169-171",
"    </a>",
"    ]. Studies suggest that some patients are already impaired at the time of their diagnosis and also follow a different cognitive trajectory after diagnosis compared with control groups",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/172-174\">",
"     172-174",
"    </a>",
"    ]. Clinical neuropsychological evaluation and cognitive rehabilitation may be helpful for some patients with cognitive complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DISCONTINUING AED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a two to four-year seizure free interval, it is reasonable to consider discontinuing antiepileptic drugs (AEDs). This decision must weigh the risk of seizure recurrence against the possible benefits of drug withdrawal.",
"   </p>",
"   <p>",
"    There are several reasons to consider discontinuing AEDs in appropriate patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It offers patients a sense of being \"cured,\" whereas the need for chronic medication confers a perception of continuing disability",
"     </li>",
"     <li>",
"      No drug is entirely benign, and adverse effects associated with chronic therapy may take years to become evident",
"     </li>",
"     <li>",
"      Cognitive and behavioral side effects of AEDs may be subtle and not fully recognized until drugs are discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/175\">",
"       175",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The newer AEDs are expensive and pose a significant financial burden for many patients",
"     </li>",
"     <li>",
"      There may be special circumstances, such as pregnancy or serious coexisting medical conditions, in which outcomes may be improved and management simplified in the absence of unnecessary AED therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main disadvantage is the possibility that seizures will recur. The psychosocial implications may be particularly significant for adults who are employed, drive, and whose lifestyle would be adversely affected by recurrent seizures. The recommendation to withdraw AEDs must be made on an individual basis, and the approach should be neither dogmatic nor inflexible. Each patient should have a reasonable understanding of the possible risks and benefits related to discontinuing drugs that are relevant to his or her own case.",
"   </p>",
"   <p>",
"    There is no certain way to prospectively identify patients who will remain seizure free after they discontinue AED therapy. At least two studies have compared continued AED treatment with drug withdrawal and reported the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first study included 1013 patients with epilepsy who had been seizure free for at least two years (range two to six years); these patients were randomly assigned to either continued AED treatment or slow withdrawal of drug therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/176\">",
"       176",
"      </a>",
"      ]. By two years after randomization, 78 and 59 percent of patients, respectively, remained seizure free. The most important factors predicting outcome were longer seizure-free periods before attempting drug withdrawal (which reduced seizure recurrence) and a history of tonic-clonic seizures treated with more than one AED (which increased recurrence).",
"     </li>",
"     <li>",
"      The second study included 330 patients with epilepsy who were also seizure free for two years on a single AED and had consented to drug withdrawal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/177\">",
"       177",
"      </a>",
"      ]. The proportion of those with persistent seizure remission for those who continued and discontinued therapy (82 and 57 percent, respectively) were remarkably similar to those found in the first study. Duration of active disease and length of remission before AED withdrawal also influenced the risk of relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Risk factors for seizure recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that have been associated with an increased risk of seizure recurrence after discontinuation of AED therapy include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/175,178-182\">",
"     175,178-182",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Identifiable brain disease (eg, brain tumor, congenital malformation, encephalomalacia)",
"     </li>",
"     <li>",
"      Mental retardation",
"     </li>",
"     <li>",
"      Abnormal neurologic examination",
"     </li>",
"     <li>",
"      Seizure onset after the first decade",
"     </li>",
"     <li>",
"      Multiple seizure types",
"     </li>",
"     <li>",
"      Poor initial response to treatment",
"     </li>",
"     <li>",
"      Combination therapy at the time of withdrawal",
"     </li>",
"     <li>",
"      Selected epilepsy syndromes (especially juvenile myoclonic epilepsy) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15849?source=see_link&amp;anchor=H6579016#H6579016\">",
"       \"Juvenile myoclonic epilepsy\", section on 'Prognosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epileptiform discharges on electroencephalogram (EEG)",
"     </li>",
"     <li>",
"      Family history of epilepsy",
"     </li>",
"     <li>",
"      Hippocampal atrophy or abnormal hippocampal signal on magnetic resonance imaging (MRI)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the physician must make the choice to taper AEDs on an individual basis, weighing the potential risk of seizure recurrence after discontinuing therapy against that of continuing therapy. As an example, one may have quite different recommendations regarding AED withdrawal in a 25-year-old woman who wishes to become pregnant than in a 25-year-old man whose livelihood depends on driving.",
"   </p>",
"   <p>",
"    Even patients who are seizure free for several years and have none of the risk factors listed above still have about a 20 to 25 percent risk of seizure recurrence after AED withdrawal, a much higher risk of seizures than the general population. Because this risk cannot be known exactly for any given patient, and as the timing of a seizure recurrence cannot be predicted, many patients elect to continue AED therapy rather than risk having seizures recur. However, one should also keep in mind that the risk is not zero even with continued AEDs; in most studies, the risk is halved if AEDs are continued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Withdrawal schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data that indicate an optimal tapering regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/183\">",
"     183",
"    </a>",
"    ]. The following considerations may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid changes in drug treatment increase the risk of provoking seizures, especially with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/184\">",
"       184",
"      </a>",
"      ]. Slow rates of AED taper (six months) were relatively similar to more moderate rates (two to three months) in one large study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/39/40570/abstract/176\">",
"       176",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exceptions are benzodiazepines and barbiturates, which should be discontinued very gradually to avoid withdrawal seizures.",
"     </li>",
"     <li>",
"      Taper one drug at a time in patients on combination therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Driving",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no guidelines or general consensus regarding driving restrictions during and after AED withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32568?source=see_link&amp;anchor=H6#H6\">",
"     \"Driving restrictions for patients with seizures and epilepsy\", section on 'Discontinuing medication'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"       \"Patient information: Seizures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=see_link\">",
"       \"Patient information: Epilepsy in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/5/30802?source=see_link\">",
"       \"Patient information: Epilepsy and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=see_link\">",
"       \"Patient information: Seizures in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with epilepsy is focused on three main goals: controlling seizures, avoiding treatment side effects, and maintaining or restoring quality of life.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate antiepileptic drug (AED) therapy is usually not necessary in individuals after a single seizure and is typically reserved for individuals who are at high risk of recurrent seizures or those who have had two or more unprovoked seizures. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link&amp;anchor=H2#H2\">",
"       \"Initial treatment of epilepsy in adults\", section on 'When to start AED therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend initiating an AED in monotherapy in individuals who are at high risk of recurrent seizures (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Selection of AED is individualized based upon the seizure type, potential adverse effects, interactions with other medications, comorbid medical conditions, age and gender, including childbearing plans, lifestyle and patient preferences, and cost. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link&amp;anchor=H5#H5\">",
"       \"Initial treatment of epilepsy in adults\", section on 'Selection of an AED'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the first AED trial is unsuccessful, a second AED trial is recommended (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). AED therapy is as likely to fail from adverse effects of medication as from lack of efficacy. The chance of successful AED treatment diminishes with each unsuccessful drug trial. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Subsequent drug trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular outpatient office visits that include patient education, review of adverse medication effects, seizure calendar, and drug monitoring are suggested to improve compliance and the likelihood of a successful outcome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Maximizing the likelihood of a successful outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women of childbearing age should be counseled regarding possible teratogenic effects of AEDs and should consider taking supplemental folate to limit the risk.",
"      <br/>",
"      <br/>",
"      Enzyme-inducing AEDs can limit the effectiveness of oral contraception; alternative forms of birth control should be considered in women taking these AEDs. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Women of childbearing age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mood problems, anxiety, and depression are more prevalent in persons with epilepsy than in the general population. In addition, AED treatment has been associated with suicidality. Patients treated with AEDs should be monitored for changes in mood and suicidality. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Specific adverse reactions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Psychosocial issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with epilepsy have a higher than expected risk of mortality (including sudden death), injury, and motor vehicle accidents. Seizure frequency is a major risk factor for these complications. It is reasonable to counsel patients regarding these risks when discussing compliance issues or aggressive treatment for medically refractory epilepsy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Complications of epilepsy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Individuals who have had a recent epileptic seizure may be restricted from driving. Patients or who are experiencing substantial neurotoxic side effects from AEDs should also be counseled about their appropriateness for driving until such side effects abate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32568?source=see_link\">",
"       \"Driving restrictions for patients with seizures and epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AED discontinuation can be considered in patients who have been seizure free for more than two years. Such decisions are individualized based on an evaluation of the individual's risk of seizure recurrence, adverse effects of AED treatment, and the medical and psychosocial consequences of a recurrent seizure. AED drug withdrawal should be slow, over a few to several months. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Discontinuing AED therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/1\">",
"      Schachter SC. Advances in the assessment of refractory epilepsy. Epilepsia 1993; 34 Suppl 5:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/2\">",
"      Schachter SC. Update in the treatment of epilepsy. Compr Ther 1995; 21:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/3\">",
"      Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989; 30:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/4\">",
"      Fountain NB, Van Ness PC, Swain-Eng R, et al. Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology 2011; 76:94.",
"     </a>",
"    </li>",
"    <li>",
"     Schachter SC. Brainstorms: Epilepsy in Our Words, Raven Press, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/6\">",
"      Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/7\">",
"      Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/8\">",
"      Petrovski S, Szoeke CE, Jones NC, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology 2010; 75:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/9\">",
"      Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/10\">",
"      L&uuml;ders HO, Turnbull J, Kaffashi F. Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology? Epilepsia 2009; 50:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/11\">",
"      Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010; 51:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/12\">",
"      Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/13\">",
"      Deckers CL, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001; 42:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/14\">",
"      Haag A, Strzelczyk A, Bauer S, et al. Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of \"newer\" versus \"classic\" drugs: results of the \"Compliant 2006\" survey in 907 patients. Epilepsy Behav 2010; 19:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/15\">",
"      Costa J, Fareleira F, Ascen&ccedil;&atilde;o R, et al. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011; 52:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/16\">",
"      Poolos NP, Warner LN, Humphreys SZ, Williams S. Comparative efficacy of combination drug therapy in refractory epilepsy. Neurology 2012; 78:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/17\">",
"      Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/18\">",
"      Kwan P, Brodie MJ. Combination therapy in epilepsy: when and what to use. Drugs 2006; 66:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/19\">",
"      Jonker DM, Voskuyl RA, Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments? Epilepsia 2007; 48:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/20\">",
"      Moeller JJ, Rahey SR, Sadler RM. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy. Epilepsia 2009; 50:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/21\">",
"      Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/22\">",
"      Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/23\">",
"      Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007; 62:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/24\">",
"      Callaghan BC, Anand K, Hesdorffer D, et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007; 62:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/25\">",
"      Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008; 70:54.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4344b1_10_03_Trileptal%20Update.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/27\">",
"      Bell GS, Gaitatzis A, Bell CL, et al. Suicide in people with epilepsy: how great is the risk? Epilepsia 2009; 50:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/28\">",
"      Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010; 75:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/29\">",
"      Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/30\">",
"      Hesdorffer DC, Kanner AM. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? Epilepsia 2009; 50:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/31\">",
"      Roeder R, Roeder K, Asano E, Chugani HT. Depression and mental health help-seeking behaviors in a predominantly African American population of children and adolescents with epilepsy. Epilepsia 2009; 50:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/32\">",
"      Shneker BF, Cios JS, Elliott JO. Suicidality, depression screening, and antiepileptic drugs: reaction to the FDA alert. Neurology 2009; 72:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/33\">",
"      Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/34\">",
"      Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/35\">",
"      Wu XT, Hu FY, An DM, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav 2010; 19:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/36\">",
"      Yang CY, Dao RL, Lee TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011; 77:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/37\">",
"      Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64:1134.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124718.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/39\">",
"      Linnebank M, Moskau S, Semmler A, et al. Antiepileptic drugs interact with folate and vitamin B12 serum levels. Ann Neurol 2011; 69:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/40\">",
"      Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/41\">",
"      Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ 2004; 328:1273.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Newer drugs for epilepsy in adults, full guidance. Technology Appraisal Guidance 76, March 2004. www.nice.org.uk/TA076guidance (Accessed on March 3, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/43\">",
"      Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/44\">",
"      Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008; 71:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/45\">",
"      Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009; 72:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/46\">",
"      Kaiboriboon K, Guevara M, Alldredge BK. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia 2009; 50:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/47\">",
"      Fisher RS. Tracking epilepsy with an electronic diary. Acta Paediatr 2010; 99:516.",
"     </a>",
"    </li>",
"    <li>",
"     My Epilepsy Diary. Available at: file://www.epilepsy.com/seizurediary (Accessed on June 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/49\">",
"      Haut SR, Hall CB, Masur J, Lipton RB. Seizure occurrence: precipitants and prediction. Neurology 2007; 69:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/50\">",
"      Dionisio J, Tatum WO 4th. Triggers and techniques in termination of partial seizures. Epilepsy Behav 2010; 17:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/51\">",
"      Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol 2007; 64:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/52\">",
"      Berg MJ, Gross RA, Haskins LS, et al. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008; 13:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/53\">",
"      McAuley JW, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav 2009; 14:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/54\">",
"      Papsdorf TB, Ablah E, Ram S, et al. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2009; 14:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/55\">",
"      Chaluvadi S, Chiang S, Tran L, et al. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia 2011; 52:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/56\">",
"      Krauss GL, Caffo B, Chang YT, et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann Neurol 2011; 70:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/57\">",
"      Liow K, Barkley GL, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007; 68:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/58\">",
"      Berg MJ. What's the problem with generic antiepileptic drugs?: a call to action. Neurology 2007; 68:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/59\">",
"      Kr&auml;mer G, Biraben A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 2007; 11:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/60\">",
"      Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007; 48:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/61\">",
"      Nielsen KA, Dahl M, T&oslash;mmerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 2008; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/62\">",
"      Zachry WM 3rd, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009; 50:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/63\">",
"      Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav 2009; 15:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/64\">",
"      Rascati KL, Richards KM, Johnsrud MT, Mann TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009; 29:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/65\">",
"      Kinikar SA, Delate T, Menaker-Wiener CM, Bentley WH. Clinical outcomes associated with brand-to-generic phenytoin interchange. Ann Pharmacother 2012; 46:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/66\">",
"      LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008; 70:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/67\">",
"      Duh MS, Paradis PE, Latr&eacute;mouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009; 72:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/68\">",
"      Labiner DM, Paradis PE, Manjunath R, et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010; 74:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/69\">",
"      Helmers SL, Paradis PE, Manjunath R, et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav 2010; 18:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/70\">",
"      Berg MJ, Gross RA, Tomaszewski KJ, et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/71\">",
"      Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010; 70:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/72\">",
"      Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/73\">",
"      Hauser WA, Ng SK, Brust JC. Alcohol, seizures, and epilepsy. Epilepsia 1988; 29 Suppl 2:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/74\">",
"      Ettinger AB, Manjunath R, Candrilli SD, Davis KL. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav 2009; 14:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/75\">",
"      Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 2009; 14:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/76\">",
"      Brown I, Sheeran P, Reuber M. Enhancing antiepileptic drug adherence: a randomized controlled trial. Epilepsy Behav 2009; 16:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/77\">",
"      Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/78\">",
"      Labiner DM, Bagic AI, Herman ST, et al. Essential services, personnel, and facilities in specialized epilepsy centers--revised 2010 guidelines. Epilepsia 2010; 51:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/79\">",
"      Tyagi A, Delanty N. Herbal remedies, dietary supplements, and seizures. Epilepsia 2003; 44:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/80\">",
"      Lee SW, Chung SS. A review of the effects of vitamins and other dietary supplements on seizure activity. Epilepsy Behav 2010; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/81\">",
"      Brigo F, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev 2012; 6:CD006967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/82\">",
"      Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2012; 6:CD009270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/83\">",
"      Pearl PL, Drillings IM, Conry JA. Herbs in epilepsy: evidence for efficacy, toxicity, and interactions. Semin Pediatr Neurol 2011; 18:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/84\">",
"      Stavem K, Kloster R, R&oslash;ssberg E, et al. Acupuncture in intractable epilepsy: lack of effect on health-related quality of life. Seizure 2000; 9:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/85\">",
"      Cheuk DK, Wong V. Acupuncture for epilepsy. Cochrane Database Syst Rev 2006; :CD005062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/86\">",
"      Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/87\">",
"      Harden CL, Hopp J, Ting TY, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/88\">",
"      Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/89\">",
"      Harden CL, Pennell PB, Koppel BS, et al. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/90\">",
"      Beghi E, Cornaggia C, RESt-1 Group. Morbidity and accidents in patients with epilepsy: results of a European cohort study. Epilepsia 2002; 43:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/91\">",
"      Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/92\">",
"      Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology 2006; 66:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/93\">",
"      Davis AR, Westhoff CL, Stanczyk FZ. Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding. Epilepsia 2011; 52:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/94\">",
"      Pennell PB, Gidal BE, Sabers A, et al. Pharmacology of antiepileptic drugs during pregnancy and lactation. Epilepsy Behav 2007; 11:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/95\">",
"      Morrell MJ, Flynn KL, Seale CG, et al. Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr 2001; 6:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/96\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Medical elgibility criteria for contraceptive use, 3rd edition. Available at: file://whqlibdoc.who.int/publications/2004/9241562668.pdf (Accessed on October 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/98\">",
"      Thorneycroft I, Klein P, Simon J. The impact of antiepileptic drug therapy on steroidal contraceptive efficacy. Epilepsy Behav 2006; 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/99\">",
"      O'Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 2006; 47:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/100\">",
"      Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance (April 2005). Drug interactions with hormonal contraception. J Fam Plann Reprod Health Care 2005; 31:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/101\">",
"      Bounds W, Guillebaud J. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/102\">",
"      Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG 2009; 116:758.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fsrh.org/pdfs/CEUstatementLevonelle1500.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/104\">",
"      Sukumaran SC, Sarma PS, Thomas SV. Polytherapy increases the risk of infertility in women with epilepsy. Neurology 2010; 75:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/105\">",
"      Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/106\">",
"      Olafsson E, Hauser WA, Gudmundsson G. Fertility in patients with epilepsy: a population-based study. Neurology 1998; 51:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/107\">",
"      Pack AM. Infertility in women with epilepsy: what's the risk and why? Neurology 2010; 75:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/108\">",
"      Verrotti A, D'Egidio C, Mohn A, et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/109\">",
"      Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/110\">",
"      Bladin CF, Alexandrov AV, Bellavance A, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/111\">",
"      Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol 2002; 59:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/112\">",
"      Sung CY, Chu NS. Epileptic seizures in thrombotic stroke. J Neurol 1990; 237:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/113\">",
"      Lossius MI, R&oslash;nning OM, Slap&oslash; GD, et al. Poststroke epilepsy: occurrence and predictors--a long-term prospective controlled study (Akershus Stroke Study). Epilepsia 2005; 46:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/114\">",
"      Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004; 35:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/115\">",
"      Heuts-van Raak L, Lodder J, Kessels F. Late seizures following a first symptomatic brain infarct are related to large infarcts involving the posterior area around the lateral sulcus. Seizure 1996; 5:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/116\">",
"      Cordonnier C, H&eacute;non H, Derambure P, et al. Influence of pre-existing dementia on the risk of post-stroke epileptic seizures. J Neurol Neurosurg Psychiatry 2005; 76:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/117\">",
"      Veliolu SK, Ozmenolu M, Boz C, Aliolu Z. Status epilepticus after stroke. Stroke 2001; 32:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/118\">",
"      Gupta SR, Naheedy MH, Elias D, Rubino FA. Postinfarction seizures. A clinical study. Stroke 1988; 19:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/119\">",
"      Gilad R, Sadeh M, Rapoport A, et al. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007; 30:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/120\">",
"      Alvarez-Sab&iacute;n J, Montaner J, Padr&oacute; L, et al. Gabapentin in late-onset poststroke seizures. Neurology 2002; 59:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/121\">",
"      Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/122\">",
"      Cockerell OC, Johnson AL, Sander JW, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997; 38:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/123\">",
"      Neligan A, Bell GS, Shorvon SD, Sander JW. Temporal trends in the mortality of people with epilepsy: a review. Epilepsia 2010; 51:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/124\">",
"      Mu J, Liu L, Zhang Q, et al. Causes of death among people with convulsive epilepsy in rural West China: a prospective study. Neurology 2011; 77:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/125\">",
"      Benn EK, Hauser WA, Shih T, et al. Underlying cause of death in incident unprovoked seizures in the urban community of Northern Manhattan, New York City. Epilepsia 2009; 50:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/126\">",
"      Day SM, Wu YW, Strauss DJ, et al. Causes of death in remote symptomatic epilepsy. Neurology 2005; 65:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/127\">",
"      Bell GS, Gaitatzis A, Bell CL, et al. Drowning in people with epilepsy: how great is the risk? Neurology 2008; 71:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/128\">",
"      St Germaine-Smith C, Liu M, Quan H, et al. Development of an epilepsy-specific risk adjustment comorbidity index. Epilepsia 2011; 52:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/129\">",
"      Annegers JF, Coan SP. SUDEP: overview of definitions and review of incidence data. Seizure 1999; 8:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/130\">",
"      Leestma JE, Walczak T, Hughes JR, et al. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 1989; 26:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/131\">",
"      Nilsson L, Farahmand BY, Persson PG, et al. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet 1999; 353:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/132\">",
"      Walczak TS, Leppik IE, D'Amelio M, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology 2001; 56:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/133\">",
"      Annegers JF, Melton LJ 3rd, Sun CA, Hauser WA. Risk of age-related fractures in patients with unprovoked seizures. Epilepsia 1989; 30:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/134\">",
"      Kirby S, Sadler RM. Injury and death as a result of seizures. Epilepsia 1995; 36:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/135\">",
"      Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999; 99:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/136\">",
"      Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002; 43:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/137\">",
"      Friedman DE, Tobias RS, Akman CI, et al. Recurrent seizure-related injuries in people with epilepsy at a tertiary epilepsy center: a 2-year longitudinal study. Epilepsy Behav 2010; 19:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/138\">",
"      Kwon CS, Liu M, Quan H, et al. The incidence of injuries in persons with and without epilepsy--a population-based study. Epilepsia 2010; 51:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/139\">",
"      Lawn ND, Bamlet WR, Radhakrishnan K, et al. Injuries due to seizures in persons with epilepsy: a population-based study. Neurology 2004; 63:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/140\">",
"      Bowman SM, Aitken ME, Sharp GB. Disparities in injury death location for people with epilepsy/seizures. Epilepsy Behav 2010; 17:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/141\">",
"      Kwon C, Liu M, Quan H, et al. Motor vehicle accidents, suicides, and assaults in epilepsy: a population-based study. Neurology 2011; 76:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/142\">",
"      Shackleton DP, Kasteleijn-Nolst Trenit&eacute; DG, de Craen AJ, et al. Living with epilepsy: long-term prognosis and psychosocial outcomes. Neurology 2003; 61:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/143\">",
"      Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012; 380:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/144\">",
"      Strine TW, Kobau R, Chapman DP, et al. Psychological distress, comorbidities, and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 2005; 46:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/145\">",
"      Schachter SC, Shafer PO, Murphy W. The personal impact of epilepsy: Correlations with seizure frequency, employment, cost of medical care, and satisfaction with physician care. J Epilepsy 1993; 6:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/146\">",
"      Holland P, Lane S, Whitehead M, et al. Labor market participation following onset of seizures and early epilepsy: Findings from a UK cohort. Epilepsia 2009; 50:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/147\">",
"      Jennum P, Gyllenborg J, Kjellberg J. The social and economic consequences of epilepsy: a controlled national study. Epilepsia 2011; 52:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/148\">",
"      Gauffin H, Landtblom AM, R&auml;ty L. Self-esteem and sense of coherence in young people with uncomplicated epilepsy: a 5-year follow-up. Epilepsy Behav 2010; 17:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/149\">",
"      Hinnell C, Williams J, Metcalfe A, et al. Health status and health-related behaviors in epilepsy compared to other chronic conditions--a national population-based study. Epilepsia 2010; 51:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/150\">",
"      Samokhvalov AV, Irving H, Mohapatra S, Rehm J. Alcohol consumption, unprovoked seizures, and epilepsy: a systematic review and meta-analysis. Epilepsia 2010; 51:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/151\">",
"      Devinsky O. Clinical uses of the quality-of-life in epilepsy inventory. Epilepsia 1993; 34 Suppl 4:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/152\">",
"      Ramaratnam S, Baker GA, Goldstein L. Psychological treatments for epilepsy. Cochrane Database Syst Rev 2001; :CD002029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/153\">",
"      Layne Moore J, Elliott JO, Lu B, et al. Serious psychological distress among persons with epilepsy based on the 2005 California Health Interview Survey. Epilepsia 2009; 50:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/154\">",
"      Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia 2009; 50:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/155\">",
"      Tellez-Zenteno JF, Patten SB, Jett&eacute; N, et al. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007; 48:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/156\">",
"      Seminario NA, Farias ST, Jorgensen J, et al. Determination of prevalence of depression in an epilepsy clinic using a brief DSM-IV-based self-report questionnaire. Epilepsy Behav 2009; 15:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/157\">",
"      Rai D, Kerr MP, McManus S, et al. Epilepsy and psychiatric comorbidity: a nationally representative population-based study. Epilepsia 2012; 53:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/158\">",
"      Reisinger EL, DiIorio C. Individual, seizure-related, and psychosocial predictors of depressive symptoms among people with epilepsy over six months. Epilepsy Behav 2009; 15:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/159\">",
"      Adel&ouml;w C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012; 78:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/160\">",
"      Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol 2012; 72:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/161\">",
"      Szaflarski M, Meckler JM, Privitera MD, Szaflarski JP. Quality of life in medication-resistant epilepsy: the effects of patient's age, age at seizure onset, and disease duration. Epilepsy Behav 2006; 8:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/162\">",
"      Kwan P, Yu E, Leung H, et al. Association of subjective anxiety, depression, and sleep disturbance with quality-of-life ratings in adults with epilepsy. Epilepsia 2009; 50:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/163\">",
"      Park SP, Song HS, Hwang YH, et al. Differential effects of seizure control and affective symptoms on quality of life in people with epilepsy. Epilepsy Behav 2010; 18:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/164\">",
"      Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia 2011; 52:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/165\">",
"      Kanner AM, Barry JJ, Gilliam F, et al. Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events? Epilepsia 2012; 53:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/166\">",
"      Stefanello S, Mar&iacute;n-L&eacute;on L, Fernandes PT, et al. Suicidal thoughts in epilepsy: a community-based study in Brazil. Epilepsy Behav 2010; 17:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/167\">",
"      Christensen J, Vestergaard M, Mortensen PB, et al. Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol 2007; 6:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/168\">",
"      Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/169\">",
"      Kwan P, Brodie MJ. Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001; 357:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/170\">",
"      Meador KJ. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002; 58:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/171\">",
"      Aldenkamp AP, Bodde N. Behaviour, cognition and epilepsy. Acta Neurol Scand Suppl 2005; 182:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/172\">",
"      Taylor J, Kolamunnage-Dona R, Marson AG, et al. Patients with epilepsy: cognitively compromised before the start of antiepileptic drug treatment? Epilepsia 2010; 51:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/173\">",
"      Hermann BP, Seidenberg M, Dow C, et al. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol 2006; 60:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/174\">",
"      Baker GA, Taylor J, Aldenkamp AP, SANAD group. Newly diagnosed epilepsy: cognitive outcome after 12 months. Epilepsia 2011; 52:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/175\">",
"      Lossius MI, Hessen E, Mowinckel P, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia 2008; 49:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/176\">",
"      Randomised study of antiepileptic drug withdrawal in patients in remission. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Lancet 1991; 337:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/177\">",
"      Specchio LM, Tramacere L, La Neve A, Beghi E. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J Neurol Neurosurg Psychiatry 2002; 72:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/178\">",
"      Britton JW. Antiepileptic drug withdrawal: literature review. Mayo Clin Proc 2002; 77:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/179\">",
"      Callaghan N, Garrett A, Goggin T. Withdrawal of anticonvulsant drugs in patients free of seizures for two years. A prospective study. N Engl J Med 1988; 318:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/180\">",
"      Cardoso TA, Coan AC, Kobayashi E, et al. Hippocampal abnormalities and seizure recurrence after antiepileptic drug withdrawal. Neurology 2006; 67:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/181\">",
"      Aktekin B, Dogan EA, Oguz Y, Senol Y. Withdrawal of antiepileptic drugs in adult patients free of seizures for 4 years: a prospective study. Epilepsy Behav 2006; 8:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/182\">",
"      Koepp MJ, Farrell F, Collins J, Smith S. The prognostic value of long-term ambulatory electroencephalography in antiepileptic drug reduction in adults with learning disability and epilepsy in long-term remission. Epilepsy Behav 2008; 13:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/183\">",
"      Ranganathan LN, Ramaratnam S. Rapid versus slow withdrawal of antiepileptic drugs. Cochrane Database Syst Rev 2006; :CD005003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/39/40570/abstract/184\">",
"      Azar NJ, Wright AT, Wang L, et al. Generalized tonic-clonic seizures after acute oxcarbazepine withdrawal. Neurology 2008; 70:2187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2220 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40570=[""].join("\n");
var outline_f39_39_40570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIEPILEPTIC DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      When to start AED therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choosing an AED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Subsequent drug trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Side effects of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Specific adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Maximizing the likelihood of a successful outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Titration and monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Patient education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Seizure calendar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Generic substitution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Noncompliance with AED therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DRUG-RESISTANT EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3824319\">",
"      ALTERNATIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Women of childbearing age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21131883\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Oral contraceptive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21131890\">",
"      - Fertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Post-stroke seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - When to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Older patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      COMPLICATIONS OF EPILEPSY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Personal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Motor vehicle accidents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Driving restrictions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Psychosocial issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H669264\">",
"      Depression and psychiatric disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H669271\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DISCONTINUING AED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Risk factors for seizure recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Withdrawal schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Driving",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/60/973\" title=\"table 1\">",
"      Classification of epileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/32/19979\" title=\"table 2\">",
"      Broad versus narrow-spectrum AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/28/3533\" title=\"table 3\">",
"      Common side effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/34/30252\" title=\"table 4\">",
"      Rare serious side effects AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/44/32461\" title=\"table 5\">",
"      AED nonAED drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/46/27374\" title=\"table 6\">",
"      AED pharmacologic properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/0/30733\" title=\"table 7\">",
"      AED mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/29/6621\" title=\"table 8A\">",
"      Carbamazepine interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/26/9645\" title=\"table 8B\">",
"      Phenytoin interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/36/39500\" title=\"table 8C\">",
"      Valproate interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/12/35020\" title=\"table 9\">",
"      Methods to improve compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/12/14541\" title=\"table 10\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36969?source=related_link\">",
"      Antiepileptic drugs and bone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23480?source=related_link\">",
"      Catamenial epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32568?source=related_link\">",
"      Driving restrictions for patients with seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31833?source=related_link\">",
"      Emergency contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2890?source=related_link\">",
"      Evaluation and management of drug-resistant epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15849?source=related_link\">",
"      Juvenile myoclonic epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=related_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39306?source=related_link\">",
"      Overview of contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/5/30802?source=related_link\">",
"      Patient information: Epilepsy and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=related_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4935?source=related_link\">",
"      Post-traumatic seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40841?source=related_link\">",
"      Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1128?source=related_link\">",
"      Sudden unexpected death in epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=related_link\">",
"      Treatment of seizures and epilepsy in the elderly patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_39_40571="History in ALTE";
var content_f39_39_40571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical history for evaluating an infant after an apparent life-threatening event (ALTE)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Event",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        State:&nbsp;Was the infant asleep, awake, crying, relationship to feeding or emesis?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory effort:&nbsp;None, shallow, increased, struggling or choking?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Color: Was the infant&nbsp;cyanotic, pallid, gray, red, purple?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Color change:&nbsp;Did the color change affect the&nbsp;entire body, extremities, face, perioral area, or&nbsp;lips?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tone: Was the infant&nbsp;limp, rigid, or tonic/clonic?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eyes: Were the infant's eyes open, closed, dazed, staring, rolled, or bulging?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noise:&nbsp;Did the infant make any sound, such as a&nbsp;cough, choking, stridor, cry, or gasp?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid: Did the infant spit up or vomit anything? If so, was it mucus, milk, vomitus or blood?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration: How many seconds or minutes did the event last?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intervention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentle stimulation or \"puff of air in the face\"?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vigorous stimulation?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mouth to mouth resuscitation?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CPR by medical personnel?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of the intervention?",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CPR: cardiopulmonary resuscitation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40571=[""].join("\n");
var outline_f39_39_40571=null;
var title_f39_39_40572="Predictors of survival HF";
var content_f39_39_40572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adverse predictors of survival in patients with heart failure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        High New York Heart Association (NYHA) functional class",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduced left ventricular ejection fraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diastolic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Right ventricular dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reduced right ventricular ejection fraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right ventricular enlargement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tricuspid regurgitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low peak VO2 with maximal exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise hemodynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resting sinus tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Signs of reduced tissue perfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Low mean arterial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neurohumoral activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hyponatremia due to increased antidiuretic hormone secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Increases in plasma renin, norepinephrine, brain natriuretic peptide, and big endothelin-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Comorbid factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ischemic heart disease, including extent of coronary artery disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Additional predictors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Echocardiographic findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hemodynamic parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Increase in pulse pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Low heart rate response to exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Reduced heart rate variability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hematologic abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Low lymphocyte percentage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        White blood cell count above 7000/&micro;L in ischemic cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Erythrocyte sedimentation rate above 15 mm/h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Left bundle branch block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Mutant allele of the adenosine monophosphate deaminase 1 gene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nocturnal Cheyne-Stokes respiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        More than 30 apneic or hypopneic episodes per hour",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40572=[""].join("\n");
var outline_f39_39_40572=null;
var title_f39_39_40573="Example of epinephrine infusion - pediatric 20 kg";
var content_f39_39_40573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66791&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of epinephrine infusion - pediatric 20 kg",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"6\">",
"        Example of preparation of epinephrine infusion for refractory symptoms of anaphylaxis for pediatric patient of 20 kg body weight for emergency/critical care units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"6\">",
"        <p>",
"         Epinephrine 10 micrograms/mL (0.01 mg/mL)",
"        </p>",
"        <p>",
"         Add 1 mg (1000 micrograms) of epinephrine to 100 mL of 5 percent dextrose water (D5W).",
"         <br/>",
"         Resulting concentration is 10 micrograms per milliliter (mL).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        1.",
"        <strong>",
"         CHECK",
"        </strong>",
"        vial strength.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        2. To prepare epinephrine infusion for a final concentration of",
"        <strong>",
"         10",
"        </strong>",
"        micrograms per mL, dilute",
"        <strong>",
"         10 mL",
"        </strong>",
"        of",
"        <strong>",
"         0.1 mg/mL",
"        </strong>",
"        epinephrine (also labeled 1:10,000) in 100mL of D5W",
"        <strong>",
"         OR",
"        </strong>",
"        1 mL of 1 mg/mL epinephrine (also labeled 1:1000) in 100 mL of D5W.*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Administration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        Infuse an initial dose of 0.1 micrograms per kg per minute using a programmable infusion pump and titrate as needed while continuously monitoring the patient's cardiac rhythm and blood pressure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        Pediatric dose for 20 kg child",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"3\">",
"        <p>",
"         Administration rate",
"        </p>",
"        <p>",
"         1 milligram epinephrine diluted in 100 mL D5W",
"        </p>",
"        <p>",
"         10 micrograms per milliliter",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"subtitle3\">",
"        Micrograms per kg per minute",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"10\">",
"        Multiply by patient weight (20 kg)",
"       </td>",
"       <td class=\"subtitle3\">",
"        Micrograms per minute",
"       </td>",
"       <td class=\"subtitle3\">",
"        mL per",
"        <em>",
"         minute",
"        </em>",
"        for 10 kg child",
"       </td>",
"       <td class=\"subtitle3\" rowspan=\"10\">",
"        Multiply by 60 minutes",
"       </td>",
"       <td class=\"subtitle3\">",
"        mL per",
"        <em>",
"         hour",
"        </em>",
"        for 10 kg child",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.05",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        0.1",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.1",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         2",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.2",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         12",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.2",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        0.4",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.3",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         6",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.6",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         36",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.4",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        0.8",
"       </td>",
"       <td class=\"centered\">",
"        48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.5",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         10",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         1",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         60",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.6",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        1.2",
"       </td>",
"       <td class=\"centered\">",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         0.7",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         14",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         1.4",
"        </span>",
"       </td>",
"       <td class=\"centered\">",
"        <span style=\"color: #0000ff;\">",
"         84",
"        </span>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        0.8",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"       <td class=\"centered\">",
"        1.6",
"       </td>",
"       <td class=\"centered\">",
"        96",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"6\">",
"        <ul>",
"         <li>",
"          To reduce the risk of making a medication error, we suggest that centers have available an institutionally approved protocol for epinephrine infusion that includes steps on how to prepare and administer the infusion and standard concentration(s)",
"         </li>",
"         <li>",
"          The above table is provided as an example; there are other acceptable concentrations",
"         </li>",
"         <li>",
"          <strong>",
"           Intravenous epinephrine, like all vasopressors,&nbsp;can cause&nbsp;life-threatening hypertension, cardiac ischemia, and ventricular arrhythmias. It should be administered ONLY by clinicians trained and experienced in dose titration of intravenous epinephrine using continuous&nbsp;non-invasive electronic monitoring of heart rate and blood pressure.",
"          </strong>",
"         </li>",
"         <li>",
"          Epinephrine is an ischemia causing agent and peripheral venous irritant. Monitor infusion site for extravasation. See Lexicomp drug reference for information on managing extravasation including infiltration of phentolamine. Central line administration is preferred when available.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Unused diluted solutions should be discarded within 24 hours or less of preparation depending on local standards.",
"    </div>",
"    <div class=\"reference\">",
"     References: Gahart BL, Nazareno AR; Intravenous Medications 28th ed. Elsevier-Mosby &copy; 2012 St. Louis, MO; Lieberman P, et al. J Allergy Clin Immunol 2010; 126(3):477.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40573=[""].join("\n");
var outline_f39_39_40573=null;
var title_f39_39_40574="Bleeding duodenal ulcer";
var content_f39_39_40574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50116/bleedingdu_conv.mp4?title=Bleeding+duodenal+ulcer\" style=\"width:191px;height:180px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bleeding duodenal ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 290px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An actively spurting artery can be seen in the base of this ulcer crater in the duodenal bulb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD and Dennis M Jensen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40574=[""].join("\n");
var outline_f39_39_40574=null;
var title_f39_39_40575="Spiculated pulmonary nodule";
var content_f39_39_40575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spiculated pulmonary nodule in the right apex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 263px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEHAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1rhjx2o5B6VVWcLIdrZHtUgnLtkNj2NAFoAEAbRn1obtlQMVTnuhEfmOTQLovHlf1oAtb92eMY7gUhIUjJ5pIslc8UpXGWODzQAoT05zSOMYCj8qXBByOB0xSZU56Z9KAGtxyccUK/wApxxTVTPJ6Gpti5GDxQA2LceGU+1S5wAuKFBH4UHJYn8qAGlinYfSgHPzHFMeTLZxzjFOUFuentQAMy5yOcdqaHGcIQB6Vo2mk3F0A2zYh/ibpWvaaJbQhTJmRh74FAGHaWt1OMRRlh3IHArYttBOAbpxn+6BzWrNcW9nGBKyxjHC4rLm8SQLkRxk+5NAFz+w7AjmEE/Wqd94at5BmABT6Gki8RxtgFB9a17O9iuhlDhvTNAHLXWnPbRkLGRx1rGmBiBY5z35r0mSNJVw6hhWJqmirJuZAAtAHAqjzzZwMZ696traKHDP+VXJ4EgkKDjFIADjg5+tADDGoX5VA9KgmzyAv5VaYEnB6U6KEbizdKAKtpCxAZh+FaSxEJjPBoVDjAGBTkzyDzQBVltFcgcnmrEVsgHTJNLhsjH61LvAIP4UAQEbDjAx71HJsfjZz9Kt4DnimHCgY6+lAGdNZxyA5HPsKpPZmMZiUketbhPOf0pu7KDcOvtQBgqF5B4J7VKqKImDY5q1c2/mngdOnFVJIXxjGaAM244Y9QR+VS2PnH+IkHoKlmgYqQf5UWe6Fhkbh7UAdb4f00y4eQcDmupWJIwFRQAPasvw1OsluVBG4c1skeuKAI8Z9KQ4XuAahv5ZIVBjxt78dK5zU9SlkJCkYHpQB0bTwqxBkGaabmDIUzLk9q4ddQfcd3bg1BJelmwp5oA7+a2hnX540YH+LAz+dY134cjfJtpCpP8LdK5+y1u4t5Rsc89VPSuksteSTAuE2k91/woAwbuwns8ieIhezA5FVsrtOCK75GjuI8rtkjPtkVj6noEUqtJaHZJ/c/hNAHMqQSPU0/ZyT29KguLe4tZvLuImjI609MjANADjwT0xUW5Qxweam24IJxionijLH5ecZoATcWHIHpml+ULgHJNR5ZTtK4GalQDrmgDOjYK3B3HrUmfMb5Rg1NHahTyCTVmGBUckjrQBnyhhHiQfSmQPkYIO2td7YSj2pv2VAMcDFADY5AE4bJpBN2xgk96m8oYKjgnvSNBwD3oAgedgcHoKUXEcak55qO8DJH7+1ZDSEg5JA9qANM3hduD8tTpcoCDvOawklIbg/L6U5XJuDxx6UAb898Ao2n5jTVmeXDZrHVv3uHBx7VtaPA00qxxjcW4GaALVnbyXMwiiQu7enauq07RYrYiSYiWb/AMdX8O9XNOsY7KELGPnP3mPrTrufycbSB3OaAEuJo4v9YwBJ4Fc/quuSxuY7c7QeM96t6jJE8Rk3AORXJzzhpDkYx60AE88rnzJpSxPqaqPckkgbeahlmLSHPQdqaSjDKH/61AFsS7VXJX8K1dAuna9RV+YZrAVDIQgPWu48J6MbZPtMw5P3Rjr70AdKPujPXFKRwfpS4/GsjVtWjgDRRfM5GCfSgDntaVRcNgjj0qgvUbc1O22d2Lk5Jp/lBOBzigCNB69KccjpyKeIWYgipjGVxnk+goAiSMkg4Iqx5PB6qB3NWrSJF/e3HEanNeEfGf4wDT5pNO0GQCQDDMrd6APWNQ13StMb/TLtAwHTINZcfjLQ7ltqXUZFfFWq+JNT1Odpbm5cs3Xmq0Gr3sOds789txoA/QDS9W0aaB91zEZD0+aoifNdjEwK9Rz2r4Ts/FeqWzhlupSR/tmvcPhB8U3lnSz1WQsGO1WZulAHvDKw5bNTRMWTBXNXYoory3jlgwUcbgR0qBYSrbcigCDzMZwpqFSOhAye9WZEK5BFEUCOOCMigCnLEr9P0qFoAqgAg1pfZ2B+XgUx4SGzwTQBBY3b2MismQRXWadrVteYVm8uX0PQ/jXIyxZ+8B1qMWpU7g3egD0ZlBUhgMH9awNV0TzFL2Z+bupP8qxrXW7uyIQMroP4XGcVvWHiCzuvllPky9MEHaT9aAOPntZLdz56EEdqz5PvcZx716rNFHcRYlRZEYcEjI/CsHUPDNvOC1u7Rv2DcigDgXY7sg4rT0yT96gckjjrVm68K3yNwnmKD1U5qeHSbiOMAxOGH+zQBfkuXhmQwOwHsa2bTUFlAWbajnuOhqlaac4tt0oO4DvWXdSOknCnA/SgDqbu1iu4tkyBl7HuPpXIanp8lhNhvmiP3W9a6bRZmltcPyV6E+lT39st3ayQv3HBHY0AefPOUJAOR7U+2PmDJJz6VQlQpdSQyEgr2pQJI2DA/KKAL0m5nAPT2p2PlAHJz19KrJdDJBIBqQ3CpnkHNAGjxn8Kch3HB6CgDkk0o2kYPBoAUbkPUFSaRlGcrTsA0ENuHp1oAYqgMcnjFPlGAGBJwO9KXC/KF5qpdZZvlzgDtQBQ1W4BG1Rz3xWRkkEnGK0JbcrywJJ7GontX25UD1oAp4ZOgz36VZtBu5xzUttA8jBW4NaUNlsXGOT1oAzCg34zXaeDLM7mnc5C9OKw1sYy4U/nmuy8Nokds0asC3Xr2oA1pCwjYoMtjpXPlZvPxJklj0roiMggZHHFNjhVORy3qetAHLapAUYBgQcZxisNYBNMeSM+1eiSwRSnMsaucY5FNW1t1YMsMYYdCBQB5rJpM8k4SKNznpgVoWXhK9kZfNAiXPJY9q7+SRY03SMEUd24FYt/4lsrXiHNxJ6LwKAJtO8P2dntOwyyjqzdPyqxe6pa2eVdw0nTYlctd65fXylUPkxH+FB1/GqsMYU5fr1OaANq/wBXnmAEWI09BzWYD5jncevepPL3N+76GlMTBgMDNACIiAkLilERY4GOaUx7ByAanCrwyDHqaAI8+WAoPzfSnxo3mAkdakAG7kAiljdTcKOeOmKAOS+MmutoHg6d4zslcBRjjrXwxqFw99fyyysWZ2JJPrmvrj9qnzR4bgAGVLjPtgV8gRDfISRx3oAYU5wSB+PFDJgnnpTpSGftjoMU1Rz1H9KAGkVa0u4e1vY3jJBzjimFAuQewz8p5NFuu64i29S1AH3N8D9Um1jwjGkzN5icbupwBXWSwPFM2SeDzXF/s52xh8LxkjAcZ5r0G9QfaZD2zQBmz8428nFPijGDnIIFPMXp3qMSeWx3CgBnzDuT7VVumkRcg44qeSbLckfSqN9dBY9oBJNAFWK8klk24LVoKJAuHxmqelpkFiNp9TV8khsgkn3oAgkt9wyQDVaS1YNkjn2rRDOOv5UkhyfmBoAisLq4sjut5CP9knI/Kt228Qr0vYgn+0gP8qwnyOQB1qM5cnOTQB3Ftd21yoMMyMT26GpyDXn5jYDckm0j3xTIta1CzlCtOWT0JzQB6EfyqvJbQudzxgmsa0195EHmRgn1zjNXYtYgb76snv1FAGgqLGAEUKB6CjpTY54ZVzHKhH1FEkiICxZTj3oA4rxZYKt20sa8nk4rm5rjawXnjtXXaxM0spz0NczeWgLFwhJoAzppARkdfSo2uM7QGzjqKbcD59wDYAxUOAr8jGKAO52lRk9PWlbKkUrqdgzgelAI2YY0AOX5wPpSPJzgHpTQT/CfzpsaktnAoAevOWNIAcjAHJowd3ORT9pYfKvSgCGSDJ+YdaQwbQckCpyGA5BFV7qdQuGPPtQA2FFUnP50ssxQcEZqv5oC7iTtqsxdmYqxCk0AXhcAqMnmprW7lhnDhiAOnNMtIUEeWI3U4yRpxjP1oA6a019RGPPUufUVJP4hRVzFDn/eNcosyk5WpjICmAeaAN0+IJ2+7DGM1TvPEF6FOxwnsAKoLGZMHdinNbgEZGf60AZ91dXV6x812Oe5PSiC3ZQCTu98VoHyoxjHP0qB5QrBY+hoAiMpjGAOe2Kcs8j8BR+dWEjxywB9adHEucqoB6UATW0nlqFPf3qVmBOTzVM7FfaWx+NTRuo43g8UAWwCqg8be1ETE5BPTtUaSbgFOaaxwTzmgCcOCDliD7UxJNlwpBLDNM8zCcYFQ7yucZFAHB/tJwSX3g2SVFP7sZ/Ovi6RSrEc8cV96/Emy/tTwTeQgbsrn8hmvhO/jeO7kVs53kY/GgCBGA4Kg/zFTIqbflyfqOlMW3ZlBA59OtSIkgOGGQOxoAXkDO47cY/KrGiRG51i3jALFmHNQPjYd68Cut+FFgNS8a6fGqhvnzj0xQB9lfDW2TTPC9jGFKHywTW47b5ixySM4NRQxtb2sMYAAVQMYpwyWPIx3oAM5jqvI6Eck5HepXzhgoAH1qlMQTgc80AQSIpy24jjiqhgLOGZiVzmtPA6DoKikz0C5/DpQBDBLhSFXBHerCMW9RVZyEfJGKsrh4yQMj60ABJ6d6cSNmD1pmEz6H60EehGfegBnA6sCaQnqO3TpSlflJY8moyCBjtQA58dFAaobi2jeIMeWFPD7Qc5xUU90FwMn8KAJLc7VAIwBxTpHATAI6VXL5Tk1GFDLgc/SgCvLcSISyvgZ7GprTV2A2yPweKpXCMCcZA96zzFlmyTmgDrQ3noGVhz2qNlzkNx9KyNMvCjiJ3yMVtRgsCc5I5oAyL+zQBmj6dSKxCq52t1rrZ4spgng9a5u9gK3BC579aAOo3A8jmmZy2P5UoIJ+7+dVLqcx5waALMk6Qr82CDUdveK8mB/wDrrLAknYEnirFuvlPlgMUAbAkUJliKPNVVJVuPesue6Eh2gYHrVeWSQKQpOKANV7vLBR36+9RtbB3Dn6Vn2bNvBP61t2+cHOMUARG0UocjGecVWaFkbPGBWsGyeRSSIsiEAYJoAxjKWfamKkS1c8sT61N9iEc24VZX5MAjOaAIY7KPaAzA4qGeIQD5D0PSrcsyp9wc+9UZGeVjtAx7UAPivNrAE4HvWhFLvHBrEuLZgQT0q5bz/Z2AyCKALF4ApLHj0qpbSlpV/i/CrdxKJIshgeKyoC8cxYdO9AG82T16elOKnbwcYqql2hTkcimyXQZSARnpigCpqWS2RzikhZhGDk8805oy43EUxkkCnDAUAS+aU5yeas21yuMNnPfNZ8ccrDB5xzx6U91ZQCiH6UAamQVyMGoXk9V4qlvcLxn6VOjLImM8+1AE8/8ApGk3ELDIdGXn3r5xvPhdcT65O2z9yzcH2r6StuImAJOfU1EkMfmMT+tAHh9n8II8DecDH1/CsrxN8H5oYmksAzkDkAV9D/Jx8vT9acdhGGAwaAPhbW9KutIunjuo2U9PmHFemfs26eLnxh50qnESM2QO9ex+PPh9Y+ILZ5AirN2IAzWL8IfCcnhXUbsyA5IwMjrzQB7POwL4BOFpiccqS1VFu1dzkYNWllXy/SgBkrqEJcbTWSZ1+0/eG3NW7+eMDBPFYUu1pDsJyaAOh42ZyMGmu+FOF4rJjuJoAu7JzwOKWTU5CMDbj6UATX0qeX1569ajs7s4CkjAqkzNM+Wxz6VK0flx8pkCgDReWMrkkbqdFPbuOWVSKwSrSyfITgdqV4JQoZiR9KANia7jUfe4Hoag+1vccRjj1NZLxu2MMSK2LAbI1JHFAEE6zKD8xyfeoIzh/wB6c1tEK3QjFNmhTbgqPyoAy7kL5eYyKZayhGGcj6mr4t0BOAMVWlti7nC9PSgBZgHPbHbFULq1KgNtrXiUKoDL0p7KrqQwFAHPGA5DDIP1rRsrw4wSc9KiuIjGxBPy+tUIZGjlJHIJoA6FmLAc1WvolfDZGfSnwlmhyeg6VFcldpDZyaANAkEDGBiqVxEZpRjoDVxCMcAc0sa4bcxwB7UAMSFUjGFFVrorkDHPtU11OcYjHPrUdvuLgsPzoArtBsIKc5qZLbcOQRj3q6UXeGwPcVYUqVwBz15FAGX9lxzk/Sr9oVCBT1qQwnqMe1RPC4GQD+VAFsgLz60ihcdKda28syD5WyPapZIZIeNox70AQOcDOKpXMnyk8irErsG6YH1qF8scsuc+lAGTJO2/klu2Ku6fhmJOB/SoL2NV+YcVRjvVgJy3JPrQBtaigEXOaycnHDE0ybWkZdjPyfesnUtahs8Fz16c0AdNpaEkhzlav+QhYbR8tcZpviW0HzM4XPqa6iw1KK5QPC6t9TQAXEUYkySRzVa7UJh0P4Zp+pzCXheO+RVEBmZVPegDRtp3dVAGAeuKvJEvBcA/jSWNtsiG7H41b+Qrg5yKAI1Cq38OPSjI3HAByacCAc9geaXAB4BzQBBNAGJ2YHGcCs5n8h8MtbS4wWz8w9az9QgDLvHUUAOSVBHkA59qarSyOMAhTVWzieYgcqAcYrXRGjwvUUAIqKAP603HJx3NSnB+8CT7U4Bd2cYxQBWl3D5WBxVdFjVmYDn+dXZxwWwDWVcyqrkUAS7gJfarXm5Xrisq3dTLjB596uzwgJkPgn3oAr3PmO21eRSi1O0YHzfSrVrC2c4zVsrzxQBmtAW4PQetUp4hHICw4xW4A27nmoLmEOpJUZoAy7JN8m49B0qa8dmyiVGHKOcjGOPaqc96kJLFwvNADrSQxS4bH0q9e3sMcJ3NyR0ri9Z15bbLlxtPeuWuvGCyNh5AVHTBoA9IEiN8wbrzwamS4lXAHT3rzex8VpuCqwPpmuq0/WVuU5wR060AdpZ3CvGN20n2NTtL/Dg4rmrO/jZgqNz0xW3FKsmMnFAFoYLc04qSCVHBppzj5RTlO7rgZ9aAGkfLn+L2FNIwoJpz4U4A/EVXmmIGwck9KAKeoKZHABx6c1BHZMBzzxWhHGpI3H5s1JIRGMEUAZwEydSTSTy7gOMVeVo5l54OKy9SQxtxQBvRjaeGpzfMMdCO9VtxYrjNSmM9A2aAGrFyc1MsJGBgU5YuhLU6TOQFJY+tADIkZ3IzxWzZ6RI6k5AB71Pomnqq+bKOe1bgdVGMgDpQBmx6OB95wfpVyKwgQcoG+tTBxjK8/SpBz1oARERAQiKv0FZXinZFo89wV+aIZyOta9cj8RdWhttKe0DqZH5cZ6AdqAOYt9TjlXc7YpZdShUn5+BXkuo+IGS4dI32qPSs++8VPHblVkyaAO98UeLoLSIhGBavOrnxnvlZt2PauH1bXZZ7hiz5X0zmspr4TuYyCG9xQB3i+KZHud5c7VyetYGveL57qfAbgDAB9awGlaPPByRis57aSVvlBJPr2oA6q08QyzxlHYhq6XwZ40ubLUI45pWMRODz1rzbSYyLhy3UA9amDzRzkgEKDnIoA+v7SeC8tUuIuVYZqW2CeaMnOfWvnbw38QLzSY0tpmLxAdzzivR/BHjJtX1KNWGAx60AewpGSgGeBQsYzgnmnoB5alQSMdqD2I60ABUr1waE6ZAOaaSQuetG5uBxQAs6lQMYNVr1/wByRjnFWSN+MnNV9RdRGq559qAG6ehEYZgQSOtWdp3bs/rTYdvkrtJxjFPIG3h8k9sUACtk46UsgKkAmoXYn72eKXJOMZzQA8bf4wc/Wsu8UGVgAK1JFJK/rzWXqBVmKrw3TIoApKDHICME1bjLSOAw4qCCJQ/IO4deauAjfkHp1oAvRjy4+nFLuBJyCOalE8bwqqjt6VDuHTAz60AOQ9cHt1oRN3J5oCA9CM1KikKeVAxmgDA1kpbK7swAArxbxj4rCXLrHIVUeh612fxd16Ows5AkvzYJ46V8x6zqz3spYk5zwTQB0Oq+LJLpWQyZUcDj+VYc2pSlgd/B6+wrnW8w/PyQeSfT2p6ytH8pA4PXrQB1mm6o0ZLFwBnH1ro7DxY0R2CQ9ccGvNPtSBMqTk8f/Xp0dyRhww5/WgD3XQfFgkkQGTB9c9a9R0HVVvEVQSTXyno+ovHMh3cepNez+BfEsMTIrOo9RmgD2+FjsG7rTickZ4rM0/Vra4jBV1JNW1mLzoq9GOAKAJJS5+6TTAmSWY54rqotExAC20SEcg1l3ulyw9BgUAZLsvH97tTXIdtrAYFTNEATuXLVTd3ikO7j3NAEMp8qUbRik3GXhjn1qWY73Abn6VX5jGOmfagDYQLjpyKfgkjaetPTZtPrTl+Q+tACOp2gHt6Vf0q2EsmTyB3xVAlicnitXw9dRrK0T4GRxmgDfI2QhYxx0pWtlfaW+9TZJlQEZAH1qBtVt40zKQPxoA0FQKML+dMnuIbeMvPIqADua868VfEaDTw8cLAHt714/wCJfiTdXDyKJTtPGAaAPafFvxGtNPheKxIMvI3E8143qniZ9Qkld3JJBPWvPdR1yW8YujcntUGl3rvOFbOSe9AC6tfbJZiuSQcfWsFLx7h2jDHb2q9qcTSySt6kmsm0gMF4vzcZznFAFO7jaKZjJ0B9c5qGNHkkymOOc1qatblrgMhyW5+lRCHyodqDDNwaACX9/HvX7wqk00okXaMY4q3ADBIAxI3Ut9YvDGJVGUbOCe5oAsacib1dj8x755NWby6iWN4TEM9mz1rEt5mjATGTjtU1wJpgGCnPQ4oAgkl+0zqgQjBAyTxXoHgXWLfSb2H7RkZbJIrhJD9mhL4xIRVKO8la5Vy/IOcDsDQB906BqEd9psUkR3KwGOa0G4I3LXhvwb8aRmOPT55D6DJ717mjhwDxjFAEa4JOPrQG3AA9ulBXJypNKoXGM/PQAPhBk8DrWTfziScBWyuORWhc7zhWNUvsDyMGQZzQBNp9wmwRNxVzyw+CoORSab4dnmkDsdoU9Qa6CDR/J+8/IoAwCNvDqPqaCjRg4Py10o02OVPvKWHeql1pMjIwQg8UAc/IxUZJ4rLmbYxI5JrRvbG5hJ3AnntWfsd5MEEc0AMhlIb5hg+wqVQzvuLYHYUpjZc4FU7q4+y/NIQBQBpQTCMgORg1cWWNgcEV55qXiy2hkO5lrn7n4lQWu4JJkelAHsjvGF+9getYev67BY28gWQZAPQ15DffFUSRlVkxx0zXnOv+N576STEjAdCc9KANL4n+KIL1pImYkn0NeVSTwumPm3Z7U/WJnmk3SHJJrOHbNAFuGQKSHHDUy6ADqUPBGRTok3424OAD83WrBi86MKgG8cc9RQBTODCvI3dMY7UmdgIzkHnjpSyxeU22QnNRMck0AWra4kReF3D61o2esywSrsLhqx03vwoPoMCnYMIyeWI4zQB6r4W8dXFoVWaXPPIJ6V778K9dj13WLVchsNk/hzXxSrspBViCOmK9T+EPjSfQdctpt52qwJFAH3aeTUc0ayrtccdvaqui6pb61psN9aMCki5I/un0q91oA53UtLKnfFzWDf6dOwLFf1rvmAIwRUMkKMhXaBQB58lu0aAPwapzoQ/GcetdLrMIhk5BGayrmEOuB+FAFo/3gacrccDPqaYyhT0yKVDtPrmgBy7nByeBSodj7hkMOmKQOSDjPH6U/IyCoHSgAvdQeOD52PFcH4s8ULHbsqSYarPjfWls4WRDhiD0rxDxLrLTlsynJ96AKviPW3ubkgsTz61zEku9znoeeT0qG7kL7jnkdaZDOJY9pwGFAFq3mZZGQ5yen1rZ0CKSa+CgZNYUS/MXJ4XHHrXSeGbpBeRtGCxyBQAutRfZrja6bcday3VXdTsIQd663xlB9slUoMORnArnNRZIrH7Pj94vOfSgDOaPzbsbmHljAJ9quXENlEfkn39unWqNnaPdW7YIXaOTTrHSmkOwSDIPc8UAVr/Y8geMYC9KjsbiW9H2d2UhegxV3VNFktETMyPu5wr5xVNLeWzt/NHc4BFAFaePyJwm7Ix+BxTFvJraU7c7O2PSgyea2WHzdMVZjQS+WCMEDgHvQBXvg93GXHJHVTWWI2D5x+J7V0l9ZmzRmycFc4HQ1zrOd7ZHNAHQ+Dr97DVoZgxG0jHvX194Z1X7dpEEqnI2gGviWCRlkLAd84FfT3wIv5rvQ8TZKL0zQB6xCCDuPAqykJd92OPfvUaMqsqtjB61oAscKgyDQAkdhnDvk1etYoljciMHFXbC3AhHmD8KtJEiZ2r1oAqp523ES4HrUiwykHe4yfSpnkRPvECoGvFDAL096AGCyYZImIz6VIsMqrxJlveov7RVThsH3qSO9RmwRj3FAFOaOYuQyfiRxWfPawkkMu1vpXRpNHIcKwJqO4tY5/vgbvXFAHKy2SID69q8u+KE09pZs0eQuDk+leyXaC2bYefQ1xnjzTVvbJkZeo9KAPjjXfEVyLhwXY89zXNz6nM5xvLDOeTXp3i7wU6PI6Jg8nGK82vdKeGVkOVZe2M5oAzzdTEnLnNMV2ZgSSTnPWiSIp7im4I45z04oAtSRtL0YMR6HrUDQMrYb0z/APWqxakQq2/g8dfSmylnfjGCOMc0AVw7xk4YjjFT2U7W86yk5x26momGzG7r14NR8saALeo3Qu3EmMH+VUycmn7SOAe9IVI//VQA+OQxDK8Me/pUbuWOWJpOlTRQiRvlPHXmgCMg7QfWprS4e3lDJjj2pbsrsVUIIHpVZRnPtQB9Q/s/fEZrWWPTr58wSYHJ6e9fT0ciTRLJEweNuQRX5w+GNRlsbyOSNguCD16V9jfCbxobvTI4bltwA4yaAPVH3I+V5U9qeenU02GZJk3xtkUrcAnvQBk+ILczQhlGdo5rljwSPSu5dw1ozvjGDmuMulBnYL0JoAlVATjOCKjJIft+daNzps0J5Ukeoqq1o7plVz7UAIhXI3KOar3JCRuwPIHBpXby8gnB6YrG1+9aG2fGMYoA8f8AiPqMhu5QXzgnGD1rym8kkmc85OetdV41vDJeSluxJ+lcNJdkNhRwehzQBZb5/lUc46morMBLorjg8HNFjdJ5uJuQPSppDbPKdhK5NAF24+RCFHB9Kv8AhCJhqCqhJOfTpVOyhefAUM6ng4r1v4a+C90iXE0fyH5s+ntQBX8Q6bJFd2xCE/uQcgd64K90iVtQmaVSLdCMt9a+przRLaeDy/LXfswDjnpXG+JvAL3OjzR2m0SvjJBoA+fhc+azwWqlI1ByfXFZTXNwsjIpKjPJHWvZtB+FtzFLO90vBjIA964Lxb4YuNLu7hY4GznHAoA4ue7cvhpWODWxp8kVzp7Qsy7wPlBPOazr3S7q2g3zRvkn0qvpdvcrcq6BlCmgBJY/s8oVsgj1FWZGYuGj4IA6VpapGk7xllG4Lz9aS006eVx8jBemSOlAFKS5klQrcE8DjJxUZsPMXcfmHXIrpb/S7O3gRTOpdsEgHNa+mLpEVukLEM+epXOaAOU0DwvcapexpDGTlvTivp/4e+HDomlRWsS5kKjdVD4f6fp0VssltGobHUCvTvDduGkeQDJVT+FAFVraRE2spFa2nSeXGqtjjpVhI0nkIxzVKVTFIVzjmgDeS7jWP5m+b0FVJtQLDMbbfpWciSMeOlWYbdypDqxB9qAI3umaRdzZ96ZOC2CGz9DUxszkFQCKDbFCdvA9qAKhY9MfmKesmACPyqX7ISc7s96R7bbgnNACxzvvyBgjvV9buRYwWIzjvVGOFtpB6etNkTGMuTjsaAHzMHLSTEEjoKxZ0e8kZWBK44rQkBeXC96tXECWiRsSu4jNAHE6n4cgmBE8XWvGviL4ChTzJYFIJ54719M6isbWHm7QTXn3iqCK5tWJUDIoA+N9R02SyuGR0OPU1mT4g5BG/wB69M8bxpFcMqKMZOcCvNtTVMZU8DtigCrDHJdTKi9felurea0f5yCc44PSm2949ud0eA2cg1HcTyXEm+VtzGgCxap9pYqV5HA9TmorpWgmaPG0jgfSizfyLyMnoG5FbfiS0VoY7uIH5lyT2oA5/dtUYIJP6UqcjGM/So6s6eV+1JvOE7mgCvsOeh/KpU3QkMQcnpXRa/cWSWqCyRtwABJPeuYZixyTzQBJIQxJbr6CmFhgqMAVLbQmXOOoxzUc0bRuQ/X+dAD7aZop1bdjnmvc/hjrjR7FEmOmea8F712XhLUmsmQFuaAPsnw3rzkIVJPrzmu0g1FJ4jnjivCfhxrazRr82445r0tb3CYHfvQBtalqCJbNAn3jWGE+X5j8xOc1Xfc7ZOevFWMg85ORQB2k92sTlZQNvrS2clvISI9uSaztfRiMr371maMJVvFHrx1oA2dY0aO7Qy26hZxzt7NXj/j68a2t5IWGGHUV7wM+nNeR/GPTEuGaWFQHx81AHzB4lmLTSYBPY5rmFsndgegY8812mv2Li5fI98msb7JuGCQF6kdaAKEOnIkg3PnvnrXQaV4OuNTZPs8bOCeTiq1mtlZTq0wL45wG/pXe+HvG586G2sbVMk4zsHH5UAdn4C+HEdnErXa5buDXq+mWMNjAI4lAAqvoAmbTopLjAkcA1eCtu+ZunagB2Pn4qT8e1KFAXd0/ComlweBx70AOVAFIAFYuq6BZ3jb7iFWPYmtjeScqKzfFEl42mMLQEuBnAGaAPPPGej6HHbOJ2jjIHBrzqK205CVimifHRQOa5vxmmrXWqz/amlSNSc5yK5eW9Nmy+XM+4+/8qAOx1u7W1TyUtMyn+Jk4/OuXvNfuolEKjyzj+Hj9KlsvE8x/4+v3qjgZbNY2p3CXUvmYw3fnpQAxb2VpTJIxb1FdHo06zXKSNzznrXHCJhls8AevWtLT7toRtQdx0oA+nfAVyrW8aQtuPTAr3nw/ZCy0pN/+tkTcxPavn/8AZ6spb6eKS4UiNSCM19IXCGSF0U4JGBQBj6Xn+0eTkc1HqAY6kYlU/N0xV7T7Qxy7yeRVmBUkvJ5OCUIQe3FACWdosMY3fM3v2q0enekdwoJzzVWS5zG3IBFAE+6NfTn2qNkjXuBn1rNglaaQqDyOmKZeyOZAq/rQBoSRr95Xx9KI0V8b+cdjWeksqbd5yKjvtQaIhI1Of50AbwRAmwDio57SOWMgDaexqDTrnz4Bv4YCrNvN5hcbcbTigDnzG8d8IiOR3o8RSAzJGo5CjpWzdRKbuGQryflzWHrsG3UGcknPQZoAv21r9p0Uo45KnbXn2sW6i3mBJJHFeoaawayj6jHFee+I7crfzKn3WP8AOgD5l8exmO+cgE8kYrg5rNb4lAgB6HHrX0d4m8Fi+V3RRk15J4ut7fw2ypEUkmyM85oA8t1DT5rOQiQEDtkYqmoJOADXT6heC/fe4A/Cs0vDG20gDPHTrQBRt48XCeb9wHqTXV67qNmdJjgtgpK4JNctdyfNt24XrilWYNbOrkdgB3oAqmilRC7hV6mpby3aCTaw4PQ9jQA62YMwjfkHpk1FMAshC9M0kbhOozSkb1yOo60ALbPsmTnjIzT79w9y5Q5XtUGMUhoAfGpboBmpre4kSVfmOP5UtuEWJmckEjAA61Xxz60AezfDHWCt2iBxjqea+iNMnE8CcAkgV8k+AZDDcwtnBJ9evNfTXhO4ElpGdw34z160AdcF4wT+NMwVzkgjrSElUyeaUkuoK0Ad1fQ+fEF255qtY2Qjl3MPmWp7C6W4tVcctjmrSMCpI+uKAFdggJYgAV5h8QbgyRyDG7Oa6/V7yQOyAcCuJ8RFp4WycdaAPAvEsYaSQYC8k8VyskotgS3OexFd/wCKLFlnbYepJ4rkhYB7tFuh8hPYUAcfOXuZ8jOM812/gSe0sJ0kCebOCOoNUNe0+JLpYbCI+hwMVueHrW30gI0w8y6cjC+lAH0l4UvjcaTEbg7ZCOB6VrMGbkEcVxvgESvCJrj+IDC+ldmwIGRgCgCNt+BmmfM+QOB6VIGH8Z4oCAtkY60AELHO3I9ql7EPjnsKYWCkAjHvTgRkYOaAPP8A4n+GI7/SpZLSBd4GSQK+U9U0/wCzXzxOwGGPBr7l1hlGl3AkX5SuDXyB480zdf3E9tnG84A60Acy+kutqJVkQgnGBVKaNUXCnd3PYf5/wpftMqq8TOxj9PSq5ycnJbngCgB4UsnUkDjnvWr4d0ufUNRhiijLguBwKoWcTzTAKpw3U9698+E/hQQxR3kic8EZoA9U+G9kNB0q2VVw4UZ9q9Qg1JJIVbA3HtmvN1n2FVHCirgu5XxsY46cUAdXqWsizikAI3MPl9jU3hOWSa1meTJLPmuVjtjcld7E59a7TSIRZ6eBg5680ASXsoWXYnLH1qJImmQqBnPU4p7QvOyyADnqT2p2qXiabZ7wOScKPX3oAolorHkEb+9VJNViafpk+9YdzctLIXLMSe3aoTgHlsNQB0yXkUjDzDjHYVYlshcgPFg46VxxZi4IfpWvo+qmznAly0R4NAG9Chh+WQYIqOCdkvQVYbCeRmtOVVlh3IVbIyprnrmN1mxGDk/pQBp+ILw2cMEuMgSZ/Ss2/u1uHilHQjnHatPWLU3mjGI/6wKCK4lPMtmIznHY0Adva3INiwXGQOtcVqpLXbZPepF1SWJMHhfas69nV5NxOfegDK8faqmj+GZrlcmTkL+VfGniDWbnUtQkmlY53d6+u/H1g2p+HZ0HzbVJAr5A120e31GdGB4Y446UAJZmRo9/BGe/eh135YdRwB6UyzkYR7SMJnFWgEG5j90+/SgDIlzvYMOQaRAM8nFLOR5z7cYz2qM0AXLWFg6SAArn0zV3UAbpECfeA6elZttcPE3DHHpVoX4QNgHdQBnupRircEdaUEqPrRI7SSF2OWPWnQo0jBR3oAmjgEsJKnDg8kmoSAuQcZrWNhNb26OW2K/cd6yZUKyEdeaAEALNhFz7DmkPX/CnK5RSBwT+dLEhc9MkYoA6bwjMq3MIJJ7fSvo7wVPmGNVJ3H2r5x8J20sl1H3OcD1xX1t8HtEjSBJbgBm6gUAdjpGiyzRrJcEpEeRnqfwrbXTbaJMIn41oMQMnoBWDqmrtF8sSjrQBmWGoPZSAgEoeua6K3vYZ185H2uB0rl3G9MKvTvUcMjRdQcE9KANrVZUlyVI3HtWDfWonjII5xVwzk5IHek3Ek479qAPMPEfh+dpCVUkZrEsvCUt1dIZ1KgEHp2r2ORA5wyj8eay9Vj8i2Z4wN46YFAHnetWul6YhWJEa4C9TyM4rgtMglfV/OnwcNlRnNdJqtrdXV842MxPbNQ6FpsqaoguYysYySSfSgD1vTLmLTdFikuMK7kY/GuhtJPtFukqklGGRXiHiTxC13drBExFvFgde4r1Hwdq0DaLAhcEooHzGgDpSVHXqKUyc56LVBdRtZZCFkXP1qb7VEOkyfjQBb3DAAO6nKVBGc/hUMboy53A/SqWuapb6Zpst1MQAlAGL8SNYfTdFkkjG4MQvFeLxJa67YzmDaZsElQMU7xV8S/t8dxa7S8RJA571ynw/u2TxXAo3eRK/zKT1FAHOazo9xb3bBo2xk+wpbHTfMjLMjLgdBX0RrPgeKUiR8EON1ZCeCUhZQseU9hQB5h4V0RJr1Mjo3519I+GbEQ6WkSHjA7e1ctpnhCGylEuAD1x3rr7dzbwhBle1AFxbYK2HbPpirEMfQLjA6e1ZS3LseMn3rY0uJiPnP4GgDT0eMtcgN0HPSu2Ta8YAwVxiuf0+3VOWGAK3oUEcYUfnQA8AAYGABXFa7di9vGIY7E4VT0rs5DtjZiOADXG6zprwt5sY/dnk+1AGcE7qc+1K4LHpjFRREqeT+Gasbl243Et6GgCvlg3Kj8BTJSSoAXvkmps/IVPrUZHBwd3sPWgDrPCl8s1ubVm+aP7vuK2ngjL7io3etc14UtJFuDMylVAxyPWupzQAmBjH4VxWtQ+Tcvhcoc12NwWERKY965rUYt7nJHNAHNXJxEQo61nJHvIyTitjUFVCRxiswI2C0WSKAJ1gDwshBKkYwa+bPi/4NkstRlmhQiNznivopbqZW54PTBrB+IDRyeGrmR4FeYr8uVzQB8eeU0LH51GOMZ5p63aKu0jcfpn/AD9Ki1bd9vmBBXLdMYqmOuc0AbNm1s6u7KOmD8vSql3bwkl4pFC9x6VGt2FXAj/WopthXejHJPINADMbQSCD2phooUFiAOSaAAGnK7LjBPHNPngaB9r4z7VEaANGLU5WRYpzuQcCqtzkTEg+9QVcswJ22MgJ9c0AQKVycitGztyeI8kdQcUq6bhumD2B611GhaWZigIPvxQBs+A7A/a4y444PFfVHgS4jhgiQDGABXj/AIO8OCJVl2ZzXq+hkWyqoGMdqAPQ3AZTg8EVzOo2DB2OOPStbS5jKCT061ceJXOTQByLckFCfSo5w+zkDiljViuCcfSnEAEA8/WgCFHGMd6l+YfdIwaikVc5zinBlTGCTQBKck7jjdUF1D56bX+UHuKlPOCKdtyQG4zQBz8thBZyeYiBmPVsVX1zRoLzTne2Gyfb2OK6KaBXBD4NYOq/aIM+Tnb6etAHgviCzuLS7MbFsgkE1c0fVrqztpP3hAwa6XxXewbz5ibn9q5e/WO+sMWg2N33GgCC38TX3nEJIxz71HB4r1Q3pXz3Cjn71c61tdWz8n5iccGo7x3tUVnUhu59fagDuD8SdR0yYEzMVHQZ61f1Xx3/AMJboT2YzHc/exu6+1eTawzSxxOOVxj6GrHgNJ5vE1nFHnLOM/SgCnc2F1HdtHJGxcNj0r0X4c+Gbl9Tt7lo2CjB6dK9jn8B6W/k3NxGolZdzcdTWvYWcNnGFt41VQMdKALWoBJIoyBgYGKrQLGv3jn6dqvbWcAlQcdBiopIQF3HAb0oApyIwc81E5crgDdjvVxgCDnqelR/ZndsjgDgmgBlup24AIbPSu68KWCzQmWXnb/OuTihC8pnd7mtnQNSudOkYMvmQN1XOKAOsvoym0ICF46Vet5N8QPpwayo9et5TtCED/arQtrmGZP3TKT0wKAJ2IFNljSaNkkXch4qO9JW2YrnOagsL0TYRwd470AcrrGnvbXZVFyp5U+oqgExyVINeiuiuAHUN9RUD2Fs7ZaJc0AcJDC87AIjH8K6XS9BSMB7rr1CituGCGEYijVfoKezBVLMcAd6AEQBV2qoVe2KXqCapi8E1wscHK5+Y1bB9aAI7hsQnrzWYunrdbiXOB6itWXZt/eEBT68VSutWsbKM7plYjoick0AcZr1k1rOynvzWIzmLG0jGa1L69e/u3lkHDE4A7Csq4+SUrtytADjIrNnjcT1pl5aQ6jaPBJyrAgCq+0ryp6mrMBCnIPzfWgD5r+KXgSXSrySeFCYic5C15VLGY5Cp7V9v+ItJi1iyaKZFY44JFfPnxA+HctkZJrdSVHJAoA8fNFXruwkts+YCMHvxVNVz3oAb0NKrbWDDqDmjGOtOWNnJ2KT9KALLFrpXkdjuXnFU6mVJFzgYOKctrK4yFz680AJb27T7th6VPpyus4wv1zV7TYmgHKg7h0b1rptI02OecN5QA4xzQBHp2ntdSoIwWPfPevWvCXhbZAjmPr396l8IeF4dqSADj1r1HT7JIYkAXkDoBQBX0nTxbRIoA+grXghUyYJwfamFXRgwAApnLN874BoA6TTpzAQof5T71Zv9ZihQrHy/r6VyiHY3+s4+tQXdwvQsCfagDTVgpyWOKl3A/NuGaq7enPOKUbvTgUATuVfjYD+FRmI4BA6VIrDbwORUsEoLDOM+tAFfyyBlRxSBiME1qIqDgAc0G1V2O4AZ6cUAZTE544FVbwJKjbx7fWtqWwOMoQfaqzafcEH5AfqKAPHPGmjNPK8kSkkDpXFLYT2sbNhhzX0NfaR5gO+EEfSsS+8LwTQkeTgk0AfOl59pV9z5xnqRWHqdxNPICEJA619C3fgQThgkLEduKo2vwpeacb4vlPqKAPFzZSahYKBEcr6Cu5+E3hCVdXgupYiojOdxHNe4eH/AIZ2ttCElgC8Y3GuxsPDNlYw4RQD/s0AYDxPMFCgnaKnjsG8sHaMDrXSLaxRKCEFR/ZnclwPkAoAwZYGRRtGKzLlmMm3dnBxit+/RolYqetc1dO7XGRtPrQBoRxoEB2g8UAjOAAPoKbBcM8e3YB7ikLHBxgHPU0ASKuT0PFOZzuwvFQREq3JB+lWmdGwQBkelADtjbfl4zzxUEN/LZ3K7SQM5zVhXDIdvYVVeEuMsOfWgD0DStQi1C2DKR5mPmWlkttjl4+B1wO1efafezafdCVGPB6V6DpeoJfwCRcBx95RQBlTau8Urx5I7UDVpYVLMcr2BFLq9gEuPNVcq3PHasHUbl0JjI49xQB00esedDvA2mobm9NyqxZbe3YVzWlTPJdrFnOT0rs9OsBbsZpceZjgf3fegCextUtIeMburN6Vl6n4gghBS3YM3rVfXdfhSN4IGz2Lev0rjpSJmLA49MUAa15f3F6dxkb8DVBow7ck7vU0kEjKp+XOKeSXOR8uPWgBrxlF4fH4VBjzSQ45Hf3qSVwDzk0kcqtyBnHrQBGkR2lcdKjlhCkf3qkuZinKnA9KjsB5s33t3egCaCFmXk5HpUGoaXDdxFZEBU+2a6G0s2J5Xg+tWJbAIvTPtigDwLxn8M4r7fLapt4PHFeR6z4DvrLO2EkDPSvtJ7GJkO7APcGsTUfDaXKMRGsgPouaAPiK80qSEYaJhsqWwtGOfkKgcHjpX0zrvw+gkYlrdhnttrlpvh7GiSbFwSfSgDxee1JJKoGHtWjpmml3+Zc474r0FPAzxTEhTtFbeneEjGnMeSeBigDzu30X7RMflwM4zXc6D4cVAgVTk9TXT6f4XZDu2jr1rqrDTY7dVyOaAG6FZraxqqjp2xXRx4UZzzUMCJjqMU8YZiMj2oAkYb85J9hUM6soU9aeQOgJDd6a7Y6EtgdaAK8sLkK56Hiq7W6s33cnPFXlLOF3ZxTo1O3nHJoAtRnOQVAPpT93QgAgcHNdDq2kCcme1OyXqygcGuZkUoxV85zyPSgCwCqqCox3IoVxn+GmIi7cZOaQoFOeoPrQBcguV3Y3Y+tacM0b4yQSKwflxhRUiMUAZemaAOlEe8Exd6cYp0A2nrWPb6g0RBMmAa27bVI3QBiCaAI1SQJ9zP4U6CBmlUSQgrnutaEdxFLjkVKZE/vD86AKMkSqT5NuuR6UsEEjAEqF74xVt7iNOrrz6U03kGMmQUAMjtJMnfJx6CplhRBluaz59YjRiEwazr7WHdflBGPSgDauWTocAD1qrcXMaQsUI6dq5bUdUdUHLcnHFEE5kiBDE5HNAE2oXIlOFyB9KyzbJuLk+9XWjZyCRTZI2AweVHegCA5j2kAbaRm8zoOauBFeLAAJ96iEJQk9KAK64jOG6nvTxg8ouDUbgtITirMUZA3ccigCMMQRkHPsKfJuaNSowKe2QScYPrmoxNk8igBDEkqdeR2qvZahcaVfq6MSnUirwb2xmq97sADE80Aeg2VxHf2Mcyj5XHQ9jXG60jy3LLt24OK2PBM4ktJogeFIIFX77Tzc3obovUnFAFHwxpCQqLuQZY/dFR+LNdW0he1gfMx++Qeg9Ku+I9TXS7DZCB5rAhR/dHrXm6mW5mLNlietAE0StcZL5xmrkFrt4UZpRGUjwFxgUsUxHAFADslDhxlaV4zsOCKeT5gwRyOaVkO0kHn6UAZc25RyPapbSIk5IzTpS2SMgg+1SQ4i6Z5oAjvIwynpjrVXTDsvF6gA88VqlFkXIPaq0MASXJXvwaAO102HzoA4bBFXHtsoN3zsPSud0zUntWA/g9K6SG8hlTeHAz1B4xQBmXlpk5CkfWq6eZAQMcA9a3t8cqj5lYdqV0SRdpVWX2oAx5mglT/SUB+prJm0K0uiWR4wfQmulnso5RwMdsVQl0k/8snAHvQBy9x4aw/7gI/41Wm0K6i58vHqBXbW1m9t827canlWSQHO0exFAHBwadOOsePwqaTT3yNyH8q6mOObzG3oAM9hzTxC5OecelAHJG0cchcZpVgCDBXJ9a6e6gJQHOPbFZNyAh+XBI70AZroF6UxYePmHX3qaWRcnpVd5cjKHJ96AA/KMAA0qsCOmMGoS7AZdcH1zSNuZB1AJxQB3ej34vbfD581OG9/eq+vaak8LTqMSqOfcUUUAc0nyEg5yPWnnr0wTRRQAhJU4/KpEbcpBUZoooAinbaNoHNLDc4GAOaKKALcV2wIXcQ1TpfNkjcefaiigCGa+yNu4mq5mcng9aKKAGNtJIOc06Oby+H5BoooAo6ifMcbRT9MuAnykc5oooA1BLuXC02TcwOOtFFAEUBYMfl4HWnFcsSOM9qKKAIiQxIPFSIpCkbs0UUAQ3DARcg0yDbhSuciiigCyHyCWA9MVXZNwO4ZA7UUUAb3gqTdPcqAAAmf1rqpHEaMzdFGTRRQB5vrNy2o6hI2eN1JaQLADgg570UUALcylSUUD8agAYgnGPpRRQBLbPy2TnFW1VnU8qBRRQBVMRVvug04qD94BcelFFABAqEnbQAQ5PpRRQBKWBAzxSNO0KHDnAoooAda6m+AN7EdqujV3h53HNFFAFiHXHLgkEj0rRTV4CBuVsmiigCdL2FyFBIP0qb8aKKAELAAkkAD2qCW8jQE5JoooAxL/U924LkVhvdO5b0PeiigBjLkDGM00gjIJoooAaWxwVBqMyEuMcL1wKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right apical bronchogenic carcinoma presenting as a spiculated nodule surrounded by paracicatricial emphysema characteristic for a corona radiata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_39_40575=[""].join("\n");
var outline_f39_39_40575=null;
